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Altered metabolism is one of the hallmarks of cancer and is known to enable the proliferation 
and survival of cancer cells in changing microenvironments. Metabolic changes can be 
interrogated using non-invasive metabolic imaging techniques, which enable the investigation 
of tumour metabolism in vivo and the identification of imaging biomarkers. Hyperpolarised 13C 
Magnetic Resonance Spectroscopic Imaging (MRSI) is a metabolic imaging technique that 
enables dynamic imaging of isotopically labelled metabolites in vivo, with [1-13C]pyruvate 
being the most widely used substrate in pre-clinical studies and the only substrate used so far 
in clinical studies. In the first part of this thesis, hyperpolarised 13C pyruvate MRSI was directly 
compared to mass spectrometry imaging in a murine lymphoma model, cross-validating both 
methods for providing information on the relative spatial distribution of 13C-labelled lactate. 
In the second part, the potential of hyperpolarised [1-13C]Ketoisocaproic Acid as a substrate for 
hyperpolarised imaging was investigated. Ketoisocaproic acid is a substrate for Branched Chain 
Aminotransferase 1 (BCAT1), the first enzyme in the catabolic pathway of Branched Chain 
Amino Acids. This enzyme is upregulated in many cancers and is linked to cancer progression. 
In this project, the role of BCAT1 in cell proliferation was confirmed in glioblastoma patient 
derived cells and tumours and BCAT1 was shown to regulate the cells’ metabolic and 
transcriptional profiles through regulation of alpha-ketoglutarate metabolism. In vivo imaging 
of BCAT1 activity is therefore suggested as a potential technique for patient stratification and 
potentially treatment monitoring. [1-13C]Ketoisocaproic acid was successfully hyperpolarised 
and showed fast uptake into subcutaneous EL4 lymphoma tumours, healthy rat brain and 
orthotopic gliomas in rat brain, following intravenous injection. Sufficient 13C leucine signal 
was generated in the lymphoma tumour models enabling in vivo imaging of BCAT activity but 
the reaction was found to be significantly slower in the healthy rat brain and in the glioma 
tumours. This was explained by low levels of glutamate, a co-substrate for the reaction, in the 








Cancer is a leading cause of death worldwide and research is aimed at better understanding the 
disease in order to develop effective treatments. The disease is characterised by a number of 
features, termed the hallmarks of cancer, that enable cancer cells to not only survive and 
replicate, leading to tumour growth, but also to develop resistance to many of the therapies that 
are used to target them. Altered cell metabolism is one of these features, meaning that cancer 
cells utilise nutrients differently to healthy cells in order to meet the high demand for energy 
and building blocks needed to enable cell growth and division. Changes in metabolism are often 
used as targets for cancer treatment and it is therefore essential to develop ways of detecting 
and measuring these changes in patients, non-invasively. 
Hyperpolarised 13C Magnetic Resonance Spectroscopic Imaging (MRSI) is a non-invasive 
imaging technique that enables measurement of specific aspects of tumour metabolism. In the 
first part of this thesis, the performance of this technique was evaluated by using hyperpolarised 
13C-labelled pyruvate as an imaging agent. Upon injection of pyruvate, a breakdown product of 
glucose, in tumour-bearing mice, its conversion to lactate was imaged. The lactate images 
generated by this technique were compared with images generated by another imaging 
technique, Mass Spectrometry Imaging. The two techniques generated images that were very 
similar, cross-validating them as techniques for imaging tumour metabolism.  
13C-labelled pyruvate is commonly used in hyperpolarised 13C MRSI to image aspects of 
glucose metabolism, but the metabolism of other nutrients, such as amino acids, is also of great 
interest in cancer. The second part of the thesis aimed to understand the role that branched chain 
amino acids, nutrients that we absorb from our diet, and their metabolism, play in brain cancers 
and to evaluate the potential of 13C-labelled Ketoisocaproate as a novel substrate for imaging 
this metabolism. The metabolism of branched chain amino acids facilitated the growth and 
division of cancer cells that were derived from patients with brain tumours. The mechanism by 
which these amino acids contribute to the aggressiveness of brain cancer and control the rate of 
division of cancer cells was explored, showing that the ability to image this metabolism in 
patients will be beneficial for developing new treatments. Hyperpolarised 13C MRSI using 13C-
labelled Ketoisocaproate was optimised and shown to perform well in mice with lymphoma 
tumours, but less so when imaging brain tumours in rats. Investigation of the poor performance 
of this imaging agent in brain tumours revealed that the tumours had low levels of glutamate, a 
metabolite that is essential for utilisation of the 13C-labelled Ketoisocaproate. More work needs 
to be done to develop an agent that can effectively image the metabolism of branched chain 
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Chapter 1 - Introduction 
1.1 Cancer  
Cancer is a leading cause of death worldwide, accounting for more than one in four deaths in 
the UK1. Despite advances in diagnosis, prognosis and treatment of cancer, cancer remains one 
of the most dreadful diseases for many patients.  
In 2000, Douglas Hanahan and Robert Weinberg, described the hallmarks of cancer2, which 
were specific characteristics observed in the cells of most types of cancer, that enabled cancer 
cell survival and proliferation. These hallmarks included: self-sufficiency in growth signals, 
insensitivity to growth inhibitory signals, evasion of programmed cell death, limitless 
replicative potential, sustained angiogenesis and tissue invasion and metastasis2. Eleven years 
later, the same authors published a second paper, where they added two more hallmarks; 
reprogramming of energy metabolism and evading immune destruction3 (Figure 1). 
 
Figure 1 The revised hallmarks of cancer, adapted from Hanahan and Weinberg3 
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1.1.1 Cancer metabolism 
Cancer cells are under high metabolic pressure, due to their high proliferation rate. Cells require 
a constant supply of nutrients which are used for biosynthetic purposes but also for ATP 
generation. Also, the high growth rate of cancer cells in a tumour leads to rapid changes in the 
microenvironment, such as hypoxia, which means that cells need to be metabolically very 
adaptable in order to survive under these changing conditions. Many metabolic pathways are 
altered in cancer, enabling favourable energy production, effective redox balance and enhanced 
biosynthetic activities, all of which provide cancer cells with a selective advantage during 
tumourigenesis4,5.  
Cancer metabolism refers not only to the metabolic reactions taking place in a cancer cell but 
also to the ability of cancer cells to acquire essential nutrients from their environment, their 
ability to use those nutrients efficiently and to use metabolites for various downstream effects4.  
1.1.1.1 Enhanced nutrient acquisition 
Two substrates that are avidly used by cancer cells are glucose and glutamine4. Both nutrients 
can be taken up into the cells and can be catabolised to generate intermediates necessary for 
macromolecule synthesis. Additionally, through the catabolism of these nutrients, reducing 
power in the form of NADH, FADH2 and NADPH is generated, which is needed to fuel ATP 
generation, enable biosynthetic reactions and maintain the cell’s redox capacity. Glutamine is 
also a nitrogen donor for the synthesis of nitrogen-containing compounds such as nucleotides 
and non-essential amino acids. Cancer cells achieve nutrient acquisition through upregulation 
of cell membrane transporters such as GLUT1, which mediates glucose uptake, but they also 
utilise other modes of nutrient acquisition such as lysosomal degradation of extracellular 
proteins which can be taken up by micropinocytosis4.   
1.1.1.2 Reprogrammed metabolic pathways 
Other than their ability to acquire nutrients, cancer cells reprogram their metabolic pathways to 
enable efficient usage of nutrients. One of the first reprogrammed metabolic pathways to be 
documented in cancer was that of aerobic glycolysis, often referred to as the Warburg effect 
since it was first observed and documented by Otto Warburg6. Many tumours are highly 
glycolytic, with an increased rate of glucose uptake, consumption and preferential conversion 
to lactate, regardless of the availability of oxygen. This property of tumours is exploited in the 
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clinic, where 18F-Fluorodeoxyglucose (FDG), an analogue of glucose, is used as a Positron 
Emission Tomography (PET) tracer to diagnose and stage cancer4,7. The conversion of glucose 
to pyruvate is much less energy efficient than pyruvate oxidation in the Tricarboxylic Acid 
(TCA) cycle, which makes the Warburg effect sound counterintuitive. However, even though 
aerobic glycolysis is less efficient than the TCA cycle in terms of ATP generation, the Warburg 
effect facilitates the generation of building blocks such as amino acids and nucleosides through 
generation of NADPH and the donation of carbons which are needed for cell growth and 
division8. Aerobic glycolysis is evident in many cancer types but in certain cancer cells, such 
as lung cancer stem cells and leukaemic cells there is evidence of higher rates of glucose 
oxidation in the TCA cycle9,10.  
The TCA cycle is still essential for cancer cells and similarly to glycolysis, it generates 
numerous intermediates that are used as precursors for macromolecule biosynthesis, such as 
amino acid and fatty acid synthesis, which happen at a faster rate in cancer cells. In order for 
TCA cycle flux to be maintained despite the losses of intermediates, a number of anaplerotic 
pathways are enhanced, which enable entry of TCA cycle intermediates at sites other than 
acetyl-CoA. Some examples of anaplerotic pathways include glutaminolysis, which generates 
alpha-ketoglutarate (α-KG) (Figure 2), and pyruvate carboxylation, which produces 
oxaloacetate from pyruvate5. 
Many tumours show high glutamine consumption11. Glutamine is transported across the plasma 
membrane through several transporters of the SLC superfamily of transporters, including 
SLC1A5 which enables sodium dependent uptake of glutamine and which is upregulated in 
many cancers12. Glutamine is used to generate intermediates that can enter the TCA cycle, thus 
maintaining oxidative metabolism, even if pyruvate is converted predominantly to lactate. 
Glutaminase catalyses the hydrolysis of glutamine, converting it to glutamate13. Glutamate 
dehydrogenase then catalyses the generation of α-KG, which can be used either for generation 
of NADH and NADPH through the action of IDH3 and IDH1/2, respectively in reverse flux in 
the TCA cycle to generate citrate, which acts as a precursor of fatty acids or in forward flux in 




Figure 2 Schematic diagram illustrating cancer cell metabolism. Glucose, glutamine and citrate are three of the most 
widely used nutrients by cancer cells. Abbreviations: OAA: oxaloacetate 
1.1.2 Regulation of cancer metabolism 
Cancer cells are characterised by their genetic instability, with many genomic alterations, a lot 
of which are thought to lead to transformation of pre-malignant cells to a cancerous state. The 
expression of a number of oncogenes, which are genes that facilitate cancer growth, are 
upregulated through genetic and epigenetic changes. Alternatively, tumour suppressor genes, 
genes that would normally suppress cancer growth are downregulated through gene deletions 
and mutations. The genetic makeup of cancer cells is thus very different to normal cells. Many 
of these genetic changes lead to changes in metabolic processes and hence the reprogrammed 
metabolism observed in cancer.  
One of the most frequently altered pathways in cancer is the PI3K-AKT-mTOR pathway 
(Figure 3). The pathway is activated physiologically when growth factors stimulate 
Phosphatidylinositol 3-kinase (PI3K) activity through receptor tyrosine kinases. PI3K then 
activates its downstream targets, AKT and mammalian target of rapamycin (mTOR), which 
promote the activity of anabolic pathways. In many tumours, PI3K-AKT-mTOR pathway is 




Another example of a genetic alteration leading to metabolic changes is increased MYC 
expression resulting from gene amplification, chromosomal translocation and single nucleotide 
polymorphisms. Increased levels of this transcription factor lead to upregulation of many 
metabolic genes, including enzymes involved in glycolysis, fatty acid synthesis and 
glutaminolysis14.  
 
Figure 3 Examples of cell signalling processes that are constitutively activated in cancer, driving metabolic changes in the 
cell. The PI3K-AKT-mTOR pathway promotes cell proliferation through increased protein synthesis. Increased expression of 
c-Myc transcription factor leads to increased glycolysis and fatty acid synthesis, promoting cell proliferation. 
Cancer metabolism is regulated by factors other than genetic alterations, including extrinsic 
factors that depend on the environment of cancer cells. This is the reason why the metabolism 
of cancer cells in culture often differs from the metabolism of the same cells in a tumour15. For 
example, lung cancer cells in culture are dependent on glutamine as a TCA cycle fuel, whereas 
tumours derived from the same cells use glucose as a fuel16. Cell lineage can also affect the way 
metabolism is affected by genetic alterations in different cancers. For example, increased MYC 
expression leads to enhanced catabolism of glutamine in liver tumours but enhanced glutamine 
synthesis from glucose in lung tumours17.   
1.1.3 Key metabolites in cancer 
1.1.3.1 Oncometabolites 
Genetic mutations that directly affect specific metabolic enzymes are much rarer in cancer than 
mutations that indirectly affect metabolic networks via changes in signalling pathways and 
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transcription factor expression. However, some specific mutations have been characterized in 
a number of cancers which often lead to the generation of oncometabolites.  
An example are the mutations in the active site of Isocitrate Dehydrogenase (IDH), which are 
present in some cases of Acute Myeloid Leukaemia (AML) and glioblastoma18,19. Mutations in 
this enzyme lead to a neomorphic activity, leading to the generation of the oncometabolite D-
2-hydroxyglutarate (D2HG). This metabolite can accumulate to millimolar levels and leads to 
epigenetic changes due to its inhibitory effect on DNA and histone demethylases20.  
Other examples include mutations of the succinate dehydrogenase complex and fumarase, 
which lead to the accumulation of succinate and fumarate, respectively21,22. Both of these 
metabolites can act as oncometabolites in a similar manner to 2HG, by inhibiting α-KG 
dependent dioxygenases23. 
1.1.3.2 α-ketoglutarate 
α-KG is an important metabolite in physiology and disease, including cancer 13,24-27. The 
metabolite is involved in the generation of ATP, amino acid biosynthesis, signalling and 
epigenetic regulation24. α-KG, also known as 2-oxoglutarate, is a central metabolite of the TCA 
cycle and is formed from isocitrate by oxidative decarboxylation catalysed by IDH. It can then 
be converted by α-KG dehydrogenase to succinyl-CoA and NADH24. Redox state in the cell 
determines the amount of α-KG in the mitochondria since an excess of NAD+ leads to more 
oxidative decarboxylation of α-KG to succinyl-CoA whereas an excess of NADH leads to 
reductive transamination of α-KG to glutamate via the action of glutamate dehydrogenase. 
In addition to its role in the TCA cycle in ATP generation, α-KG also takes part in other 
metabolic reactions in the mitochondria and in the cytosol. It is transported through the inner 
and outer membranes of mitochondria through the α-KG/malate antiporter and the voltage-
dependent anion channel (VDAC), respectively27.  
Both glucose and glutamine can be used for α-KG production. α-KG can be generated from 
carbohydrate metabolism, through the TCA cycle and through the action of glutaminase and 
glutamate dehydrogenase. α-KG also takes part in transamination reactions, catalysed by 
Glutamate Pyruvate Transaminases (GPT1/2) and Glutamate Oxaloacetate Transaminases 
(GOT1/2) 27 as well as by Branched Chain Aminotransferases (BCAT) 1 and 2.  
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1.1.3.2.1 α-ketoglutarate and cell homeostasis 
Metabolically, α-KG contributes to the regulation of protein synthesis since it is a substrate for 
the reversible reaction catalysed by glutamate dehydrogenase, leading to glutamate synthesis, 
which is then used to produce proline, arginine and glutamine. It can also control L-carnitine 
biosynthesis and is therefore involved in the regulation of lipid metabolism27.  
α-KG plays an active role in signalling pathways in cellular physiology. For example, it 
regulates activation of the transcription factor NF-κB by activating PHD1, which leads to 
activation of inhibitory kB-α28. α-KG can also inhibit the mitochondrial ATP synthase, leading 
to inhibition of mTOR signalling29. 
α-KG also protects the cell against oxidative stress. For example, α-KG takes part in non-
enzymatic oxidative decarboxylation, neutralizing hydrogen peroxide27. 
 
Figure 4 The role of α-KG in cell homeostasis, reproduced from Abla et al27. α-KG controls lipid synthesis by controlling L-
carnitine biosynthesis and protein synthesis by controlling glutamine, proline and arginine biosynthesis. It also plays a role in 
protecting the cell against oxidative stress and is involved in the regulation of transcription factors including NFkB and HIF. 
1.1.3.2.2 α-ketoglutarate and epigenetic regulation 
Chemical modifications to chromatin can regulate DNA transcription, repair and replication, 
therefore regulating the function of the genome. Chromatin modifications include DNA 
methylation and histone post-translational modifications24. Many of the enzymes involved in 
these reactions belong to the family of 2-oxoglutarate dependent dioxygenase enzymes, which 
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require α-KG as a co-substrate. These enzymes include histone demethylases such as JmjC 
domain demethylases (JHDMs) and DNA demethylases such as Ten-eleven Translocation 
Enzymes (TETs)30. Succinate, fumarate and 2-HG have been shown to inhibit TETs leading to 
enhanced DNA methylation, which may increase carcinogenesis31-33, while α-KG can reverse 
this. For example, hypermethylation of promoter CpG islands results in transcriptional silencing 
of tumour suppressor genes and carcinogenesis in IDH mutant gliomas where 2HG inhibits 
DNA demethylases34. DNA and histone methylation status is also important in modulating 
stemness, depending on the pluripotency state, with high α-KG levels favouring self-renewal 
in naïve mouse embryonic stem cells but favouring differentiation in primed human or mouse 
epiblast stem cells27,29,35.  
1.1.3.2.3 Role of α-ketoglutarate as an anti-cancer agent 
Altered metabolism is a hallmark of cancer, and α-KG plays an important role in controlling 
metabolic flux. In cancer cells, α-KG is produced by glutaminolysis and it can then either be 
oxidised to succinyl-CoA to feed the TCA cycle or undergo reductive carboxylation to citrate, 
to support lipid synthesis27.  
α-KG as well as its structural analogues succinate and fumarate are known to be involved in the 
regulation of signalling pathways that are linked to carcinogenesis. PHDs 1-3 regulate the 
stability of HIF-1α and hence the activity of HIF as a transcription factor. These enzymes are 
strongly dependent on the concentration of α-KG in the cells, as the Km for α-KG of many of 
these enzymes is around 50 μM, similar to the physiological concentration of α-KG, meaning 
that small changes in concentration can lead to large changes in enzyme activity36. 
Studies in vitro and in vivo have shown that exogenous α-KG exhibited anti-tumour activity by 
reducing the levels of HIF-1α in the tumours, thus inhibiting angiogenesis24 and also by 
inducing apoptosis via a HIF-independent mechanism, through regulation of PHD337. In a study 
in vitro, addition of 5-50 mM α-KG to three colon adenocarcinoma cell lines, Caco-2, HT-29 
and LS-180 led to antiproliferative effects and disruption of the cell cycle by increasing 
expression of cyclin dependent kinase inhibitors p21 Waf/CIP1 and p27 Kip138. Additionally, 
α-KG addition to the cells led to reduced cyclin D1 and reduced phosphorylation of Rb leading 
to cell cycle arrest in G1 phase. The concentrations used in this study are much higher than the 
physiological concentrations of α-KG due to the low cell membrane permeability for α-KG24. 
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Accumulation of endogenous α-KG has also been shown to inhibit cancer progression. For 
example, α-KG dehydrogenase inactivation in breast cancer leads to accumulation of α-KG, 
which limits cell migration and EMT27.  
Therefore, α-KG is a promising metabolite for the treatment of cancer, especially in cases where 
tumourigenesis is associated with inhibition of 2-oxoglutarate-dependent dioxygenases. α-KG 
is a hydrophilic molecule with low cell permeability, which is why various esters of α-KG have 
been used to increase the intracellular concentrations of α-KG39.  
1.1.3.3 Glutamine 
Glutamine is a non-essential amino acid that plays a crucial role in cancer metabolism, as an 
energy source for the cell but also as a nitrogen donor. Glutamine is the most abundant amino 
acid in plasma and many tumours show enhanced glutamine uptake even though glutamine can 
be synthesised de novo40.  
Glutaminolysis, which describes a series of reactions that convert glutamine into substrates that 
can enter the TCA cycle, is extremely important for maintaining ATP production in cancer 
cells, especially in  cells with high HIF-1α activity leading to inhibition of pyruvate 
dehydrogenase and thus inhibition of glucose carbon entry into the TCA cycle. In addition to 
this, glutaminolysis provides nitrogen for nucleotide and amino acid synthesis and leads to 
NADPH production for lipid and nucleotide synthesis13.  
The first step in glutamine catabolism is its conversion to glutamate, which is catalysed by the 
glutaminase enzymes, which have been shown to be upregulated and to promote tumour growth 
in a number of models40. Glutamate can then be used in the cell for glutathione synthesis, 
generation of α-KG and as a donor of amino groups for the synthesis of non-essential amino 
acids including alanine, aspartate, serine and glycine.  
More recently, it has been suggested that the role of glutamine in promoting tumour growth is 
context dependent. For example, in a panel of non-small cell lung cancer cell lines, variability 
in the response of cells to glutamine deprivation was observed41, and Kras-driven non-small 
cell lung cancer tumours were shown to be less dependent on glutamine than cultured cells in 
vitro16. Similarly, variability in glutamine dependence was observed in breast cancer cells with 
basal-type cells showing higher dependence than luminal-type cells42. 
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1.1.3.4 Branched Chain Amino Acids 
Leucine, isoleucine and valine constitute the group of branched chain amino acids. They are 
essential amino acids that are preferentially taken up by tumours43. Upregulation of the enzymes 
catalysing branched chain amino acid catabolism has been observed in most cancers. The 
cytosolic isoform of the enzyme catalysing transamination of the amino acids to their respective 
ketoacids, Branched Chain Aminotransferase 1 (BCAT1), has been of great interest in the field 
of cancer metabolism recently as it has been implicated in tumour growth and because in normal 
cells it is only expressed in the brain, gonadal tissues and activated T lymphocytes, making it 
an attractive therapeutic target43. 
1.1.3.4.1 BCAT1 is implicated in the progression of different cancers 
Over the last decade, BCAT1 upregulation has been shown in a number of cancers, including 
breast cancer44, non-small cell lung carcinoma45, colorectal cancer46, urothelial carcinoma47, 
ovarian cancer48, gastric cancer49, leukaemia50 and glioblastoma51,52. In low-malignant potential 
(LMP) and high-grade (HG) serous epithelial ovarian tumours, BCAT1 upregulation correlated 
with hypomethylation of a 425 nucleotide CpG-rich region of the BCAT1 gene48. It appears that 
the enzyme can play different roles in different cancers, and that net flux in the transamination 
reaction is also dependent on the tissue of origin of the cancer.  
1.1.3.4.2 Role of BCAT1 in cell proliferation and migration 
BCAT1 was found to be significantly upregulated in early and later stages of nasopharyngeal 
carcinoma when compared to normal epithelium, as seen on immunohistochemistry. The role 
of BCAT1 was investigated in nasopharyngeal carcinomas by transfecting cells with BCAT1 
shRNA and searching for phenotypic changes. BCAT1 knockdown led to reduced colony 
formation in clonogenic assays, reduced mobility in migration assays and reduced invasion 
capability in Matrigel-coated transwell chamber assays53. Similar experiments in hepatocellular 
carcinoma cells revealed very similar results in terms of the role of BCAT1 in cell migration 
and invasion. In this same study, BCAT1 expression levels were correlated with overall and 
disease-free survival rates54. Zheng et al demonstrated that BCAT1 expression accelerated 
hepatocellular carcinoma growth in vivo, in mice55 and in the same study, the effects on cell 
proliferation of BCAT1 overexpression and BCAT1 suppression were explained by changes in 
cell-cycle distribution, with BCAT1 overexpression reducing the percentage of cells in S phase 
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and increasing the percentage of cells in G2/M phase. BCAT1 knockdown in ovarian cancer 
cells also led to cell cycle arrest in S phase48.  
One of the proteins that BCAT1 interacts with and that is involved in tissue remodelling is 
CD147, also known as basigin and Emmprin (Extracellular Matrix Metalloproteinase Inducer). 
This is a cell membrane glycoprotein which has been implicated in tissue remodelling56, since 
it is released by cancer cells and stimulates fibroblasts and endothelial cells to release MMPs57. 
Inhibition of CD147 expression by siRNA in U251 human glioma cells led to reduced migration 
and invasion in vitro, as measured by scratch-wound assays and Boyden chamber assays, 
respectively58. In human glioblastoma studies, expression of CD147 was shown to be 
upregulated in glioblastoma tissue and increased CD147 expression was associated with poor 
overall survival of patients59. BCAT1 is proposed to be in a complex with CD147 in the cytosol 
of human breast cancer cells and suppression of BCAT1 activity in these cells with a specific 
inhibitor led to suppression of CD147 in conditioned media60. This suggests that BCAT1 might 
play a role in enabling the secretion of CD147 from cancer cells which could be linked to the 
migratory potential of the cells. 
1.1.3.4.3 Role of BCAT1 in chemoresistance 
BCAT1 was shown to play a role in rendering hepatocellular carcinoma cells resistant to 
cisplatin treatment55. The proposed mechanism was the enhancement of autophagy in the cells 
upon BCAT1 overexpression. In contrast, BCAT1 knockdown in ovarian cancer cells had no 
significant effect on the cells’ sensitivity to cisplatin and paclitaxel48.  
1.1.3.4.4 Role and importance of BCAT1 are cancer-type dependent 
Although many studies have now linked BCAT1 expression to an aggressive tumour 
phenotype, it appears that the importance of BCAA metabolism in tumour growth is dependent 
on the tissue of origin. In a study comparing pancreatic ductal adenocarcinoma and non-small 
cell lung cancer, both resulting from the same TP53 and KRAS mutations, the dependence of 
the tumours on BCAA metabolism was very different, with lung cancer cells showing enhanced 
uptake of BCAAs and incorporation of the nitrogen from these amino acids into protein and 
non-essential amino acids, while pancreatic tumour cells did not show any differences in BCAA 
metabolism from healthy pancreatic tissue61. In addition, deletion of both BCAT1 and BCAT2 
genes led to a significantly reduced ability of the lung cancer cells to grow into tumours in vivo 
but not of the pancreatic ductal adenocarcinoma cells in the pancreas61. More recently, BCAT2 
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instead of BCAT1 has been linked to progression of pancreatic intraepithelial neoplasia in mice 
and BCAT2-mediated catabolism of branched chain amino acids has been shown to be critical 
for the development of KRAS mutation-driven pancreatic ductal adenocarcinoma62.  
1.1.4 Metabolic Heterogeneity in Cancer 
Cancer is characterised by a high degree of intertumoural and intratumoural heterogeneity, 
which is one of the factors contributing to the poor prognosis associated with many types of 
cancer. Cancer cells are heterogeneous in terms of their genetic make-up, their transcriptional 
profile and their metabolism. Therefore, even though there are some well-characterised 
metabolic alterations that commonly occur in cancer, not all of them are present in all cancer 
cells. 
Intratumoural metabolic heterogeneity can arise as a result of the heterogeneity of tumour 
perfusion, with some areas of the tumour being more vascular than others. This means that 
cancer cells in different regions of the same tumour experience different conditions in terms of 
nutrient availability and oxygen concentration. Cancer cells will adapt their metabolic 
phenotype to maximise survival and proliferation under the conditions where they reside, 
leading to metabolic heterogeneity within the tumour. 
Tumour heterogeneity poses many problems in clinical practice and in cancer research. Specific 
treatment for tumours works for cells that are sensitive to the treatment but due to the 
heterogeneity of the tumour, some cells will tend to be resistant to treatment and hence lead to 
cancer recurrence. Currently, the field of oncology is heavily reliant on tumour biopsies which 
are often used for staging the disease and for determining the treatment process to follow. 
However, due to intratumoural heterogeneity, the tumour biopsy sample is not necessarily 
representative of the whole tumour.  
In cancer research, many techniques involve studying tumour models, mainly xenografts in 
rodents, where the tumour is homogenised, and conclusions are drawn from studying the 
tumour homogenate. However, any measurements taken from the homogenate represent an 
average of the cells making up the tumour rather than the measurements of each individual cell. 
Therefore, techniques that can capture tumour heterogeneity are necessary for cancer research 
and for guiding treatment in clinical practice.  
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1.1.5 Targeting metabolism for cancer therapy 
Research into cancer metabolism has shown how metabolic changes facilitate cell proliferation 
and survival. These metabolic changes are sometimes essential for particular cancers, making 
them potential therapeutic targets. An example is the effective treatment of Acute 
Lymphoblastic Leukaemia (ALL) using asparaginase63. This enzyme reduces the concentration 
of circulating asparagine in plasma, which is essential for protein synthesis in cancer cells.  
Identifying targets for effective cancer therapy is challenging for a number of reasons. Firstly, 
toxicity can be a problem because metabolic enzymes play important physiological roles in 
healthy tissue. Secondly, many of the pathways that are reprogrammed in cancer cells are also 
reprogrammed in normal proliferating cells such as immune cells, therefore targeting those 
pathways will most likely lead to immunosuppression and other toxic effects64. Targets with a 
good therapeutic window are thus challenging to identify. 
Importantly, the high metabolic flexibility possessed by cancer cells as well as their ability to 
adapt to changing conditions, leads to the problem of resistance to treatment. A very small 
number of metabolic activities are involved in tumourigenesis, some are required for cancer 
progression, but many are dispensable in some cases15. For this reason, it is crucial to identify 
true metabolic liabilities of cancer cells, which will most likely require simultaneous targeting 
of different pathways, in order to effectively suppress tumour growth and significantly slow 
cancer progression.  
Over the last few years, research into cancer metabolism has identified a number of targets for 
potential therapy. For example, the observation that cancer cells consume high amounts of 
glucose, has triggered a lot of research into inhibitors of glycolysis. 2-Deoxyglucose, an 
analogue of glucose that is converted to 2-deoxyglucose-6-phosphate and accumulates in the 
cells, inhibiting hexokinase, has shown promising results in slowing down the proliferation of 
cancer cells in preclinical studies, but unfortunately has shown high toxicity in clinical 
trials64,65. In cancer types where specific enzymes are mutated, inhibitors against the mutated 
enzymes are being developed to target cancer cells. For example, inhibitors of mutant IDH1 
and IDH2 enzymes are currently being tested in clinical studies for the treatment of IDH mutant 
glioblastoma and AML64.  
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Further research into cancer metabolism will enable identification of novel metabolic 
dependencies of cancer as well as potential pathways that can be targeted simultaneously for 
maximising therapeutic effect. Importantly, methods of characterising the metabolism of 
individual tumours, such as metabolic imaging will facilitate targeted approaches to therapy 
which will maximise the chances of survival.   
1.2 Metabolic imaging 
Metabolic imaging techniques are valuable in cancer research and clinical practice, enabling 
investigation of cancer metabolism in a spatially dependent manner, thus capturing the 
metabolic heterogeneity of tumours. Metabolic Imaging techniques include Positron Emission 
Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), 13C 
Hyperpolarised Magnetic Resonance Spectroscopic Imaging (MRSI) and Mass Spectrometry 
Imaging (MSI). All these have shown promising results in pre-clinical and clinical studies in 
imaging cancer metabolism, characterising the metabolic profile of tumours, and in predicting 
and measuring treatment response. 
1.2.1 18F-FDG Positron Emission Tomography (PET) 
18F-FDG is a positron emitting glucose analogue that has been used extensively in the clinic to 
detect metastases using PET, hence staging the disease, and for monitoring treatment response. 
18F-FDG enters cancer cells through the upregulated GLUT transporters and accumulates in the 
phosphorylated form through the action of hexokinase. Tumours that are glucose avid show 
enhanced uptake and accumulation of 18F-FDG. One of the disadvantages of 18F-FDG, other 
than its radioactive nature, is that it can only provide information on the uptake of glucose but 
gives no information on glycolytic flux or downstream metabolism.  
1.2.2 13C Hyperpolarised Magnetic Resonance Spectroscopic Imaging 
(MRSI) 
13C Hyperpolarised MRSI is another promising metabolic imaging technique, that enables 
dynamic imaging of label exchange from a substrate of interest to one or more products of 
interest in vivo. The main principles of Nuclear Magnetic Resonance (NMR) are introduced 
here, followed by a brief introduction on 13C MRSI and its potential applications. 
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1.2.2.1 Nuclear Magnetic Resonance (NMR) 
NMR is based on the magnetic properties of some atomic nuclei. Several nuclei, including 1H 
and 13C, possess spin angular momentum, which gives them a magnetic moment. Nuclear 
magnetic moments are quantized, with nuclei existing in a set number of possible spin states66. 
1H and 13C nuclei have a spin quantum number of ½ and can only exist in two spin states. When 
an MR active spin ½ nucleus is placed within an external magnetic field, its magnetic dipole 
aligns either parallel or antiparallel with the direction of the external magnetic field. These two 
alignment options represent the two energy levels of the nuclear spin, with the energy difference 
between the two states being dependent on the magnetic field strength (B0) and the 
gyromagnetic ratio (g) of the nucleus. Usually, there is a small excess of parallel spins (low 
energy level) relative to antiparallel spins (high energy level), giving rise to a net magnetisation 
vector67. The spins do not align exactly with the external magnetic field but precess about this 
field (Figure 5) at a frequency, !, which depends on the identity and chemical environment of 
the nucleus. The precession frequency, !, is given by the Larmor equation: 
! = 	$ × &!"" 
where $ is the gyromagnetic ratio of the nucleus and Beff is the effective magnetic field that the 
nucleus experiences, which depends on the shielding effect of surrounding electrons68. 
Application of a radiofrequency (RF) oscillating magnetic field (B1) at frequency !, so that it 
is resonant with the precession frequency, results in the absorption of energy, flipping the spins 
between the two energy levels (Figure 5). Upon removal of the oscillating magnetic field, the 
excited nuclei realign with the external magnetic field (B0). Rotation of the decaying net 
magnetization vector within the x,y plane creates a current in the receiver coil, which represents 
the signal and is called the Free Induction Decay (FID). Applying the RF oscillating magnetic 
field in the form of a short pulse covers a range of resonance frequencies and Fourier transform 
of the resulting FID produces a spectrum of absorbances, from which the chemical structure of 




Figure 5 Net magnetisation vector. (A) When MR active nuclei are positioned in a magnetic field B0, the magnetisation vectors 
associated with their nuclear spin precess around B0 at a characteristic precession frequency, with the net vector aligned with 
B0. (B) Upon application of an oscillating magnetic field B1 in the form of an RF pulse, the net magnetisation vector that lies 
along B0 is tilted into the xy plane. 
The most commonly imaged nucleus in MRI is 1H due to the sensitivity of the proton to NMR 
detection (high g) and the abundance of water in biological systems. The voxel intensity 
depends on the proton density of the tissue as well as two tissue-specific parameters: the 
longitudinal relaxation time, T1, which is a measure of the time required for the magnetic 
moments of the excited nuclei to return to equilibrium and the transverse relaxation time, T2, 
which is a measure of the time taken for the FID signal to decay in the x,y plane as a result of 
natural interactions at the atomic or molecular level. However, in real NMR experiments, the 
observed signal in the x,y plane decays faster than what would be expected by these 
interactions. Therefore, another time constant, the effective T2, also known as T2* is defined, 
which is mainly the result of inhomogeneities in the magnetic field. Many of the processes 
leading to T2* decay are reversible, meaning that if a second RF pulse is applied some time 
after the initial RF pulse, the dephased spins can be rephased, generating a spin echo (Figure 
6). The time between the middle of the first RF pulse and the peak of the spin echo is defined 
as the echo time (TE). The repetition time, TR, is the time delay between the repetition of the 




Figure 6 Principle of a spin echo. After the 90o excitation pulse, the signal decays quickly due to T2* relaxation processes. In 
order to eliminate the T2* related effects, a rephasing 180o excitation pulse is applied which refocuses the magnetisation and 
generates a second FID, enabling measurement of T2 relaxation. 
The pulse sequence used for signal acquisition determines the contrast created between different 
tissues by determining which of the decay parameters will more significantly affect the 
observed signal. In general, a long TR minimises the effects caused by T1 relaxation since the 
spins have enough time to relax before the excitation pulse is repeated. A short TE minimises 
the T2 mediated effects because there is not enough time for T2 relaxation to be observed 
between the excitation and the echo. Therefore, a pulse sequence with a short TR and a short 
TE enables T1 weighted contrast, where the contrast generated will depend on the differences 
in T1 constants between the tissues being imaged. For T2 weighted imaging, a long TR and a 
long TE are used.  
In MRI, magnetic field gradients enable spatial encoding of the FID. The resonant frequency 
of the detected nucleus is directly proportional to the applied magnetic field, therefore by 
varying the magnetic field across the sample, the resonant frequency of the nucleus becomes a 
function of its position in the sample. For encoding in the axial dimension, a magnetic field 
gradient is added to the constant homogeneous magnetic field, B0, enabling excitation of a 
specific slice by modulating the frequency of the RF pulse (Figure 7). For two dimensional in-
plane spatial reconstruction, phase encoding (Figure 7) and frequency encoding gradients are 
implemented. For frequency encoding, a magnetic field gradient is applied during signal 
acquisition. As a result, nuclei at different locations along the gradient resonate at different 
frequencies. For phase encoding, the gradient is applied between the excitation and signal 
acquisition, leading to changes in the precession frequencies of nuclei in different locations and 
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hence a phase difference at the time of acquisition. This enables three-dimensional localisation 
of the signal and hence the acquisition of images. 
 
 
Figure 7 Spatial encoding of NMR signal using gradients.(A) Slice selection is achieved by frequency encoding. A linear 
gradient is applied in the direction of B0, modulating the total magnetic field for each axial slice in the magnet. The Larmor 
frequency is therefore different for nuclei located at different axial positions, enabling slice selection by excitation with a 
specific bandwidth. (B) Phase encoding uses gradients in the x or y dimension, after the nuclear spins have been excited. The 
top trace represents the signal from a reference nucleus and the second trace represents the signal from a nuclear spin 
subjected to a magnetic field gradient. The gradient causes the nuclear spin to precess at a different frequency and over time 
this leads to a permanent phase shift. 
Magnetic Resonance Spectroscopic Imaging (MRSI) enables the determination of the spatial 
distribution of nuclei with a particular resonance frequency, as opposed to conventional MRI, 
where no distinction is made with regard to the chemical shift of the resonance68. By taking 
advantage of the differences in resonance frequencies of nuclei in different molecules, specific 
molecules of interest can be imaged, as long as they are abundant enough to generate sufficient 
signal. 
1.2.2.2 Chemical Shift Imaging 
Chemical Shift Imaging (CSI) is a pulse sequence that enables MRSI. It applies phase encoding 
in one, two or three dimensions, to image a column, slice or volume, respectively, before the 
read phase of the sequence to enable the acquisition of a spectrum for each voxel in the image69 
(Figure 8). More complex versions of this sequence are being developed to maximise the 




Figure 8 Chemical Shift Imaging (CSI). (A) For acquisition of spectra from a slice with spatial encoding, a slice selection  
gradient can be used, along with phase encoding gradients in the x and y dimensions. An FID is acquired for every combination 
of phase encoding gradients. (B) Spatial encoding splits the slice into a grid whose resolution is determined by the number of 
phase encoding steps in the x and y dimensions. (C) A spectrum is acquired from each of the voxels in the grid.  
13C is an MR active spin ½ nucleus, therefore carbon spectra could potentially be acquired at 
different locations in a tissue using MRSI. However, the very low natural abundance of 13C 
(1.1%) in combination with its small gyromagnetic ratio, renders 13C MRI very insensitive67. 
Therefore, even when multiple scans are acquired and averaged over long periods of time, the 
13C spectra acquired would suffer from very low signal-to-noise ratios (SNR)67. 
Hyperpolarisation has been used to increase the SNR of 13C MRI, by increasing the excess of 
spins aligned with the external magnetic field. Polarisation refers to the number of spins that 
are aligned parallel to the external magnetic field relative to the total number of spins. 
Therefore, by increasing the number of spins aligned with the external magnetic field, the 
percentage polarisation in the sample is increased, and this leads to a larger net magnetisation 
vector and hence larger signal following an excitation pulse.  
Dissolution dynamic nuclear polarization (DNP) is the most commonly used hyperpolarisation 
method67. This technique involves polarising electron spins, which are more easily polarised 
than 13C nuclear spins, using very low temperatures (~ 1K). The polarisation can then be 
transferred from electrons to protons using microwave irradiation. A 13C labelled metabolite of 
interest is dissolved in a suitable solvent, usually containing a stable radical as the source of 
unpaired electrons, and a glass forming agent70. The role of the glass forming agent is to ensure 
that an amorphous solid is formed upon cooling of the sample, so that the electron spins are 
homogeneously distributed70. This solution is placed in a strong magnetic field at very low 
temperatures (~1 K), where the electron spins of the free radical are almost fully polarised. This 
polarisation can then be transferred to the nuclear spins using microwave irradiation at the 
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electron spin resonance frequency, achieving nuclear spin polarisations of 20% - 40%71. Then, 
to remove the hyperpolarised compound from the polariser, rapid dissolution is performed with 
a superheated buffer67. Upon injection of the hyperpolarised substrate in an animal, the 
distribution of the substrate and its conversion to different metabolites can be traced, achieving 
a >10,000-fold increase in the SNR70. 
The limitation, however, of this technique is that the hyperpolarisation is transient, with the 
lifetime of the hyperpolarisation being dependent on the T1 relaxation time constant of the 
hyperpolarised nucleus. Additionally, part of the hyperpolarisation is lost as a result of each 
excitation pulse. Therefore, long acquisitions cannot be performed71. For this reason, very 
efficient MRI sequences need to be developed to achieve maximum signal acquisition for the 
duration of the hyperpolarised spin state. The short-lived polarisation also limits the reactions 
that can effectively be imaged in vivo. For a hyperpolarised experiment to be successful, the 
substrate needs to enter cells and be converted to the product of interest quickly.  
Many substrates of interest have been hyperpolarised and used in pre-clinical imaging studies 
in cancer. These include hyperpolarised 13C-labelled pyruvate, glucose72, glutamine73 and 
glutamate74. Hyperpolarised [1-13C]pyruvate has already been translated to the clinic, where it 
has shown promising results in a number of cancers, including prostate 75 and breast cancer76. 
The 13C label on position 1 of pyruvate does not enable the investigation of the TCA cycle 
whereas uniformly labelled 13C pyruvate would be more informative. However, only [1-
13C]pyruvate has been translated to the clinic owing to its advantageous polarising 
characteristics77. 
1.3 Glioblastoma 
Gliomas constitute a group of tumours of the cerebral hemispheres. They are classified by the 
World Health Organisation (WHO) into four grades based on histopathological and clinical 
criteria (WHO I-IV)78. WHO I tumours are benign, WHO II and WHO III are low-grade diffuse 
gliomas (LGG), and WHO IV tumours are highly malignant glioblastoma tumours. 
Glioblastoma Multiforme (GBM) constitutes the most common and most malignant type of 
primary tumour of the adult central nervous system (CNS)79. The annual incidence of 
glioblastoma is 5.26 per 100 000 population78. Glioblastoma has a very poor prognosis, with a 
5-year survival rate of less than 5%, coupled with the poor quality of life and cognitive decline 
that it can cause78. These tumours are highly infiltrative in the surrounding parenchyma but are 
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typically confined within the CNS. Grade II gliomas have low cell proliferation rates and hence 
progress more slowly, therefore they tend to show better survival rates (median 12-16 years) 
compared to Grade IV glioma (median survival less than 17 months)80. 
Multiple genetic changes have been associated with glioma genesis, including mutations, 
amplifications, deletions and translocations of oncogenes such as EGFR, PI3K and KRAS and 
tumour suppressors such as TP53, PTEN, and NF1. A subgroup of gliomas also harbour 
mutations in the isocitrate dehydrogenase genes IDH1 and IDH219,81. 
The classification of gliomas based on histological features does not provide good prognostic 
information and cannot guide treatment. Therefore, glioblastoma tumours have also been 
characterized based on their genomic profiles, leading to the identification of four molecular 
subtypes of glioblastoma: proneural, neural, classical and mesenchymal81. 
Diagnosis of GBM is usually achieved following clinical presentation of unilateral, 
progressively more severe headaches, personality changes and occasionally, gait imbalance, 
which lead to a diagnostic brain MRI examination. These symptoms are the result of oedema 
and raised intracranial pressure, caused by angiogenesis and blood vessel hyperpermeability, 
and high secretion rates of excitotoxic glutamate from tumour cells, leading to neuronal cell 
death80. The current treatment guidelines for glioblastoma include surgery if indicated, followed 
by adjuvant radiotherapy combined with chemotherapy (e.g. temozolomide)78. However, 
treatment is not curative, primarily due to the high invasiveness of the cancer, which means that 
at the time of treatment initiation, the cancer has already infiltrated the surrounding brain 
parenchyma. At the time of surgical resection, individual groups of cells can be found at sites 
as far as 2 cm from the main tumour site and hence escape detection by imaging (MRI) and 
removal by surgery80. 
1.3.1 Pre-clinical Models of Glioblastoma 
Cancer research, including glioblastoma is dependent on pre-clinical models. Pre-clinical 
models of glioblastoma are usually tumours grown in mouse or rat brains and include cell-based 
xenografts, patient derived xenografts and genetically engineered mouse models79. 
Commercially available glioblastoma cell lines such as U87 and U251 cells were derived from 
glioblastoma patients and are commonly grown in vitro in culture media which are 
supplemented with Foetal Bovine Serum (FBS). These cells can also be implanted intracranially 
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in the brains of immunocompromised rats or mice. They are characterized by high engraftment 
rates and reproducible tumour growth, but are not representative of human glioblastoma. Some 
of these cell lines in particular, including U87 and U251 cells, have been in culture for many 
years and have drifted from the original cells over the years82. Genetic profiling and 
transcriptome analysis of commercially available U87 cells, revealed that these cells were of 
CNS origin but they did not match the original patient derived cells83. Also, recent sequencing 
of U87 cells revealed many indels, copy number variations and translocations, which have 
probably been acquired through culturing the cells in vitro84. Additionally, the histopathological 
features of xenografts derived from U87 cells are not similar to human glioblastoma85. 
Patient-derived xenografts perform better in terms of maintaining the genetic and histological 
features of the original primary tumour. These models can be established by directly implanting 
biopsied tissue into immunocompromised mice, or by culturing patient-derived cells in vitro in 
serum-free media and then injecting these intracranially in mice84. The main disadvantage of 
these models is their poor engraftment rate. Xenografts in immunocompromised rodents, either 
derived from commercially available cell lines, or directly from patients have the limitation that 
the immune component of the microenvironment cannot be studied. 
Genetically engineered mouse models are established by manipulating gene expression, leading 
to overexpression or inactivation of particular genes at particular timepoints or in specified 
cells. These models are useful for identifying genetic alterations causing tumour initiation and 
progression while preserving the tumour microenvironment86. In glioma models, 
overexpression of certain oncogenic proteins, such as wild type EGFR87 or mutant IDH1 and 
PDGF88 can be used to generate tumours. Limitations of these models include the time and cost 
associated with generation and maintenance of the transgenic mice. Recently, injection of viral 
vectors have been used to allow temporal and spatial control of tumour development87.  
1.3.2 Genetic changes associated with gliomas 
1.3.2.1 Isocitrate Dehydrogenase (IDH) mutations in gliomas 
IDH catalyses the oxidative decarboxylation of isocitrate to α-KG and the concomitant 
reduction of NAD(P) to NAD(P)H. IDH1 is localised to the cytoplasm and peroxisomes and 
IDH2 is the mitochondrial isoform of the enzyme. In the human brain, it is estimated that IDH 
catalysed reactions are responsible for the generation of 65% of cytosolic NADPH, which is 
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required for the production of scavengers of reactive oxygen species80. IDH1 and IDH2 
heterozygous point mutations have been described in gliomas and acute myeloid leukaemia. In 
glioma, they are likely to be involved in gliomagenesis89. These mutations usually occur on 
residue R132 of IDH1 and residue R172 of IDH2, which are in the catalytic domains of the 
proteins. IDH1 mutations are very common in low-grade gliomas (present in 80% of grade II 
and III gliomas and secondary glioblastoma) but quite rare in primary glioblastoma (present in 
10% of primary glioblastoma)89. These mutations lead to a reduced affinity of the catalytic 
domain for isocitrate and an increased affinity for α-KG as well as a neomorphic function of 
the enzyme, the reduction of α-KG to 2-hydroxyglutarate (2HG) and the consumption of 
NADPH80. Hence, IDH mutations lead to reduced activity of wild type IDH, reduced formation 
of α-KG and conversion of α-KG to the oncometabolite 2HG, while consuming NADPH. As 
discussed earlier in this chapter, 2HG resembles α-KG structurally and as a result it inhibits 
competitively many α-KG dependent enzymes including the TET (Ten-Eleven-Translocation) 
family and Jumonji-C-domain containing histone demethylases (JHDMs)80. This results in 
DNA and histone hypermethylation.  
Despite the role of IDH mutations in gliomagenesis, IDH mutations were shown to be 
independent prognostic markers for improved overall survival and progression free survival in 
a meta-analysis89. 
1.3.2.2 TP53 mutations in gliomas 
The TP53 gene is a tumour suppressor gene that is commonly mutated in many cancers, 
including glioblastoma. It encodes the p53 protein, a tetrameric transcription factor. In healthy 
cells, the levels of p53 are kept low through ubiquitination and degradation and p53 activity is 
induced in response to stress signals, in particular relating to DNA damage. P53 induction leads 
to cell cycle arrest, senescence and apoptosis and more recently it has been shown to regulate 
amongst others, stem cell differentiation and cellular metabolism90. 
The p53 pathway is commonly deregulated in glioblastoma with the highest prevalence of TP53 
mutations being observed in the proneural and mesenchymal molecular classes of glioblastoma. 
The pathway is also deregulated through changes in other components of the pathway, such as 
amplification of MDM2 and MDM4 genes and deletion of the CDKN2A/ARF locus, all of 
which are regulators of p53 activity. 
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1.3.3 Glioma Stem-like cells (GSCs) 
The notion that there is a population of cells within glioblastoma, known as the glioma stem-
like cell (GSC) population, has become increasingly popular. These cells, also known as 
tumour-initiating cells (TICs), share properties with neural stem cells and are believed to be 
responsible for tumour maintenance and progression91. They have also been associated with 
tumour recurrence and resistance to treatment92,93. GSCs are characterised by expression of 
certain stem cell markers, including Sox2 and CD133 and they are enriched near necrotic 
regions in the tumour, with low oxygen and nutrient levels94. 
Functionally, GSCs are identified by their ability to form neurospheres, also known as 
tumourspheres, in cell culture, and also tumours in vivo. Limiting dilution assays have been 
used, both in vivo and in vitro, to estimate the frequency of glioma stem-like cells in a mixed 
population of cells. This is achieved by establishing the minimum number of cells in the mixed 
population that is required for a tumoursphere to form in vitro, or a tumour to form in vivo. 
Limiting Dilution Analysis (LDA) is a statistical interpretation of these assays, which assumes 
a Poisson single-hit model, where the number of glioma stem-like cells, in this case, follows a 
Poisson distribution and where a single glioma stem-like cell is sufficient to generate a 
tumoursphere in vitro or a tumour in vivo95. 
A number of transcriptional and metabolic pathways have been shown to facilitate the 
maintenance of a stem-like phenotype in cells. For example, Forkhead box protein M1 
(FOXM1) is a transcription factor that has been shown to play an important role in the 
proliferation of GSCs96,97,98. ALKBH5 (alpha-ketoglutarate-dependent dioxygenase alkB 
homolog 5) is upregulated in glioblastoma and is associated with a poor prognosis based on 
data from The Cancer Genome Atlas (TCGA), R2 and REMBRANDT92. Immunohistochemical 
analysis of human GBM tissue showed ALKBH5 to be co-expressed with SOX2, indicative of 
stem-like cells. Knockdown of ALKBH5 in patient-derived cells led to reduced tumoursphere 
formation frequency and downregulation of SOX2, Nanog and Oct5, which are the transcription 
factors enabling self-renewal. In the same study, FOXM1 was shown to be a direct downstream 
target of ALKBH5 in GBM. 
Other genes whose expression levels correlated with SOX2 in the TCGA GBM dataset include 
ABHD4, ANP32E, CENPF, FANCI and FOXM1, suggesting that these might be related to the 
glioma stem-like cell profile92. 
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1.3.4 Epithelial to Mesenchymal Transition in Glioblastoma 
The highly invasive nature of GBM has been partly attributed to the migratory capacity of 
glioma cells, which is thought to result from an epithelial to mesenchymal transition of the cells. 
Epithelial to mesenchymal transition (EMT) is the process whereby epithelial cells undergo 
several biochemical processes and gain mesenchymal properties, characterised by weak cell 
adhesions and enhanced migratory capacity99. EMT is a phenotypic switch that is associated 
with cancer initiation, invasion and metastasis100. Three types of EMT have been described, 
namely Type I, which is involved in embryogenesis and organ formation, Type II, which is 
involved in wound healing and scar formation and Type III, which is associated with cancer 
progression and metastasis. EMT is different in glioblastoma, when compared to other cancer 
types and for this reason, it is sometimes referred to as Glial-to-Mesenchymal (GMT) transition 
instead. The reason for this is that glial cells originate from neuroepithelial cells, which are 
different from classical epithelial cells, but nonetheless glioma cells transition into a more 
mesenchymal-like phenotype.  
A number of signalling pathways and transcription factors have been associated with EMT in 
glioblastoma, including Snai1, ZEB and Twist. Snai1 is a transcriptional repressor which binds 
to epithelial phenotype promoting genes. It is regulated by a number of signalling pathways, 
including Wnt, HIF-1α, TGFβ and PI3K/AKT99. Similarly, ZEB1 binds to E-boxes in the 
regulatory regions of genes, leading to repression of epithelial genes and activation of 
mesenchymal genes. ZEB1 expression has been shown to be inversely correlated with survival 
in GBM patients and ZEB1 knockdown cells were shown to grow less invasive tumours in mice 
compared to ZEB1 expressing cells99.  
1.3.5 Cancer cell invasion 
The ability of cancer cells, especially glioblastoma cells, to invade through the surrounding 
normal tissue is closely related to the dismal prognosis of the disease because by the time of 
diagnosis, enough cancer cells have already invaded normal surrounding tissue, which can lead 
to relapse following tumour resection. Cancer cells penetrate the basement membrane by 




Cancer cell invasion is dependent on tissue remodelling, involving degradation of the 
extracellular matrix surrounding the tumour57. Tissue remodelling is enabled through the action 
of matrix metalloproteinases (MMPs), which are mostly produced by stromal fibroblasts within 
tumours.  
1.3.6 Transcription Factors in Glioblastoma 
Cancer progression and its ability to adapt to the changing environment is dependent on a 
number of different transcription factors which regulate gene expression in the cancer cell. 
Some transcription factors that have been implicated in glioblastoma and more generally in 
cancer are Hypoxia Inducible Factor (HIF), FOXM1 and c-Myc. 
1.3.6.1 Hypoxia Inducible Factor 
HIF1 is one of the transcription factors orchestrating the response of cells to hypoxia. It is a 
heterodimer, consisting of HIF1-α and HIF1-β subunits. HIF1-β is expressed constitutively, but 
HIF1-α stability is tightly controlled by oxygen availability. Under normoxic conditions, both 
prolines of the oxygen-dependent degradation (ODD) domain of HIF1-α are hydroxylated by 
prolyl hydroxylase domain (PHD) – containing proteins, in the presence of iron, α-KG and 
ascorbate. The best-studied PHD enzyme is PHD2, also known as EGLN1 (Egl-9 family 
hypoxia inducible factor 1). Proline hydroxylated HIF1-α is recognised by the von Hippel-
Lindau tumour suppressor (pVHL) E3 ligase complex leading to its ubiquitination and 
degradation by the proteasome102. PHDs act as oxygen sensors owing to their Km of around 100 
μM for oxygen. Oxygen concentrations in tissues is around 10-30 μM, therefore, oxygen is 
normally the rate-limiting factor for the activity of PHDs under physiological conditions27. 
Under hypoxic conditions, the activity of PHD is reduced, leading to HIF1-α stabilisation. 
When HIF-1α is stabilised, it binds to HIF-1β and the heterodimer translocates to the nucleus 
and binds to the hypoxia-responsive element of target genes, which is located either proximal 
or distal to the promoter region103,104.  
HIF1 has been shown to play an important role in cancer, not only in enabling survival of cells 
where oxygen availability is limited, but also in facilitating growth and progression of cancer. 
It is implicated in glucose metabolic processes, shifting energy metabolism from oxidative 
phosphorylation to glycolysis104, extracellular matrix remodelling and EMT103 and 
angiogenesis in tumours via upregulation of genes for proangiogenic factors including Vascular 
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Endothelial Growth Factor (VEGF), Platelet-derived Growth Factor type B (PDGF-B), 
hepatocyte growth factor, epidermal growth factor and angiopoeietin-2. It also regulates cell 
proliferation and chemotaxis and is implicated in stem cell maintenance through induction of 
NANOG, Oct-3/4 and SOX2 expression. Hypoxic tumours have been associated with an 
increased risk of mortality independently of other prognostic factors105.  
In cancer, HIF-1α is commonly stabilised even in the presence of high O2 tension, in a process 
known as pseudohypoxia. Pseudohypoxia can be a result of mutations in succinate 
dehydrogenase (SDH) and fumarate hydratase (FH), which lead to accumulation of succinate 
and fumarate, respectively. Both metabolites compete with α-KG for PHD binding thereby 
inhibiting PHD and leading to HIF-1α stabilisation102. In addition, mutations in isocitrate 
dehydrogenase leading to reduced generation of α-KG and accumulation of 2HG can cause 
HIF-1α stabilisation. 
1.3.6.2 Forkhead box M1 (FOXM1) 
FOXM1 is one of the target genes of HIF1103,106. It is a member of the Forkhead box protein 
family and it has been shown to be upregulated in human GBM and is associated with poor 
prognosis107. Additionally, the expression levels of FOXM1 were correlated with glioma 
grade107. 
FOXM1 is known to regulate the cell cycle in the G1/S transition, G2/M transition and M phase 
progression92. Other than its regulatory role in cell proliferation, FOXM1 has been shown to 
play many roles in glioblastoma, including cell invasion108, maintenance of a stem-like 
phenotype92, regulation of tumourigenesis through Wnt signalling97 and radioresistance96,109,110. 
The expression of FOXM1 was shown to be upregulated in irradiated GBM cells in vitro and 
in vivo109. Conversely, inhibition of FOXM1 radiosensitised cells109. 
1.3.6.3 C-Myc 
c-Myc belongs to a family of Myc oncogenes that regulate cell growth and differentiation. 
These encode DNA-binding proteins that act as transcription factors. C-Myc forms a 
heterodimer with Max, which can then bind to DNA and promote transcription of target genes. 
c-Myc is a well-known oncogene, which has been shown to lead to transformation of normal 
cells in cooperation with an activated RAS oncogene111. 
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c-Myc regulates metabolic reprogramming in cancer cells, with target genes involved in 
glycolysis, glutaminolysis and nucleotide and lipid synthesis pathways14. In addition to its role 
in metabolic regulation, c-Myc is involved in the maintenance of stem-like cells. In transformed 
human keratinocytes, ectopic overexpression of c-Myc led to an increased stem cell fraction 
and enhanced tumourigenicity112. In gliomas, c-Myc expression correlates with grade of 
malignancy113. In a mouse model of glioblastoma, higher levels were expressed in the glioma 
cancer stem cell population when compared to the matched non-stem cell population in the 
same tumour, and c-Myc activity enabled the proliferation and survival of these cells91. 
Conversely, knockdown of c-Myc in stem-like glioma cells abolished tumour formation in 
mice91. 
1.4 Thesis Overview 
The primary aim of this project was to explore the utility of hyperpolarised 13C imaging in non-
invasive imaging of cancer metabolism. In the first part of the thesis, hyperpolarised [1-
13C]pyruvate imaging was cross validated by comparison with Mass Spectrometry Imaging, 
another novel metabolic imaging technique. This was achieved by comparing the [1-13C]lactate 
tumour images that were generated by hyperpolarised 13C MRSI in vivo in a subcutaneous 
murine lymphoma tumour, with [1-13C]lactate images from corresponding tissue sections of the 
tumours ex vivo. 
In the second part, the role of branched chain amino acid metabolism in glioblastoma was 
investigated and the potential of hyperpolarised 13C-labelled ketoisocaproic acid as a novel 
substrate for imaging BCAT activity in glioblastoma was assessed. The roles of BCAT1 and 
BCAT2 in the metabolism of patient derived models of glioblastoma were explored and the use 
of hyperpolarised 13C-labelled ketoisocaproic acid for imaging BCAT activity was evaluated in 
these same models. 
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Chapter 2 - Co-registering Mass 
Spectrometry Images with Hyperpolarised 
13C MRI 
 
2.1 Abstract  
There has been increasing interest in using Mass Spectrometry Imaging and Hyperpolarised 13C 
Magnetic Resonance Imaging for interrogating metabolism in vivo. However, concerns have 
been expressed about the validity of the measurements obtained using these two techniques. 
This study compared dynamic, in vivo magnetic resonance images of [1-13C]lactate in a 
subcutaneous murine lymphoma tumour following a bolus injection of [1-13C]pyruvate with 
endpoint ex vivo mass spectrometry images of [1-13C]lactate in the corresponding frozen 
sections from the same tumours. A positive correlation was observed when comparing the 
lactate maps generated by the two modalities. The complementary additional data provided by 
each modality was used to gain further insight into the dynamics of tumour lactate labelling 





2.2.1 Principles of Mass Spectrometry 
Mass Spectrometry is an analytical technique that is used to quantify specific compounds and 
their isotopic composition. The principle behind the technique is the generation of ionized 
species, which are separated according to their mass-to-charge (m/z) ratios. Detection of these 
ions can be used to generate a spectrum whereby the abundance of each ionized species is 
plotted against its m/z ratio. A mass spectrometer consists of an ion source, which generates the 
ionised species from the compound or compound mixture to be analysed, a mass analyser, 
which separates the ions according to their m/z ratio using electromagnetic fields, and a 
detector, which generates an abundance profile for each species114.  
2.2.2 Mass Spectrometry Imaging 
Mass Spectrometry Imaging (MSI) adds another dimension to the data, which is the spatial 
distribution of the compounds. Ionized species are generated from a surface, such as a tissue 
section, in a raster scan fashion. The ions are fed into a mass spectrometer and a mass spectrum 
is generated per pixel analysed, hence the spatial information is preserved (Figure 9). MSI can 
be applied in an exploratory manner, whereby the molecular patterns of different parts of the 
tissue, as segmented by histology, are compared and the molecules that are significantly 
different in the different regions are identified. Alternatively, MSI can be used to visualise the 




Figure 9 Principles of Mass Spectrometry Imaging. (A) The surface is scanned in a raster fashion and ions are generated 
from each pixel, resulting in the acquisition of a mass spectrum per pixel (B). (C) False colour images illustrating the relative 
intensities of specific metabolites across the surface can be generated. 
2.2.2.1 Ion source 
The ionization process in MSI is different to bulk Mass Spectrometric analysis in that the ions 
need to be generated from each pixel on the surface, therefore the ionizing beam needs to be 
directed onto the surface and moved with high precision to scan the surface pixel-by-pixel. The 
methods used in conventional mass spectrometry to extract the analytes and separate them 
chromatographically cannot be used in this case because the topographic information needs to 
be preserved and hence novel methodologies have evolved115. A number of different ionization 
techniques have been applied to MSI, which include MALDI (Matrix Assisted Laser 
Desorption Ionisation), SIMS (Secondary Ion Mass Spectrometry) and DESI (Desorption 
Electro-Spray Ionisation). The performance of MSI is highly dependent on the efficiency with 
which the ions are generated from the surface to be analysed115.  
In MALDI, the surface to be analysed is coated with a matrix, usually an organic acid, which 
forms uniform microcrystals and protects the analytes from being destroyed from the high 
energy laser beam. For imaging, the section is placed on a stage which moves very precisely 
(less than 1 μm lateral resolution) and at each pixel the laser beam is directed onto the section, 
generating ions from a 5 μm diameter circular region114. MALDI has the advantage of detecting 
molecules with a wide range of molecular weights, but the application of a matrix could be seen 
as a disadvantage since it might affect the spatial distribution of molecules. Another 
disadvantage of MALDI is that it usually needs to be performed under vacuum115. 
60 
 
SIMS is another ion generating technique, which utilises a beam of very high energy primary 
ions to hit the surface to be analysed. The high energy collisions generate secondary ions from 
the surface very efficiently, which can then be analysed by mass spectrometry. SIMS can 
produce spatial maps of small molecules with high efficiency. However, due to the high energy 
of the primary ions, SIMS needs to be performed under vacuum to prevent collisions of the 
primary ions before they reach the surface115.  
DESI is an ionisation method that can be used in ambient conditions, leaving the sample in its 
native condition, hence enabling further analysis (e.g. histology) to be performed. In DESI, an 
electrospray emitter is used, which generates and directs charged droplets of solvent onto the 
surface to be analysed. In this way, the surface is coated with a thin layer of solvent, which 
dissolves the compounds on the surface. The charged solvent particles generate secondary 
ionised droplets from the surface which are then fed into the mass analyser. The secondary 
droplets, which contain the ionised analyte, can be transported through the air for some distance 
before entering the mass analyser (Figure 10). This ionisation method has a lower spatial 
resolution that SIMS and MALDI, with DESI images generally acquired at 180-220 μm, 
although resolutions of up to 100 μm are achievable116. Due to the differences in ionisation 
mechanisms, these techniques differ in the efficiency with which they ionise particular 
molecules. For example, lipids are more readily ionised by DESI whereas peptides and proteins 
are more readily ionised by MALDI117. 
 
Figure 10 Schematic Diagram of DESI MSI. An electrospray is guided towards the surface to be analysed. Charged solvent 
particles hit the surface and dissolve the analytes on it to generate secondary ionised droplets which are fed into the mass 
analyser. The stage usually moves in a raster scan to generate ionised particles from each pixel. 
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2.2.2.2 Mass analyser  
The Mass analyser is the component which determines the m/z ratio. Different types of mass 
analysers have been developed, including quadrupole, ion trap, time-of-flight and Fourier 
transform analysers118. Orbitrap analysers are a type of Fourier transform analyser, where an 
electric field is used to induce oscillations in the paths of the generated ions. The time-domain 
signal generated by these oscillations is Fourier transformed to the frequency domain, whereby 
the axial harmonic frequencies of individual ions are proportional to the m/z ratio. Orbitrap 
analysers have very good mass resolving power118. 
2.2.3 Applications of Mass Spectrometry Imaging in Medicine 
Molecular imaging is of crucial importance to medicine as it enables the gathering of 
information about the pathology of a tissue, in addition to the morphological information that 
is obtained using traditional imaging techniques. Biomarkers of disease can be detected using 
molecular imaging which can then have diagnostic and prognostic importance.  
The ability of MSI to perform chemical imaging in a non-targeted and label-free way119, makes 
it a good discovery tool in the field of biology and biomedicine120. MSI can be performed on 
biological tissue sections, generating an enormous dataset which can then be analysed 
according to the purpose of the study. For example, the spatial distribution of particular ions of 
interest can be imaged. Alternatively, a more explorative approach can be used, where non-
supervised clustering analysis can be performed to delineate regions of similar molecular 
phenotypes. Then, by comparing the mass spectra of different regions, the molecular signatures 
of particular regions can be identified. The very high spatial resolution of MSI, typically on the 
subcellular scale, enables direct comparison between the MSI image and histological images of 
the same or an adjacent section.  
MSI has already been applied to the study of cancer, mainly as a way of looking for novel 
tumour biomarkers or as a way of better visualising tumour margins. For example, in a proof-
of-concept study in breast cancer, DESI was used to distinguish between cancerous and healthy 
breast tissue. The intensities of several fatty acids, such as oleic acid were used to identify 
tumour margins and the delineation generated by DESI correlated well with histological 
staining. The authors suggested that this study demonstrates the potential for DESI to be used 
as a quick intraoperative way of increasing the accuracy of tumour resection121. Similarly, DESI 
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has been used in the operating room during surgical resection of IDHmut glioblastoma. In this 
case, DESI was used to detect the oncometabolite 2-hydroxyglutarate, which correlated with 
tumour content and thus delineated the tumour margin122.  
Even though MSI seems to be a very promising technique, it comes with some limitations, 
which have slowed down its translation into clinical practice. One of its limitations includes the 
strong dependence of the data acquired by MSI on sample collection and preparation, which 
creates problems with reproducibility. Also, despite the many efforts to obtain quantitative data 
from this technique, this still proves to be difficult, due to the high dependence of the ion signal 
on the chemical and morphological environment of the location of interest123. This is because 
the efficiency with which ions of the substrate of interest are generated from the surface depends 
on the other substrates that are present. It is therefore necessary to include internal standards in 
any sample, otherwise, no quantitative conclusions can be drawn123. Another limitation of MSI 
is that peak assignment is often solely based on the m/z values, which can sometimes be a 
problem for distinguishing metabolites with very similar masses. A lot of research is now 
focusing on developing better protocols to enable the acquisition of reproducible and 
quantitative data using MSI. 
The ability of MSI to detect small molecules could potentially revolutionise the study of 
metabolomics. For example, MSI could be used to image a section containing a tumour next to 
healthy tissue and from this, metabolic differences between healthy tissue and cancerous tissue 
could be derived, leading to a better understanding of tumour metabolism. Additionally, 
metabolic heterogeneity within the tumour tissue could be explored by utilising the high spatial 
resolution of MSI.  
2.2.4 Hyperpolarised 13C pyruvate imaging 
13C MRSI of hyperpolarised 13C-labelled cell substrates enables rapid non-invasive imaging of 
tissue metabolism in vivo124. Exchange of hyperpolarised 13C label between injected [1-
13C]pyruvate and the endogenous lactate pool, in the reaction catalysed by lactate 
dehydrogenase (LDH) has been the most commonly studied metabolic reaction. Hyperpolarised 
[1-13C]pyruvate has been used clinically, with promising applications, such as disease staging 
in prostate cancer125,126, and for detecting tumour responses to treatment75. The limitations of 
13C MRSI with hyperpolarised substrates include the transient nature of the hyperpolarization, 
which means that only relatively rapid metabolic reactions can be studied, and the difficulty of 
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relating signal intensity to concentration, which means that typically only apparent first order 
rate constants describing the isotope flux are quoted, rather than the metabolically relevant 
fluxes, expressed for example in mM/min127. 
2.2.5 Aims of the study 
The combination of hyperpolarised MRSI with MSI offers new opportunities to investigate the 
metabolic phenotypes of cancers. Coupling the capability of hyperpolarised MRSI to produce 
dynamic images of the interconversion of metabolites in three dimensions, with the ability of 
MSI to acquire information on a very large number of metabolites with high spatial resolution, 
we will be able to better understand tumour metabolism and interpret the hyperpolarised MRSI 
data.  
The aim of this study was to perform hyperpolarised [1-13C]pyruvate imaging and MSI on the 
same tumours, to directly compare the data generated by the two techniques as a way of cross 
validating both methods and as a way of better understanding the factors determining the 





2.3.1 Optimisation of tumour freezing  
For optimisation of the tissue freezing technique, healthy, female C57BL/6 mice were used. 
The mice were anaesthetised by inhalation of 2% isoflurane gas in air/O2 (50/50% vol/vol, 2 
L/min) and a dorsal incision was made. The two kidneys were exposed and isolated from 
surrounding tissue. The left kidney was excised and freeze-clamped in liquid nitrogen-cooled 
tongs, whereas the right kidney was excised and immersed in liquid isopentane that had been 
pre-cooled in liquid nitrogen. The surgical procedure took around 5 minutes each time. Excision 
of the kidney and either freeze-clamping or immersion in isopentane were completed in a 
maximum of 5 seconds. The specimens were then stored at -80oC until extraction. 
The kidneys were kept on dry ice during the extraction procedure. They were weighed and 
homogenised in 10 µl/mg 2M Perchloric Acid (PCA), using a Precellys homogeniser (Birton 
Instruments). After homogenisation, the samples were kept on ice for 30 minutes and then 
centrifuged at 13,000g for 2 minutes at 4oC. The homogenate was then neutralised using 2M 
KOH and then re-centrifuged at 13,000g for 15 mins at 4oC. The samples were then lyophilised 
before 31P NMR and 1H NMR analysis. 
The lyophilised extracts were dissolved in 550 µl Deuterium Oxide and Trimethylsilyl 
propanoic acid (TMSP) and methylenediphosphonic acid, at 100 nmol/g tissue, were added as 
chemical shift and intensity standards. Proton decoupled 31P NMR spectra were acquired with 
an 11µsec pulse with a flip angle of 90o and a repetition time of 7.2 seconds. More than 8000 
scans were summed, with a spectral width of 57 ppm (14006 Hz) and 32768 data points. 1H 
spectra were acquired with an 11 μsec pulse with a flip angle of 90o and a repetition time of 5.3 
seconds. 650 scans were summed, with a spectral width of 17 ppm (10000 Hz) and 65536 data 
points. All spectra were processed using a Gaussian window function of 3 Hz. 
2.3.2 Tumour model 
A suspension of 5 x 106 EL4 cells in 200 µl Foetal Bovine Serum (FBS) was injected 
subcutaneously on the right flank of female C57BL/6 mice (Charles River). Tumours were 
grown for 8-11 days before they were imaged. 
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2.3.3 13C pyruvate imaging experiments 
[1-13C]pyruvic acid was purchased from Cambridge Isotope Laboratories (MA). 44 mg [1-
13C]pyruvic acid was mixed with 15 mM OX063 radical (GE Healthcare) and 1.4 mM 
gadoterate meglumine (DOTAREM, Guerbet) and loaded in the HyperSense polarizer, where 
it was polarised for about an hour. The substrate was then dissolved in 6 ml of buffer containing 
40 mM Hepes, 94 mM NaOH, 30 mM NaCl and 100 mg/L EDTA and 400 μl of this solution 
was immediately injected intravenously into the tail vein of the mouse to be imaged. 
T2-weighted axial 1H MR images of the mouse were acquired with a Fast Spin Echo sequence 
before substrate injection and used for positional reference. These were 16 40 x 40 mm2 slices 
with a slice thickness of 1.25 mm. Data were acquired in a 256 x 256 matrix, with a TR of 2 
seconds and an effective TE of 48 ms, with 8 echoes acquired. Following intravenous injection 
of hyperpolarized [1-13C]pyruvate via a tail vein, 13C images were acquired with a single shot 
3D volume imaging sequence128 which used spectral spatial pulses to alternately excite [1-
13C]pyruvate and [1-13C]lactate with flip angles of 7o and 45o, respectively and a fast spin echo 
train of 8 adiabatic, non-localised, 180-degree pulses with a stack of spiral acquisitions at the 
echoes129. The 3D volume acquired was 40 mm x 40 mm x 20 mm with a matrix size of 32 x 
32 x 16 with a TR of 1s so that each metabolite was imaged every 2s for 90 s. The 8th pair of 
acquisitions were performed without the phase encoding in the third dimension and were used 
as a reference scan for this dimension in reconstructing the other time points. 
2.3.4 Snap-freezing and sample preparation for Mass Spectrometry Imaging 
The whole mouse was snap-frozen in liquid isopentane, pre-cooled in liquid nitrogen, 
immediately following the MRI acquisition. Ten μm thick sections of animals injected with [1-
13C]pyruvate and non-injected control animals were cut on a Leica cryostat and thaw-mounted 
onto superfrost slides (ThermoScientificTM). To preserve the rapidly changing tissue 
metabolome, the sections were air-dried, and vacuum packed for storage at -80oC prior to 
MSI130. Adjacent to these sections, sections of 6 μm thickness were also taken, to be used for 
immunohistochemical staining.   
2.3.5 DESI MSI 
The slides were shipped to AstraZeneca (The Darwin Building, Cambridge) where they were 
processed for DESI MSI. Just before DESI MSI, the slides were equilibrated at room 
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temperature and immersed in chloroform for 1 min 45 seconds. MSI was performed using a Q-
Exactive plus mass spectrometer (Thermo Scientific, Bremen, Germany) equipped with an 
automated DESI ion source (Prosolia Inc., Zionsville, IN, USA). Data were acquired in negative 
ion mode between m/z 80 and 500. The nominal mass resolution was set to 70,000. The 
injection time was fixed at 150 ms resulting in a scan rate of 3.8 pixel/s. A home-built DESI 
sprayer131 was operated with a mixture of 95 % methanol, 5 % water delivered at a flow rate of 
1.5 µL/min and nebulized with nitrogen at a backpressure of 6 bar. The spatial resolution was 
set to 100 µm. Sections were then stained with Hematoxylin and Eosin (H&E) and imaged on 
an Aperio (Leica Biosystems, Nussloch) scanner. 
2.3.6 Immunohistochemistry (IHC) 
For immunohistochemical analysis, 6 μm thick sections were cut and submitted to the 
Histopathology core in the institute for processing. IHC was run on Leica’s Polymer Refine 
Detection System on the Bond-III platform. For CD31 staining, a rat anti-mouse antibody was 
used (BD Biosciences, catalogue number 553370), at a concentration of 0.5 μg/ml, followed by 
a rabbit anti-rat secondary antibody (Bethyl Labs, catalogue number A110-322A).  
2.3.7 Data analysis and Statistics 
MRSI data were processed using an in-house MATLAB (MathWorks) script128, for image 
reconstruction and overlaying the metabolic images on the anatomical 1H MR images. The MSI 
.raw data files were converted into .mzML files using ProteoWizard msConvert132 (version 
3.0.4043) and compiled subsequently into an .imzML file (imzML converter133 version 1.3). 
All subsequent data processing was performed in SCiLS Lab (version 2019c, Bruker Daltonik, 
Bremen, Germany). The MSI data were analysed following root mean square normalization to 
compensate for pixel-to-pixel variability and data variation between experiments134. For 
visualization of the relative distribution of [12C] and [1-13C]lactate across the tissue, hotspot 
removal and weak denoising were applied.  
The [1-13C]lactate MS images were co-registered with the 1H MRI anatomical images using a 
custom MATLAB script. The tumour in the MS image and the corresponding anatomical MR 
image were contoured manually to yield binary masks, which were first co-registered by affine 
transformation using the imregister function. The registration was then fine-tuned with the 
imregdemons function, in order to account for arbitrary shape distortion of the MSI sections 
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resulting from sample preparation. Non-spatial and spatial statistical techniques were used to 
quantify the level of association between the co-registered images. For each section, the level 
of association was defined by means of the Spearman’s rank correlation on the raw pixel 
intensities (estimated by means of the cor function in RStudio software) and the Cohen’s kappa 
coefficient135,136 on standardized intensities (obtained by categorizing the raw intensities in 20 
quantile based levels, estimated by means of the function cohen.kappa of the R package 'psych'). 
One-sided T-tests were used to assess if the mouse mean association levels were greater than 0 
and thus to exclude the null hypothesis that there was negative or no correlation between the 
two techniques (by means of the t.test R function). Linear mixed models (fitted by means of the 
function lme of R package nlme) were then used to predict the standardized MSI intensities by 
means of the MRI intensities, with mice and tumours as hierarchical random effects to take the 
within-mouse and within-tumour dependence into account and assuming a spherical correlation 
structure for the residuals137,138. Sensitivity analyses considering other spatial dependence 
structures led to similar conclusions. Significance of the relationship between MRI and MSI 
was assessed by means of a Wald T-test on the MRI fixed effect parameter estimate. Pearson 
correlation coefficients were used to assess the correlation between the [1-13C]lactate and [1-





2.4.1 Comparison between snap-freezing techniques 
In order to optimise the sample processing pipeline before MSI, two freezing methods were 
compared, namely immersion in liquid nitrogen-cooled isopentane and freeze-clamping in 
liquid nitrogen cooled tongs. Immersion in liquid nitrogen was not investigated here due to the 
higher risk of tissue damage upon immersion in liquid nitrogen and the slower freezing rate 
caused by the vapor barrier created by liquid nitrogen around the immersed solid as discussed 
in the literature140. The comparison was achieved by freezing each of two kidneys of healthy 
mice by either of the two methods and comparing the ATP:ADP ratios of lyophilised extracts 
of the frozen samples. 31P NMR analysis on kidney sample extracts suggested that immersion 
in cold isopentane is comparable to freeze-clamping in terms of preservation of the ATP:ADP 
ratio (Figure 11). There was a small increase in the preservation of ATP levels with immersion 
in isopentane when compared to freeze-clamping but the adenylate energy charge141 measured 
after freezing with either of the two techniques was very similar. Immersion in cold isopentane 
also preserves the architecture of the tissue as opposed to freeze clamping, thus enabling co-
registration of in vivo images to images generated on sections of the frozen tissue. Therefore, 
for subsequent experiments, the metabolism was effectively stopped by immersion of the whole 
mouse in liquid isopentane which was pre-cooled in liquid nitrogen.  
 
Figure 11 Comparison of freezing techniques. The 31P NMR spectrum of an extract of a freeze-clamped kidney (a) is very 
similar to the spectrum of the extract of a kidney which was immersed in cold isopentane (b), in terms of their relative ATP, 
ADP and AMP peak areas. The ATP/ADP ratio was calculated from the integrals of the peaks (β-ADP at -4,76 ppm and γ-ATP 
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at -4.35 ppm), as measured by TopSpin software (Bruker), and absolute concentrations of ATP, ADP and AMP were estimated 
by comparing their peak integrals to that of a Methylenediphosphonic Acid standard (at 17.5 ppm). From these, the adenylate 
energy charge was calculated (c). 
2.4.2 Optimised pipeline for direct comparison of hyperpolarised 13C MRSI 
and DESI MSI 
The pipeline followed for this study is outlined in Figure 12. EL4 murine lymphoma cells were 
implanted subcutaneously in female C57BL/6 mice. Once the tumours reached a diameter of 
approximately 1.5 cm, the MRI protocol was followed which included T2-weighted MRI in the 
axial, sagittal and coronal directions, while [1-13C]pyruvate was being hyperpolarised. For [1-
13C]pyruvate imaging, the hyperpolarised substrate was dissolved in superheated buffer and 
immediately injected into the tail vein of the anaesthetised mouse for the fast 13C imaging 
acquisition. As soon as the acquisition finished (180 seconds after injection), the deeply 
anaesthetised mouse was frozen by immersion in liquid isopentane, pre-cooled in liquid 
nitrogen. Whole mouse axial sections were cut at -20oC, vacuum packed and stored at -80oC to 
maximise the preservation of metabolites until DESI MSI was performed. Following DESI 
analysis, H&E staining was performed as well as immunohistochemical staining.  
 
Figure 12 Outline of pipeline used for direct comparison of hyperpolarised 13C pyruvate imaging with mass spectrometry 
imaging. 
2.4.3 Four-dimensional imaging of pyruvate and lactate in tumour bearing 
mice 
Following injection of hyperpolarised [1-13C]pyruvate into EL4 tumour-bearing mice, four- 
dimensional MRSI was performed using an optimised spectral and spatially selective 
hyperpolarised 13C MRSI sequence, which was developed by Jiazheng Wang128. Axial 1.25 mm 
thick slices, with an in-plane resolution of 1.25 mm x 1.25 mm, were acquired every second 
with alternating [1-13C]pyruvate and [1-13C]lactate excitations. The subcutaneous EL4 tumours 
showed increased pyruvate uptake and conversion to lactate, as expected. A core with high 13C 
lactate signal intensity closer to the body of the mouse and areas with lower signal intensities 
were consistently observed (Figure 13). Label exchange between pyruvate and lactate was fast, 
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with the maximum lactate signal being observed within 20 seconds of the start of acquisition 






Figure 13 Representative images acquired with hyperpolarized [1-13C]pyruvate in EL4 subcutaneous tumours. (A) Axial 1H 
images were acquired before [1-13C]pyruvate injection using a Fast Spin Echo sequence. (B-C) Following injection of 
pyruvate, a 13C MRSI fast spin echo sequence with spiral acquisition was used to obtain images of [1-13C]pyruvate (B) and [1-
13C]lactate (C). False colour images illustrate the summed signal over 14 seconds, overlaid on the grey scale 1H images. 
 
Figure 14 Representative time course of [1-13C]pyruvate and [1-13C]lactate signal intensities. Each metabolite was imaged 
every 2 seconds for 90 seconds. The total signal acquired from the tumour region is plotted over time. 
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2.4.4 DESI MSI on frozen tissue sections 
Immediately after MR imaging, three mice were snap frozen by immersion in liquid isopentane 
pre-cooled in liquid nitrogen and samples prepared as outlined in the methods section for MSI 
analysis at AstraZeneca. [1-13C]lactate and [12C]lactate were detected by negative ion mode 
DESI MSI and metabolic maps were generated from the peak intensities. Control tissue, which 
consisted of sections of EL4 subcutaneous tumours from mice that were not injected with 
hyperpolarised [1-13C]pyruvate, was used to confirm the peak assignment for [1-13C]lactate and 
to control for the natural isotopic abundance of 13C (Figure 15). The natural isotopic abundance 
from these control tumours was calculated to be 3.3%, as expected. This was not subtracted 
from the images displayed. Similarly to the MRS images the [1-13C]lactate distribution 
measured by MSI showed higher signal intensity at the base of the tumour, suggesting that label 
exchange in those areas is characterised by faster kinetics, which could be a reflection of 




Figure 15 Detection of 12C and [1-13C]lactate by DESI MSI. (a) The mean mass spectrum across a whole slice is plotted, with 
the insert showing the peaks corresponding to 12C lactate (89.02 m/z) and [1-13C]lactate (90.03 m/z). (b) Representative slide 
including a section from a dosed mouse and a section from a control mouse. The distribution of 12C lactate and [1-13C]lactate 
are shown. 12C lactate shows a homogeneously high distribution in both tumours. The low abundance of [1-13C]lactate in the 
control tissue confirmed the correct assignment of the m/z peak, and the [1-13C]lactate image from the dosed tissue showed 
higher labelled lactate nearer the body of the mouse. 
2.4.5 Hyperpolarised 13C MRI and DESI MSI generated positively correlated 
[1-13C]lactate maps 
The 13C MR images of hyperpolarized [1-13C]lactate were compared with the [1-13C]lactate MS 
images of the corresponding excised tissue sections. Three tumour-bearing mice were used for 
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the comparison and for each mouse at least three sections were used. The 1H MRI slice 
corresponding to each MSI section was manually selected using anatomical landmarks within 
the tumour which were visible on both the H&E images acquired after DESI MSI analysis and 
on the T2-weighted MR images (Figure 16).  
By visual comparison of the [1-13C]lactate MR images and their corresponding MS images, 
good agreement was observed between the two techniques (Figure 17A). High [113C]lactate 
intensity as measured by both techniques was localised in similar regions of the tumour, which 
was usually at the base of the tumour. In order to quantify the agreement between the two 
techniques, the selected slices from the T2-weighted 1H images, which served as reference 
images for the 13C MRS images, were co-registered with the MS images using an in-house 
MATLAB co-registration script, developed by Vencel Somai. The correlation between the 
lactate MR image, overlaid on the co-registered T2-weighted 1H images, and the co-registered 
MS image could then be assessed.  
For assessing the agreement between the images generated by the two modalities, Spearman’s 
correlation analysis was used instead of Pearson’s correlation analysis because the data were 
not linearly correlated, due to the different sensitivity and scales of the two modalities. In 
addition to Spearman’s correlation analysis, Cohen’s weighted kappa estimates were used to 
further validate the comparison. Both measures generated similar coefficients that were 
significantly positive, suggesting that the co-registered images were significantly correlated 
(Figure 17). Based on the Landis and Koch interpretation of Cohen’s weighted kappa 
coefficients142, the association in this case is ‘fair’ on average. This is expected given that the 
data were generated by different modalities, with different spatial resolutions and more 
importantly, the comparison was made between intact tissue in vivo and frozen tissue sections 
ex vivo. To further validate the significance of the association between the images generated by 
the two modalities, a linear mixed model - a more powerful parametric analysis able to model 
the within-mouse, within-tumour and spatial dependence of the MRSI and MSI pixel intensities 
- was fitted. This showed a highly significant relationship between the MRSI and MSI pixel 
intensities (p-value of 1.75*10-9) but a marginal R-squared - fraction of variance of MSI 




Figure 16 Comparing [1-13C]lactate maps generated in vivo, using hyperpolarised 13C imaging with those generated on 
sections of the same mouse using MSI. For registration of the images, the H&E image of the section used for DESI MSI (a) 
was manually co-registered with one of the 16 T2-weighted MR image slices (b). This was achieved by matching anatomical 
landmarks within the tumour as well as overall tumour morphology. (c) DESI MS images showing the same section (top images) 
as well as a section from a control mouse that was not injected with [1-13C]pyruvate (bottom images). The calculated natural 
isotopic abundance of 13C lactate in the control tissue was 3.3%. The metabolite abundance is portrayed on a relative scale 
following application of hotspot removal. Any abundance values over 100% are given the same colour. (d) The hyperpolarised 




Figure 17 Correlation of metabolic images generated by MSI with images of hyperpolarised [1-13C]lactate generated by 13C 
MRSI. (A) Representative paired [1-13C]lactate MRSI slices and MSI sections from two of the three mice used in the study. (B) 
Correlation of [1-13C]lactate signal intensities in the MS and MRS images, as quantified by pixelwise Spearman’s rank 
correlation (ρ) and Cohen’s kappa coefficient (κ) analysis. Each point corresponds to the correlation coefficient calculated 
from all tumour-containing pixels of each section/slice comparison and the line represents the mean value. The points in blue, 
red and green correspond to the coefficients calculated from the top, middle and bottom image pairs in (A), respectively. One-
sided one-sample t-test on the mean values from different mice on both Spearman’s and Cohen’s kappa coefficients showed a 
statistically significant correlation (p=0.02). 
2.4.6 [1-13C]lactate distribution is not correlated with [12C]lactate on the MSI 
maps 
The [12C]lactate distribution, as determined by MSI, was consistently different from the [1-
13C]lactate distribution, suggesting that lactate labelling does not simply reflect the endogenous 
lactate pool. [12C]lactate was generally homogeneously distributed throughout the tumour, 
whereas [1-13C]lactate showed a more heterogenous distribution (Figure 15, Figure 16 and 
Figure 18). The Pearson correlation coefficient between [12C]lactate and [1-13C]lactate was 
calculated for all sections analysed, using Scils software, and this revealed very small positive 
correlation values, confirming that 13C lactate labelling is not strongly dependent on the 
endogenous lactate levels in this tumour model (Figure 18) suggesting that the rate of label 




Figure 18 [12C]lactate and [1-13C]lactate show different distributions in EL4 tumours. (a) [1-13C]lactate (left) and 
[12C]lactate (right) maps from two representative sections from two different mice, showing the different distributions of the 
two metabolites. (b) The Pearson correlation coefficients calculated between the [12C] and [1-13C]lactate maps (tumour region 
only) from all sections of all three mice are plotted, demonstrating the very low positive correlation between the two 
metabolites. 
2.4.7 [1-13C]lactate distribution is correlated with [1-13C]pyruvate 
distribution 
Similarly to the correlation analysis between [12C] and [1-13C]lactate MS images, the 
correlation between [1-13C]pyruvate and [1-13C]lactate was assessed on the MRS images. The 
correlation coefficients in this comparison were higher than between [12C] and [1-13C]lactate, 
suggesting that 13C lactate labelling is limited principally by the availability of labelled pyruvate 
in the tumour (Figure 19). Substrate delivery to the tumour depends on perfusion of the tumour 
as well as the presence of monocarboxylate transporters MCT1 and MCT4 for enabling 
pyruvate entry into the cells. 
Immunohistochemical staining using an antibody against mouse CD31 was performed on 
sections adjacent to the sections used for MSI, to assess the vasculature throughout the tumour. 
The staining pattern can be compared to the [1-13C]lactate maps to better understand the limiting 
factor for lactate labelling in the tumours. CD31 staining showed some heterogeneity across the 
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tumour, with some areas of the tumour appearing to be more well-vascularised than others, 
possibly contributing to the heterogeneity in pyruvate delivery (Figure 20).  
 
Figure 19 [1-13C]lactate MRS images are well correlated with [1-13C]pyruvate MRS images. (A) The 2D correlation 
coefficient between pyruvate and lactate maps was calculated for each slice imaged from two mice using Matlab’s corr2 
function. Each point on the graph represents the correlation coefficient for each slice. (B-C) Representative examples of images 
of the summed [1-13C]pyruvate (B) and [1-13C]lactate (C) signal intensities overlaid on the anatomical grey scale 1H image of 
a slice through one of the mice imaged, demonstrating the good correlation between the two maps.  
 
Figure 20 Tissue vasculature is heterogeneous across the tumour. (A-D)Immunohistochemical staining for CD31 on a frozen 
section containing EL4 tumour tissue as well as healthy mouse tissue (A). Three areas of the tumour are demonstrated at high 
magnification (B-D) as labelled on the low magnification image (A). (E) Quantification of the positivity of the tumour regions 




Dynamic 13C MRSI measurements following injection of hyperpolarised [1-13C]pyruvate were 
used to measure the rate of interconversion of pyruvate and lactate in vivo, with a time resolution 
of 2 seconds, a nominal spatial resolution of 1.25 mm x 1.25 mm x 1.25 mm and an effective 
spatial resolution of 1.25 mm x 1.25 mm x 4.5 mm, when taking into account the z-direction 
point spread function128. The EL4 tumours showed rapid [1-13C]pyruvate uptake and very fast 
conversion to [1-13C]lactate, as has been observed previously in this tumour model72,143. Sixteen 
13C MRSI axial slices were acquired from each of three EL4 tumours and spatial maps of [1-
13C]lactate and [1-13C]pyruvate were overlaid on the anatomical T2-weighted 1H MR images. 
The [1-13C]lactate signal was largely localised to the tumour and showed a heterogeneous 
distribution. Inhalation anaesthesia (isoflurane) was used throughout the hyperpolarised MRI 
experiment which undoubtedly had effects on the measured metabolism as suggested in 
previous studies144, but in this case these effects do not pose a problem as comparisons are made 
between images of the same animals or between different animals that were treated in the same 
way with isoflurane. 
MSI has a much better spatial resolution than MRI, therefore, a more detailed map of labelled 
lactate could be acquired from tumour sections. However, the lactate images acquired by MSI 
represent an endpoint measurement, compared to the dynamic metabolism interrogated by 
hyperpolarised 13C MRSI. The mice were snap-frozen immediately after the end of the MRI 
acquisition, using an optimised freezing technique in order to preserve metabolite 
concentrations. For this reason, the [1-13C]lactate MS images were expected to match the maps 
of summed [1-13C]lactate signal acquired over the time using MRSI. Indeed, there was a good 
correlation between the MRS and MS images (Figure 17). 
Co-registration of MRS tumour images with the MS images of excised tumours proved to be 
challenging since when the tumour is excised, frozen and then sectioned, the orientation of the 
tumour with respect to the mouse anatomy was lost and co-registering the sections to the MR 
slices was impossible. For this reason, the whole mouse was frozen and whole mouse axial 
sections were taken for MSI. Even then, the changes in morphology due to rapid freezing, the 
difficulty of taking intact sections through the whole frozen mouse body and the differences in 
thickness of the MSI sections (10 μm) and the MRSI slices (1.25 mm) meant that the excised 
sections did not match perfectly the MR images. Anatomical landmarks in the tumour, which 
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appeared in both the T2-weighted 1H images and in the images of the H&E-stained sections, 
were used to facilitate manual alignment of MS images with their corresponding MRI slice. 
The co-registration MATLAB routines were successful in registering the tumour masks, 
defined by drawing a region of interest around the tumour, by applying rigid and non-rigid 
transformations. However, in most cases, the tumour outline was distorted during snap-freezing 
and during sectioning, thus limiting the accuracy of the registration. Therefore, the magnitude 
of the correlation between the MS and MRS images is an underestimate of the true agreement 
between the two imaging modalities. The statistical significance for the correlation between the 
two modalities was confirmed using spatial and non-spatial statistical tools, enabling the cross-
validation of hyperpolarized 13C MRSI and MSI techniques. Both techniques are relatively new 
and are still undergoing development. Therefore, showing that the two techniques generated 
similar results in a well-controlled experiment, where we directly assessed the spatial 
distribution of one metabolite, is encouraging for both methodologies.  
There has been a lot of discussion with regard to the ionisation efficiency in MSI and whether 
ionisation suppression effects in the tissue could affect the accuracy of the spatial maps 
generated by the technique. Also, due to the small concentrations of ions analysed, tandem mass 
spectrometry is usually not possible in MSI, therefore, the fractionation pattern of the ions is 
not investigated. This could mean, that the mass spectra generated are not always specific, since 
different metabolites could have the same m/z value. Here we show that the accuracy and 
specificity of DESI MSI for detecting 13C lactate were not compromised. Using negative control 
tissue which contains [13C]lactate at its natural isotopic abundance, we have shown that the 
peak we have assigned to [13C]lactate is specific. Also, the good correlation between the 
[13C]lactate map generated by DESI MSI and 13C hyperpolarised MRSI, suggests that the 
ionisation efficiency was consistent across the whole tumour and no ionisation suppression 
effects were visible. The quickly shifting tissue metabolome often presents a challenge in MSI 
as sample processing can affect the quality of results. In these experiments, an optimised 
freezing method was used to ensure fast arrest of metabolism and although the samples were 
brought to room temperature for MSI, processing and storage did not seem to impact the quality 
of the lactate data, since the MSI data was in agreement with the MRI data. 
The exchange of 13C label between pyruvate and lactate in a tumour is dependent on [1-
13C]pyruvate delivery, uptake into the tumour cells via the MCT1 and MCT4 transporters, the 
concentration of LDH and the size of the endogenous tumour lactate pool145. The relative 
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importance of these factors will likely vary according to the tumour type. Previous studies on 
EL4 cells showed that the activities of the MCTs and LDH are nearly equally important in 
determining the exchange velocity145. Using MSI, we have shown that in EL4 tumours in vivo, 
the size of the endogenous tumour lactate pool, and therefore LDH activity, was poorly 
correlated with lactate labelling, but that there was a stronger correlation between the [1-
13C]pyruvate and [1-13C]lactate signals, suggesting that delivery of labelled pyruvate has the 
greatest effect on the exchange velocity under these conditions. Additionally, evidence from 
immunohistochemical staining of tumour sections pointed towards a heterogeneous pattern of 
vasculature that could affect pyruvate delivery. This does not mean that the activities of the 
MCTs and LDH are unimportant, but it suggests that under these conditions and in this tumour 
model, pyruvate delivery is more important. Immunohistochemical staining of the sections for 
MCT and LDH expression would be very interesting but we were unable to investigate that due 
to the low specificity of antibodies against these mouse antigens. A recent clinical study in 
prostate cancer patients, showed positive correlation between MCT1 expression and lactate 
labeling125 and it has also been shown previously in the EL4 tumour model that the MCT 
inhibitor, α-Cyano-4-hydroxycinnamic acid (injected at 150 mg kg1) produced a 40% decrease 
in label exchange146. 
Another factor that has not been investigated in this study is the contribution of the stroma in 
label exchange. The combination of MSI with the Imaging Mass Cytometer could enable the 
involvement of the immune compartment and other parts of the stroma to be imaged147. 
2.6 Conclusion 
In this study, hyperpolarised 13C pyruvate imaging and MSI generated positively correlated 
tumour images of [1-13C]lactate following injection of hyperpolarised [1-13C]pyruvate, thus 
cross-validating the two techniques. The [1-13C]lactate maps in the tumour were poorly 
correlated with the endogenous tumour lactate levels but more closely correlated with maps of 
[1-13C]pyruvate, suggesting that in this tumour pyruvate delivery has the greatest effect on the 
rate of lactate labelling. This study highlighted the possibility and benefits of combining these 
two novel metabolic imaging techniques to better understand cancer metabolism. The addition 
of MSI to the pipeline enabled the visualisation of endogenous metabolites in addition to the 











Upregulation of the cytosolic isoform of Branched Chain Aminotransferase (BCAT1) has been 
associated with the progression of different types of cancer, including glioblastoma, but its role 
in cancer pathophysiology is still unclear. The role of BCAT1 in glioblastoma was investigated 
in cells derived from glioblastoma patients. Differential expression of BCAT1 was observed in 
a panel of glioblastoma cell lines. Modulation of BCAT1 expression in the A11 line led to 
changes in cell phenotype, including changes in proliferation, migration and invasion. These 
effects were not observed in the S2 cell line, which appears to be unaffected by changes in 
BCAT1 expression. The phenotypic effects of BCAT1 knockdown in A11 cells were not 
mediated via changes in the levels of Branched Chain Ketoacids (BCKAs), mTOR signalling 
or changes in glutamate synthesis but by global transcriptional changes, including 
downregulation of HIF and FOXM1 target gene expression. The levels of 5-
hydroxymethylcytosine in DNA were increased in BCAT1 knockdown cells suggesting TET 
enzyme activation. We suggest that BCAT1 regulates the cells’ phenotype through regulation 





3.2.1 Branched Chain Amino Acid Metabolism 
Leucine, isoleucine and valine are Branched Chain Amino Acids (BCAA) with hydrophobic 
side chains that are essential in the diet and comprise 20-40% of most dietary protein148. A high 
proportion of these amino acids are absorbed through the intestine and are then circulated to the 
peripheral tissues, where they are incorporated into proteins or catabolised. Interestingly, unlike 
other amino acids, these amino acids are not metabolised in the liver, due to the absence of the 
transaminase enzyme which catalyses the first catabolic reaction149. Therefore, upon ingestion 
of a high-protein diet, the circulating levels of BCAA show a dramatic increase, while other 
amino acids do not show significant changes in their plasma levels, due to their hepatic 
metabolism149. 
Most of BCAA catabolism takes place in muscle cells, where the enzymes of the catabolic 
pathways are abundant. The first enzymatic step in the catabolism of BCAAs is a reversible 
transamination reaction catalysed by Branched Chain Aminotransferase (BCAT). This reaction 
(Figure 21) uses α-KG as the amino acceptor, leading to transamination of BCAAs leucine, 
isoleucine and valine to their respective ketoacids (α-ketoisocaproic acid (KIC), α-keto-β-
methylvaleric acid (KMV) and α-ketoisovaleric acid (KIV)) and the generation of glutamate148. 
Two isozymes of BCAT have been described in eukaryotes; the cytosolic isozyme, BCAT1, 
also called BCATc and the mitochondrial isozyme, BCAT2, also called BCATm150. These 
enzymes belong to the Type IV class of Pyridoxal Phosphate-containing enzymes, with 
catalysis occurring on the pyridoxal phosphate cofactor151. The isozymes show differential 
distribution in the human body, as demonstrated by western blot and enzyme activity 
measurements. More specifically, BCAT1 seems to be primarily localised in the brain, ovary 
and placenta, whereas BCAT2 can be found in most tissues150. Immunohistochemical studies 
in rat brain have demonstrated that BCAT1 is primarily expressed in the neurons, whereas 




Figure 21 Schematic overview of the reaction catalysed by BCAT. In the presence of BCAT, BCAAs will be transaminated to 
their respective ketoacids. α-KG will accept the amino group and will thus be converted to glutamate. 
The ketoacids generated from the transamination reaction are then oxidatively decarboxylated 
in a reaction catalysed by the branched chain ketoacid dehydrogenase complex, found on the 
inner leaflet of the mitochondrial membrane149. This is an irreversible reaction and represents 
the rate limiting reaction in the catabolism of the BCAAs. The dehydrogenase activity is 
modulated by phosphorylation and dephosphorylation events, in response to stimuli such as 
hormones and cytokines. Further catabolism differs between the ketoacids, with KIC generating 
acetyl-CoA and acetoacetate, KIV generating succinyl CoA and KMV generating both acetyl-
CoA and succinyl CoA149. Evidence suggests that BCAA metabolism is self-regulated with 
high BCAA levels inducing higher catabolic enzyme activities153. A number of disorders, 
including Maple Syrup Urine Disease (MSUD), are caused by dysregulation of these metabolic 
pathways148.  
An overview of the metabolic fate of BCAAs in the cell is shown in Figure 22.  
 
Figure 22 Overview of the metabolic fate of Branched Chain Amino Acids. They can be incorporated into proteins, or 




BCAAs play many roles in metabolism. They are essential for protein synthesis. Their 
metabolism plays a role in energy production but they also act as nitrogen donors for the de 
novo synthesis of other amino acids, including alanine and glutamine150. The nitrogen in 
BCAAs is also used in the Central Nervous System (CNS) for the synthesis of the excitatory 
neurotransmitter, glutamate150.  
In addition to the metabolic roles of BCAAs, they also take part in signalling, by activating the 
mammalian target of rapamycin (mTOR) pathway. mTOR is a serine/threonine kinase that 
regulates numerous cellular processes, which include cell growth, protein synthesis and 
proliferation. Protein synthesis is controlled by the mTOR complex 1 (mTORC1), which is 
composed of mTOR and other regulatory proteins. This complex is regulated by amino acids, 
such as leucine as well as some growth factors and hormones including insulin and leptin153. 
More specifically, leucine acts as an activator of mTORC1 through the enzyme catalysing the 
ligation of leucine to its transfer RNA (tRNA), leucyl tRNA synthetase, which also acts as a 
sensor for leucine153. Downstream targets of mTORC1 include p70-S6 kinase 1 (S6K1) and 
eukaryotic initiation factor 4E binding protein 1 (4E-BP1), which are responsible for mRNA 
translation initiation and protein synthesis. Leucine is also thought to regulate protein synthesis 
through modulation of the General Control Non-repressible Kinase 2 (GCN2) pathway.  
BCAAs are necessary for neurotransmission in the brain. The proposed mechanism for 
regulation of glutamate synthesis (Figure 23) suggests that BCAAs enter the astrocytes, where 
they are transaminated to the BCKAs by BCAT2, while glutamate is produced from α-KG152. 
The BCKAs are then released by the astrocytes and taken up by the neurons, where they can be 
converted to BCAAs by BCAT1 using the amino group of glutamate and returned to the 
astrocytes, thus forming a cycle between astrocytes and neurons152. This is an important 
mechanism for replenishing the lost glutamate in astrocytes, which is needed for the 
glutamate/glutamine cycle. The glutamate/glutamine cycle (Figure 23) involves exchange of 
glutamate and glutamine between neurons and astrocytes. Neurons release glutamate at the 
synapse, as a neurotransmitter, which is then taken up by the astrocytes. It is converted to 
glutamine in the astrocyte by glutamine synthetase and the glutamine is then released by the 
astrocytes to be taken up by the neurons, which use it to produce more glutamate. Some 
glutamate is oxidised in the astrocytes and is thus lost, requiring the de novo synthesis of new 
glutamate. This role can be fulfilled by the BCAA shuttle, since BCAT2 activity in astrocytes 
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leads to the generation of glutamate from α-KG152. Thus, BCAA metabolism plays an important 
role in brain physiology. 
 
Figure 23 The role of the BCAA shuttle in brain glutamate metabolism, reproduced from Hutson et al152. Glutamate is 
synthesised from glutamine in the neurons and secreted as a neurotransmitter. Following synaptic transmission, glutamate is 
taken up by the astrocytes and converted to glutamine. Some of the glutamate is oxidised in astrocytes and replenished by the 
BCAA shuttle, whereby BCAAs are transaminated to their corresponding BCKAs by BCAT2, generating glutamate from α-KG.  
3.2.2 BCAT1 in glioblastoma 
Tonjes et al showed an inverse relationship between IDH mutations in glioma and BCAT1 
expression, with almost all IDH mutant cancers showing low BCAT1 levels. It was also shown 
that the increase in expression of BCAT1 was the best classifier to distinguish primary 
glioblastoma from secondary glioblastoma, diffuse astrocytoma and anaplastic astrocytoma51. 
The authors observed expression of three BCAT1 transcripts (T1, T4, T6) in normal brain and 
glioblastoma tissues, with T6 being the most predominant transcript in primary gliomas. 
Treatment of U-87 MG and U-373 MG cells with gabapentin, a leucine analogue that inhibits 
BCAT1 but not BCAT2, led to intracellular accumulation of BCAAs and reduced glutamate 
release into the cell media. Additionally, knockdown of BCAT1 using shRNA, led to 
morphological changes in the cells, which appeared more rounded as well as a reduction in the 
invasion capacity of the cells, as measured using a microchannel migration assay. Cell 
proliferation was also impaired upon BCAT1 inhibition using gabapentin and by BCAT1 
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knockdown. Cell proliferation measured using EdU (5-ethynyl-2’-deoxyuridine) incorporation 
was reduced and the cells showed partial G1 arrest, which was partially rescued by ectopic 
overexpression of BCAT1. The effects of BCAT1 knockdown were investigated in vivo as well, 
where mice implanted intracranially with U-87 cells transduced with BCAT1 shRNA grew 
significantly smaller tumours than those implanted with cells transduced with the non-targeting 
shRNA. 
Taken together, these data suggest that BCAT1 could play a role in glioblastoma development 
and progression but the mechanism for this is still not well understood. BCAT1 upregulation 
could lead to enhanced BCAA metabolism, promoting biosynthesis and generation of ATP as 
well as increased utilisation of nitrogen for glutamate production. Alternatively, since the 
reaction is reversible, it is also possible that glioma cells take up BCKA and convert them to 
BCAA for protein synthesis, or even as a mechanism to deal with excess nitrogen. In fact, some 
of these hypotheses, as well as others have been suggested already and some evidence has been 
provided for them.  
Tonjes et al51 hypothesised that the catabolism of BCAAs promotes proliferation of 
glioblastoma cells by providing fuel for the TCA cycle. Silva et al suggested that upregulation 
of BCAT1 leads to increased BCKA synthesis by glioblastoma cells. Using ultra high-
performance liquid chromatography, the in vitro intracellular and extracellular concentrations 
of BCKAs were measured and a very fast accumulation of BCKAs in the media was observed. 
This accumulation of BCKAs in the cell media was reduced upon shRNA-mediated knockdown 
of BCAT1. The authors also showed that the efflux of BCKAs is mediated by MCT1 and 
provided some evidence of specific protein interactions between BCAT1 and MCT1 in U-87 
and U-251 cells. The authors suggest that BCKAs released by glioblastoma cells in the tumour 
stroma are taken up by macrophages and reaminated to their respective amino acids and this 
results in reduced phagocytic activity. Therefore, upregulation of BCAT1 in glioblastoma might 
have immunosuppressive effects in the tumour microenvironment154.   
Another potential role that BCAT1 could play in glioblastoma metabolism is the generation of 
glutamate, which can be used for glutathione synthesis, necessary for resistance to reactive 
oxygen species155. In this study, IDH1 mutations were shown to inhibit BCAT1 via the 
production of 2HG. When human glioma cells were infected with a lentivirus expressing mutant 
IDH1, levels of BCKAs and glutamate in the media were reduced while levels of BCAAs were 
elevated, similarly to when BCAT1 was inhibited, either pharmacologically or genetically. 
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Using a cell-permeable version of 2HG, the authors showed that 2HG reduced BCAT1 activity 
in vitro, leading to lower intracellular levels of glutamate. The authors suggested therefore that 
in IDHmut gliomas, the cells are highly dependent on glutaminase for glutamate generation, in 
line with upregulation of a more active glutaminase splice isoform in these tumours. By 
performing 15N isotope labelling studies in immortalized human astrocytes and human 
oligodendroglioma cells, the authors showed that half of the nitrogen in the glutamate pool is 
derived from BCAAs and the rest is derived from glutamine. By expressing mutant IDH1 in 
these cells, the authors saw reduced flow of nitrogen from 15N-labelled BCAAs to glutathione, 
suggesting that 2HG-mediated inhibition of BCAT1 in IDH mutant gliomas can lead to reduced 
levels of glutathione. Finally, the authors demonstrated that combining IDH mutation with 
glutaminase inhibition rendered the cells sensitive to oxidative stress in vitro and led to reduced 
tumour growth and increased survival in vivo when radiotherapy was used in combination with 
a glutaminase inhibitor.  
Regardless of the mechanism of action, BCAT1 appears to be important in primary IDH wild 
type gliomas and it could potentially be targeted pharmacologically. Gabapentin, a drug used 
for neuropathic pain relief and seizure control, is known to be a competitive inhibitor of BCAT1 
with a Ki similar to the Km of leucine, while having no effect on BCAT2 activity156. Recently, 
a specific inhibitor of BCAT1, 4-methyl-5-oxohexanoic acid has been described with an IC50 
of 0.1-1 nM, which has been used in vitro to investigate the effect of BCAT1 inhibition in 
macrophages but also in vivo, in the treatment of inflammatory disease157.  
3.2.3 Aims 
From the published work on BCAT1 in glioblastoma, it is evident that BCAT1 is upregulated 
in IDH wild type glioblastoma and that it plays a role in the proliferation of glioma cells. Since 
most of the aforementioned research was primarily based on U87 cells and other conventional 
human glioblastoma cell lines, known not to represent human glioblastoma, the role of BCAT1 
in cell proliferation and other suggested phenotypes was investigated in patient-derived 
glioblastoma cell lines. The aims of this project were to characterise a panel of patient derived 
glioblastoma cell lines with regard to their expression profiles and activity levels of BCAT1 
and BCAT2 and to assess the role of BCAT1 in the different phenotypes that have been 
associated with BCAT1 upregulation, including cell proliferation, migration and invasion and 
radioresistance. The final aim was to understand the mechanism through which BCAT1 enables 




3.3.1 Cell Culture 
All cell lines were mycoplasma tested and Short Tandem Repeat (STR) profiled regularly and 
prior to freezing any stocks by the Research Instrumentation and Cell Services core facility in 
the institute. 
The cell lines included two rat glioma cell lines (C6 and 9L), two human glioma cell lines (U87 
and U251), and four patient derived cell lines (A11, SP20, S2 and A25). 
U87, C6 and 9L adherent cells were grown in flasks in high glucose containing DMEM medium 
(Gibco) supplemented with 10% FBS. U251 cells were grown in low glucose containing 
DMEM medium (Gibco), which was also supplemented with 10% FBS. Cells were harvested 
following trypsinisation and washing with PBS. 
The patient derived adherent cell lines were grown in serum-free Neurobasal A Media (Gibco) 
supplemented with B27, N2, 20 ng/ml Epidermal Growth Factor (EGF) (Sigma) and 20 ng/ml 
Fibroblast Growth Factor (FGF) (Gibco), as well as 2 mM glutamine and Penicillin-
Streptomycin antibiotic (100 U/ml) (Gibco) in flasks which were precoated with Extracellular 
Matrix (Gel from Engelbreth-Holm-Swarm murine sarcoma) (Sigma). Hank’s Balanced Salt 
Solution (HBSS) (Gibco) was used to wash the cells and StemPro Accutase Cell Dissociation 
Agent (Gibco) to detach them from the flask surface. 
Cells were kept in a humidified incubator set at 37°C, 5% CO2 (Heracell, ThermoFisher).  
3.3.2 In vivo tumour models 
A 5 µl suspension of 106 cells (A11, S2, A11shCtrl, A11shBCAT1, A11Strawberry, 
A11BCAT1 and S2BCAT1) was loaded into a clean Hamilton syringe, which was stabilized 
on a stereotaxic stage. The rat/mouse was anaesthetized in an induction chamber using 3% 
isoflurane at 2 L/min air flow, weighed and transferred to the surgery table. Analgesia (Rimadyl 
and Buprofen) was administered subcutaneously before incision. Temperature was monitored 
by a rectal thermometer and maintained throughout the procedure using a heat pad. A midline 
incision was made on the head and a retractor placed to expose the skull. A hole was drilled on 
the skull at a point 2 mm to the right and 2 mm posterior to the bregma. The Hamilton syringe 
91 
 
was inserted into the brain (4 mm and 3 mm deep for the rat and mouse respectively) and the 
cells were slowly injected intracranially. The hole on the skull was sealed with bone wax and 
the skin incision sutured. Surgical glue was applied over the incision site. The animal was then 
placed in the recovery chamber for about 20 minutes, before it was returned to its cage. Twenty-
four and 48 hours after surgery, subcutaneous analgesia (Rimadyl) was administered. 
Following implantation, tumour growth was monitored using T2-weighted MRI scans, which 
were performed at least monthly. 
3.3.3 Cell and tissue protein extraction for western blots 
Cells were harvested by centrifugation and the pellets resuspended in about 80 μl per 106 cells 
of cold Pierce RIPA buffer (ThermoFisher Scientific) containing EDTA-free Protease Inhibitor 
Cocktail (Roche). Excised tissue was snap-frozen in liquid nitrogen and homogenised in 10 μl  
per mg tissue of the same buffer using a Precellys homogeniser (Bertin Instruments). The 
solution was then agitated on an end-over-end shaker at 4oC for 30 minutes. The lysed cells and 
homogenised tissue were then centrifuged at 21,000g for 20 minutes at 4oC. Protein content 
was quantified using a Direct Detect Infrared Spectrometer (Merck). 
3.3.4 Western blots 
For the western blots, 30-35 μg protein were mixed with LDS Sample Buffer (4X) (NuPAGE) 
and Sample Reducing Agent (10X) (NuPAGE). The protein samples were then denatured at 
70oC for 10 minutes, before being loaded onto a NuPAGE™ 4-12% Bis-Tris precast 
polyacrylamide gel (8 x 8 cm) (ThermoFisher Scientific) or onto a Bolt™ 4-12% Bis-Tris Plus 
Gel (ThermoFisher Scientific), which was run with MES (2-(N-morpholino)ethanesulfonic 
acid) buffer (2.5 mM MES, 2.5 mM Tris Base, 0.005% SDS, 0.02 mM EDTA, pH 7.3) or 
MOPS (3-(N-morpholino)propanesulfonic acid) buffer (2.5 mM MOPS, 2.5 mM Tris Base, 
0.005% SDS, 0.02 mM EDTA, pH 7.7) at 60 V for 30 minutes and then at 120 V for a further 
90 minutes. The protein marker used was the Precision Plus Protein All Blue marker (BioRad).  
Following gel electrophoresis, the proteins were transferred onto a nitrocellulose membrane 
using either dry transfer (iBlot 2 Dry Blotting System (Thermofisher)) or wet transfer (in 10% 
Methanol containing transfer buffer (NuPAGE)). The membranes were blocked in Odyssey 
Blocking Buffer (Licor) or 5% Milk for 1 hour with gentle shaking at room temperature. 
Following blocking, primary antibody diluents were prepared in Odyssey Blocking Buffer 
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(Licor) with 0.2% Tween-20 or in 5% Bovine Serum Albumin in Tris Buffered Saline with 
0.1% Tween-20. The primary antibodies used were: 
1. Rabbit BCAT1 Antibody (#12822 CST) at a 1:1000 dilution 
2. Rabbit BCAT2 Antibody (#9432 CST) at a 1:1000 dilution 
3. Rabbit c-Myc Antibody (#9402 CST) at a 1:1000 dilution 
4. Rabbit FOXM1 Antibody (#5436 CST) at 1:1000 dilution 
5. Rabbit Hexokinase II Antibody (#2867 CST) at 1:1000 dilution 
6. Mouse S6 Antibody (#2317 CST) at 1:1000 dilution 
7. Rabbit PS6 antibody (#4858 CST) at 1:2000 dilution 
8. Rabbit COX-IV antibody (#4850 CST) at 1:2000 dilution 
9. Mouse HIF-1a antibody (ab16066 Abcam) at 1:1000 dilution  
10. Rabbit CAIX antibody (NB100-417) at 1:1000 dilution 
11. Mouse GAPDH (G8795 SIGMA) at a 1:25000 dilution  
12. Mouse beta actin (A5441 SIGMA) at a 1:5000 dilution 
13. Rat Beta Tubulin (ab6160-100 Abcam) at 1:2000 dilution 
The membrane was incubated with primary antibodies overnight, with gentle shaking, at 4oC 
and was then washed three times for 5 minutes each time with Tris Buffered Saline (TBS) 
containing 0.1% Tween 20 before incubation with secondary antibodies. 
For fluorescent detection, the membrane was incubated with IRDye 800CW Goat anti-Rabbit 
IgG (Licor) and IRDye 680LT Goat anti-Mouse IgG antibodies (Licor) for 45 minutes – 1 hour, 
with gentle shaking, at room temperature. For chemiluminescent detection, the membrane was 
incubated in Goat Horseradish Peroxidase (HRP) – conjugated secondary antibodies (Cell 
Signalling Technology and Amersham) for 1 hour. Following three washes, 5 minutes each, 
with TBS containing 0.1% Tween 20 and a final wash with TBS, the membranes were imaged 
using a LiCor Clx scanner for fluorescent detection and analysed using Image Studio (Licor). 
For chemiluminescent detection, Pierce ECL Plus Western Blotting Substrate (ThermoFisher 
Scientific) was added to the membranes, which were then imaged using a standard film 





For immunohistochemical analysis, rat brains were dissected and fixed in 10% neutral buffered 
formalin for 24 hours and submitted in 70% ethanol to the Histopathology core in CRUK 
Cambridge Institute for Formalin Fixed Paraffin Embedded (FFPE) processing. Sections were 
cut from these blocks at the level of the frontal lobe, where the tumour was visible. IHC was 
run on Leica’s Polymer Refine Detection System on the Bond-III platform. The antibodies used 
for staining and their respective conditions are summarised in the table below. 
Target Catalogue No. Dilution/Conc. Retrieval 
BCAT1 (hu) Proteintech, 13640-1-AP 4.07 μg/ml Sodium Citrate, 20’ 
CAIX (hu) BioScience Slovakia, AB1001 1:1000 Sodium Citrate, 20’ 
MCT1 (hu) Atlas, HPA003324 1:500 Tris EDTA, 20’ 
MCT4 (hu) Atlas, HPA021451 1:500 Tris EDTA, 20’ 
3.3.6 Normoxia vs Hypoxia experiments 
For investigating the effects of hypoxia in vitro, cells were seeded on 100 mm diameter dishes. 
For normoxia experiments, the cells were incubated in 5% CO2 at 37oC in a Heracell incubator 
(Thermofisher). For hypoxia experiments, the cells were incubated in a Tri-Gas incubator set 
at 1% O2, 5% CO2 and 37oC or in a hypoxia chamber set at 0.1% O2, 5% CO2 and 37oC for at 
least 72 hours. 
3.3.7 IDH1 and IDH2 sequencing 
DNA was extracted from cell pellets using the Purelink Genomic DNA Mini Kit (Invitrogen) 
and eluted in H2O and quantified using a spectrophotometer. Genomic DNA (1000 ng) from 
each cell line was used for a PCR reaction, along with 25 μl Taq 2X Master Mix (New England 
Biolabs), 1 μl of each forward and reverse primers (0.2 μM final concentration) and H2O to 50 
μl total reaction volume. The specific primers used for amplification of IDH1 and IDH2 were: 
IDH1 
Forward: 5'- TGG CAC CAT ACG AAA TAT TCT GG -3' 




Forward: 5’- GTG GGA CCA CTA TTA TCT CTG TC -3’ 
Reverse: 5’- CTG CGG GGA AGT TGT ACA CT -3’ 
 
Thermocycling conditions included an initial denaturation step at 95oC for 30 seconds, followed 
by 40 cycles of 30 seconds at 95oC, 45 seconds of annealing at 51oC and 20 seconds of extension 
at 68oC. Following a final extension step at 68oC for 5 minutes, the PCR products were cooled 
to 4oC and stored at -20oC. The PCR products were run on a 2% agarose Size-Select gel 
(Invitrogen) using E-gel Power Snap equipment (Invitrogen), to confirm the purity of the 
product. The PCR products were subsequently purified using the ExoSAP-IT PCR Product 
Cleanup Kit (ThermoFisher Scientific) and were sequenced by GATC (Eurofins Genomics), 
using the same primers as for amplification. 
3.3.8 Cell protein extraction for enzyme assay 
For enzyme assays, cells and fresh frozen tissue were used. Cells were harvested by 
centrifugation. About 80 μl per 106 cells of cold lysis buffer (50 mM HEPES, 1 mM EDTA, 
0.7 % sodium deoxycholate, 1 % Nonidet P-40, 0.5 M lithium chloride, pH 7.6 with EDTA-
free Protease Inhibitor Cocktail (Roche)) was used to resuspend the pellet. Tissue 
(subcutaneous tumour or brain sample) was resected and snap-frozen in liquid nitrogen. Ten μl 
of cold lysis buffer was added per mg of tissue and the tissue was homogenised in a Precellys 
homogeniser.  
In both cases, the solution was then agitated on an end over end shaker for 30 minutes at 4oC, 
followed by centrifugation at 21,000g for 20 minutes at 4oC. Protein content was quantified 
using a Direct Detect Infrared Spectrometer (Merck), which uses Mid-Infrared Spectroscopy 
and integrates the amide band in the absorbance spectrum.  
3.3.9 Spectrophotometric BCAT Assay 
The assay described in Cooper et al158 was optimised for measuring BCAT activity in cell and 
tissue extracts. In summary, the reaction contained 5 mM leucine, 5 mM α-KG, 5 mM 
ammonium sulphate, 0.05 mM NADH, 0.5 mM GTP, 1 mM DTT, 1.9 U leucine dehydrogenase 
and 5 μl to 20 μl of cell extract in 100 mM potassium phosphate buffer (pH 7.4) in a final 
volume of 200 μl. All reagents were purchased from Sigma Aldrich except leucine 
dehydrogenase, which was purchased from Merck. All reagents except α-KG were added to the 
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wells of a UV transparent 96 well plate (Corning), which was incubated at 37oC, and the 
reaction initiated by addition of α-KG. Absorbance at 340 nm was measured every 30 seconds 
to 1 minute for about 45 minutes at 37oC in a Pherastar or Clariostar microplate reader (BMG 
Labtech). For every extract, a control with no leucine dehydrogenase was measured.  
3.3.10 Competitive inhibition of BCAT1 in vitro 
Gabapentin, purchased from Sigma-Aldrich, was dissolved in potassium phosphate buffer (100 
mM, pH 7.4) to give a 400 mM stock solution. 4-methyl-5-oxohexanoic acid, purchased from 
Chemspace, was dissolved in potassium phosphate buffer (100 mM, pH 7.4). The reaction 
mixture for the BCAT spectrophotometric assay was prepared as described earlier, with slight 
modifications. Varying volumes of gabapentin or 4-methyl-5-oxohexanoic acid were added to 
give the required final inhibitor concentrations (0, 5, 10, 20, 40 mM). Appropriate volumes of 
potassium phosphate buffer were added to each reaction mixture to ensure equal total volumes 
of 200 μl. The reduction in NADH absorbance at 340 nm was measured. 
3.3.11 Reverse Transcriptase Quantitative PCR 
RNA extraction of frozen cell pellets was performed using the Qiagen RNA isolation kit 
(RNeasy Mini Kit). RNA was quantified using the Qubit RNA BR Assay Kit. A mixture of 1 
μg of the RNA sample, 2 μl of 50 μM oligo dT solution, 1 μl of 10 μM dNTP solution and the 
appropriate volume of nuclease free water to make a 17 μl volume, was incubated at 65oC for 
10 minutes. Upon addition of M-MuLV Reverse Transcriptase (NEB) and M-MuLV Buffer 
(NEB), as stated in the manufacturer’s protocol, the solution was incubated at 42oC for 1 hour, 
65oC for 10 minutes and was then placed on ice. The resulting cDNA solution was stored at -
20oC. For qPCR, the following oligonucleotides were used as primers: 
BCAT1 Forward: 5’ CTGCCCCAGGTCTTGCTG 3’ 
BCAT1 Reverse: 5’ TGCAATCCTTCATTGTTCCGTC 3’ 
BCAT2 Forward: 5’ GGGCAGATCTGGGCACG 3’ 
BCAT2 Reverse: 5’ GTCTGCAGCCTTGAAACTGG 3’ 
Beta-Actin Forward: 5’ CGCCCTATAAAACCCAGCGG 3’ 
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Beta-Actin Reverse: 5’ GCGCGGCGATATCATCATCC 3’ 
Each reaction contained 10 μl Fast SYBR Green master mix (Applied Biosystems), 200 nM 
forward and reverse primers, 20 ng cDNA and nuclease free water, in a total volume of 20 μl. 
The thermal cycling conditions used were an enzyme activation step at 95oC for 20 seconds, 
followed by 40 cycles of a denaturation step at 95oC for 1 second and an annealing/extension 
step at 62oC for 20 seconds. Then, for the Melt Curve Stage, the plate was incubated at 95oC 
for 19 seconds, at 62oC for 1 hour and then at 95oC for 15 seconds. The data were then analysed 
using the QuantStudio software (Applied Biosystems).  
3.3.12 Quantification of Branched Chain Amino Acids in plasma samples 
3.3.12.1 Collection of plasma from rats 
Rats (healthy and tumour-bearing) were fasted for five hours before blood collection. The rats 
were restrained manually, the tail vein punctured using a needle and 20-50 μl of blood was 
collected in an EDTA-coated tube (BD) and immediately placed on ice. The samples were then 
centrifuged at 2000 g for 10 minutes and the plasma transferred to an Eppendorf tube and stored 
at -20oC until analysis. 
3.3.12.2 Branched Chain Amino Acid assay 
For quantification of BCAA concentrations in the plasma samples, Abcam’s BCAA Assay kit 
was used, following the manufacturer’s protocol. The kit uses an enzyme assay in which 
BCAAs are deaminated producing NADH which then reduces a substrate to generate a coloured 
product which absorbs at 450 nm. Increasing volumes of leucine stock solution were added to 
wells of a 96-well plate to make 0, 2, 4, 6, 8 and 10 nmol/well standard samples. 5-20 μl of 
plasma sample was used for the assay and the total volume of the standard and test samples was 
adjusted with assay buffer to 50 μl. To each well, 50 μl of a mixture of the enzyme and substrates 
was added. For background subtraction of endogenous NADH and NADPH, samples were also 
mixed with a background control mixture which lacked the enzyme. The plate was incubated 
at room temperature for 30 minutes before measuring the absorbance on a plate reader 
(Clariostar, BMG Labtech). 
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3.3.13 In vitro 13C leucine labelling experiment 
[1-13C]leucine (Sigma-Aldrich) was used to quantify the label exchange between leucine and 
ketoisocaproate. Cells were seeded at 70-80% confluency in T75 flasks in DMEM BCAA-free 
media. For media formulation, amino acid free DMEM media (Genaxxon) was used and 
supplemented with glutamine and non-essential amino acids as well as the growth factors B27, 
N2, FGF, EGF. [1-13C]leucine was added at a final concentration of 0.8 mM. The cells were 
incubated at 37oC, in 5% CO2 for 48 hours before metabolite extraction. For metabolite 
extraction of cell media, the media was collected and added to 20 ml of cold methanol, followed 
by centrifugation at 21000 g for 5 minutes at 4oC. The extracts were then dried in a nitrogen 
stream and lyophilised overnight. They were then dissolved in D2O containing TMSP at a final 
concentration of 20 mM and proton decoupled 13C NMR spectra were acquired at 14 T using 
the following parameters: 6000 scans, 249 ppm spectral width, 1.7 sec acquisition time, 12 sec 
delay time, 90o flip angle. 
3.3.14 Extracellular glutamate quantification 
For quantification of glutamate levels in the cell media, the Promega GlutamateGlo assay was 
used, following the manufacturer’s instructions. Cells (2 x 104) were seeded in each well of a 
96 well plate with 100 μl of fresh Neurobasal medium. The cells were incubated for 18 hours, 
before collecting the media and quantifying the glutamate in it using the GlutamateGlo assay 
in a white plate.  
3.3.15 BCAT1 and BCAT2 knockdowns 
3.3.15.1 Lentiviral plasmid generation 
Two plasmids were used for the generation of stable BCAT1 knockdowns in the A11 patient-
derived glioblastoma cell line. pLKO.1 - TRC cloning vector was a gift from David Root159 
(Addgene plasmid # 10878; http://n2t.net/addgene:10878; RRID:Addgene_10878) and 
pLKO.1-Tet-OnTet-pLKO-puro was a gift from Dmitri Wiederschain160 (Addgene plasmid # 
21915; http://n2t.net/addgene:21915 ; RRID:Addgene_21915). 
The plasmids were digested using AgeI (New England BioLabs) and EcoRI (New England 
BioLabs), as stated in the manufacturer’s protocol. Five μg PLKO.1 vector was digested with 
1 μl of each enzyme and 5 μl CutSmart buffer was used in a total volume of 50 μl. Control 
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reactions with both or either of the two enzymes missing were also performed. The reaction 
mixtures were incubated at 37oC for 2 hours, followed by an inactivation step at 65oC for 5 
minutes. 
The restriction digest products were then mixed with DNA Gel Loading Dye (6X) 
(ThermoFisher Scientific) and run on a 1% Agarose TAE gel containing SYBR™ Safe DNA 
Gel Stain (ThermoFisher Scientific) at 80V for one hour. The band corresponding to the 
digested vector backbone was extracted and purified using the PureLink® Quick Gel Extraction 
Kit (ThermoFisher Scientific) and quantified on a Nanodrop Spectrophotometer.  
The shRNA oligos used for BCAT1 knockdown were as described in Tonjes et al51: 
shBCAT1 Forward: 
5' - CCGGCCCAATGTGAAGCAGTAGATACTCGAGTATCTACTGCTTCACATTGGGT 
TTTT - 3’ 
shBCAT1 Reverse: 
5’ - AATTAAAAACCCAATGTGAAGCAGTAGATACTCGAGTATCTACTGCTTCACA 
TTGGG - 3’ 
The shRNA oligos used for BCAT2 knockdown were: 
shBCAT2 Forward: 
5’ - CCGGACTACAAGTTAGGTGGGAATTCTCGAGAATTCCCACCTAACTTGTAGTT 
TTTTG - 3’ 
shBCAT2 Reverse: 
5’ - AATTCAAAAAACTACAAGTTAGGTGGGAATTCTCGAGAATTCCCACCTAACT 
TGTAGT - 3’ 




5’ - CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG 
- 3’ 
shCtrl Reverse: 
5’ – AATTCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG 
- 3’  
The forward and reverse oligos were resuspended in nuclease-free water to give a 100 μM 
solution. 1 μl of each of the forward and reverse oligos were mixed with 48 μl of annealing 
buffer (100 mM NaCl in 50 mM HEPES pH 7.4) in Eppendorf tubes, which were placed in a 
beaker containing boiling water and incubated overnight to cool down slowly. 
The annealed oligos were diluted (1:100) in annealing buffer and the ligation reaction between 
the annealed oligos and the digested vector was set up as follows: 20 ng of the digested vector 
was mixed with 2 μl ligase buffer (New England BioLabs), 1 μl T4 DNA ligase enzyme (New 
England BioLabs), 1 μl of the annealed oligos and nuclease-free water in a total volume of 20 
μl. The reaction was incubated at room temperature for two hours followed by an enzyme 
inactivation step at 65oC for 5 minutes. 
Thirty μl of One Shot™ Stbl3™ Chemically Competent E. coli (ThermoFisher Scientific) were 
transformed with 1 μl of the ligated product. The bacteria were mixed with ligated product and 
placed on ice for 15 minutes. They were then heat-shocked for 45 seconds at 42oC and placed 
on ice for a further two minutes. S.O.C. (Super Optimal Broth with Catabolite repression) 
medium (250 μl) was added to the bacteria and the mixture was shaken at 37oC for about two 
hours and then spread on a LB plate containing Ampicillin and incubated overnight.  
Colonies from each plate were inoculated in an overnight culture in 5 ml LB Ampicillin (0.1 
mg/ml) and the DNA extracted using the QIAprep Spin Miniprep Kit and sequenced by GATC 
(Eurofins Genomics), using primers: 
PLKO.1 Sequencing primer:  
5’ CAA GGC TGT TAG AGA GAT AAT TGG A 3’ 
TetON-PLKO.1 Sequencing primer: 
5’ GGC AGG GAT ATT CAC CAT TAT CGT TTC AGA 3’ 
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Colonies with the correct sequence were inoculated in 2 ml LB supplemented with ampicillin 
(0.1 mg/ml) for 2 hours and then overnight in 200 ml LB supplemented with ampicillin (0.1 
mg/ml). DNA was extracted from the bacterial cultures using QIAprep Spin Maxiprep Kit. 
3.3.15.2 HEK 293 cell transfections 
HEK 293 cells were seeded in 10 cm culture dishes and grown to almost confluency. For each 
transfection reaction, 80 μl Lipofectamine™ 3000 Transfection Reagent were mixed with 500 
μl serum-free DMEM media in an Eppendorf tube. In a second Eppendorf tube, 7.5 μg psPAX2, 
2.5 μg D2G and 10 μg of the lentiviral plasmid were mixed with 500 μl serum-free DMEM 
media. psPAX2 and pMD2.G were gifts from Didier Trono (Addgene plasmid # 12260; 
http://n2t.net/addgene:12260; RRID:Addgene_12260 and Addgene plasmid # 12259; 
http://n2t.net/addgene:12259; RRID:Addgene_12259). 
The diluted transfection reagent mixture was then added to the plasmid mixture and following 
brief vortexing, the solution was incubated at room temperature for 30 minutes. The HEK 293 
cells were washed with PBS and 4 ml fresh serum-free DMEM media were added. The 
transfection reagent and plasmid solution were added to the cells, which were then incubated at 
37oC overnight. Five ml fresh DMEM media supplemented with FBS were added to the cell 
cultures the following morning and incubated for a further 30 hours. The cell medium, 
containing viral particles, was then collected in 15 ml Falcon tubes and centrifuged at 1500 g 
for 3 minutes. The supernatant was passed through a 0.45 μm filter to remove any cells and 
stored at -20oC.  
3.3.15.3 PDX glioma cell infections 
A11 PDX cells were seeded and grown to confluency in a 6-well plate. The viral particles were 
defrosted in a water bath at room temperature. The cells were washed with HBSS and 1 ml of 
fresh serum-free Neurobasal media (with no antibiotics) was added to each well followed by 8 
μl of 5 mg/ml polybrene solution. One ml of the viral particle solution was then added to the 
cells. The virus containing media were removed 24 hours after the infection and 2 ml fresh 
serum-free Neurobasal media were added to the cells, which were incubated for a further 24 
hours to enable recovery.  
The infected cells were selected with puromycin (Gibco™ Puromycin Dihydrochloride), which 
was added to the media at a final concentration of 2 μg/ml. Fresh puromycin containing media 
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was added to the cells every 2 days, for 8 days, until the control cells were dead from puromycin 
toxicity. The selected cells were then grown, and stocks frozen for subsequent experiments. 
For induction of BCAT1 and BCAT2 knockdown in the cells infected with the inducible 
knockdown construct, Doxycycline Hyclate (Sigma) was used at a concentration of 50 ng/ml 
for time periods ranging from 48 hours to 7 days. 
3.3.16 BCAT1 overexpression 
The coding region of human BCAT1 was isolated from a GeneArt plasmid (Thermo Fisher 
Scientific), by restriction digestion using BamHI (NEB) followed by gel extraction and 
purification. The BCAT1 coding region was then ligated onto an EF1 plasmid backbone at an 
insert to vector ratio of 3:1 and the ligated product was used to transform Stbl3 bacteria. The 
plasmid was isolated from the bacterial culture and sequenced to confirm the presence of the 
correct coding sequence for BCAT1. 
HEK293 cells were transfected as described in section 3.3.2 using pMDL packaging plasmid 
(Addgene #12251), pCMV-VSV-G envelope vector (Addgene #8454) and pRSV-Rev 
(Addgene #12253). Lentiviral isolation and infection of GBM cells were performed as 
described in section 3.3.3. 
Cells that were successfully infected with the lentivirus and hence expressed mStrawberry, were 
FACS sorted into a 6-well plate and expanded to form BCAT1 overexpressing cell lines or 
luciferase overexpressing control cell lines. 
3.3.17 Cell proliferation assays 
3.3.17.1 Measuring confluency over time 
The rate of cell proliferation was quantified using an Incucyte Live Cell Analysis System (Essen 
BioScience). Equal numbers of cells were seeded in 6-well, 48-well or 96-well plates in 1000, 
250, and 100 μl of growth medium, respectively. The plates were incubated in 5% CO2 at 37οC 
in the Incucyte. Phase contrast images were taken every 3 hours until the cells reached 100% 
confluency. For assessing cell death, Incucyte Cytotox Red Reagent (Essen BioScience) at a 
final concentration of 250 nM was also added to the medium and dead cells were imaged using 
the red fluorescence lasers on the Incucyte. Cell proliferation was measured using the % 
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confluence mask of the Incucyte Cell Analysis software, while cell death was monitored using 
the Red Object Count per mm2.  
3.3.17.2 Measuring cell number over time 
For assessing the proliferation rate of the cells in terms of the increase in cell numbers over 
time, cells were seeded in 6-well plates at a starting density of 100 000 cells/well with 2 ml of 
media. Cells were collected at different timepoints and the number of viable cells as well as the 
percentage viability were measured using the Vi-Cell (Beckman Coulter).  
3.3.17.3 Luciferase based assay 
A luciferase assay (RealTime Glo, Promega) was performed to monitor the number of live cells 
over time in a 96 well plate, following the manufacturer’s protocol. Briefly, 3000 live cells were 
seeded per well in an opaque white 96-well plate in 100 μl media containing 1X Nanoluc 
luciferase enzyme and 1X MT cell viability substrate. In a live cell, the MT cell viability 
substrate is reduced to the Nanoluc luciferase substrate which will then react in the presence of 
luciferase to produce a luminescent signal. The plates were incubated at 37oC for 72 hours and 
luminescence was read on a plate reader (Clariostar, BMG Labtech) at different timepoints.  
3.3.18  Cell Migration and Invasion Assays 
3.3.18.1 Scratch Wound Assay for Cell Migration 
For investigating cell migration, a scratch wound assay was used. Cells were seeded in a 96-
well plate (Essen Bioscience, Image lock plate) at high density (40000-50000 cells per well) 
and grown to confluence before a scratch wound was made using the WoundMaker (Essen 
Bioscience). The cells were incubated in 5% CO2 at 37oC in the Incucyte and cell migration 
was monitored over three to four days, by recording images every 3 hours. The initial scratch 
wound mask was used to calculate relative wound density over time. 
3.3.18.2 Scratch Wound Assay for Cell Invasion 
For cell invasion assays, a similar setup was used as for cell migration. Once the scratch wound 
was made, the wound was filled with 50 μl Matrigel Growth Factor Reduced (Corning) and the 
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plate incubated at 37oC for 30 minutes for the Matrigel to solidify. Media (100 μl) was then 
added in each well and the plate placed in the Incucyte.  
3.3.18.3 Three-dimensional spheroid invasion assays 
For a better representation of glioblastoma invasion, the glioblastoma cells were grown as 
neurospheres. This was achieved either by using hanging drop cultures, or by seeding the cells 
in Ultra Low attachment 96-well plates (4000 cells/well), as described in the tumour spheroid 
invasion assay protocol101.  
For the hanging drops, droplets of 30-50 μl of a 106 cells/ml cell suspension were deposited on 
the lid of a 10 cm dish and incubated for 4 days, for the spheroids to form. The droplets were 
then collected, centrifuged at 300 g for 5 minutes, resuspended in a 1:1 matrigel: collagen 
mixture and seeded in a 96- or 48-well plate. The spheroid-containing wells were then imaged 
on a Zeiss Live cell imaging microscope.  
In Ultra Low attachment 96-well plates, glioblastoma cells self-assembled into uniformly sized 
spheres. The spheres were grown for two days. On the day of the invasion assay, 100 μl of cold 
Matrigel was added on top of the neurospheres and the plates were incubated at 37 oC for the 
Matrigel to solidify. Fresh media was then added on top of the Matrigel layer and the plates 
were placed in the Incucyte microscope for images to be taken at 3-hour intervals over four 
days. 
For manual image analysis Fiji (ImageJ) software was used to draw regions of interest and 
measure parameters such as sphere area and diameter, total area covered by cells, distance of 
invading cells from the sphere at different timepoints. For automated analysis of the Incucyte 
data, the images were exported and analysed using a Python script. The algorithm used 
implemented established contrast enhancement (Contrast Limited Adaptive Histogram 
Equalization), denoising (Non-local means denoising) and thresholding tools. The areas 
containing cells were identified by measuring the standard deviation within small contiguous 
regions. To distinguish between the invaded area and the spheroid area, regions of interest 
around the spheroids were drawn.  
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3.3.19 Flow cytometry experiments 
3.3.19.1 Cell surface expression of CD147 
For assessing cell surface expression of CD147, approximately 1 million cells were collected 
using Accutase (Gibco, StemPro) and stained with Alexa Fluor 647 anti-CD147 antibody 
(BioLegend) at a dilution of 1:100 in Flow cytometry staining buffer (3% FCS, 0.05% Sodium 
Azide in PBS) for 30 minutes at 4oC. Following three washes with staining buffer, DAPI (5 
μg/ml) or Propidium Iodide (200 ng/ml) were added to the cells, which were filtered and 
analysed using an LSRII Flow Cytometer. For data analysis FlowJo software was used, where 
dead cells were excluded and the median fluorescence intensity of live cells bound to CD147 
antibody was measured. 
3.3.19.2 Cell Cycle Analysis 
For cell cycle analysis of the BCAT1 knockdown A11 cells, following 6-day long doxycycline 
treatment for knockdown induction, approximately 1 million cells were harvested using 
Accutase, washed with PBS and fixed in 4.5 ml of ice cold 70% ethanol for at least 2 hours at 
4oC. The fixed cells were kept at -20oC until stained and analysed.  
For synchronizing the cells before fixation, a double thymidine block protocol was used161. 
Equal number of cells (around 500 000) were seeded in 6 well plates and allowed to attach 
overnight. Cells were then incubated with 2 mM thymidine for 18 hours, fresh media for 9 
hours and another dose of 2 mM thymidine for 18 hours. After the second thymidine incubation, 
the synchronized cells were released and collected at different timepoints for fixation. 
For staining, the fixed cells were centrifuged for 5 minutes at 300 g and the pellets were washed 
with PBS. Following centrifugation, the pellets were resuspended in 600 μl of Propidium Iodide 
Staining Solution (0.1% Triton X, 2 mg RNAse, 20 mg/ml Propidium Iodide in PBS) and 
incubated at 37oC for 15 minutes with gentle shaking. The cells were then filtered and analysed 
on an LSRII (BD) flow cytometer, without any washing steps. 




3.3.19.3 Cell death assessment 
For assessing cell death, cells were harvested using Accutase treatment and washed with HBSS. 
Following centrifugation at 1000 g for 3 minutes, they were washed once in flow cytometry 
staining buffer and centrifuged again. The pellets were resuspended in 100 μl Sytox Green 
(Invitrogen) at 100 nM final concentration and the cell suspension mixed for 10 minutes at 
37oC. The cells were then washed in 400 μl flow cytometry staining buffer and finally 
resuspended in 500 μl buffer for flow cytometry analysis on a FACSymphony (BD) cytometer. 
3.3.20 Cell irradiation 
For radiotherapy experiments, cells were seeded in 6 well plates and irradiated using a caesium 
gamma ray irradiator (IBL 637). Irradiation time was varied to adjust the total desired dose in 
Gy.  
3.3.21 Limiting Dilution Assay 
For determining the neurosphere formation capacity of GBM cells, a limiting dilution assay 
was performed. Inducible shScr and shBCAT1 expressing A11 cells were treated with 
doxycycline for 6 days. They were then harvested by Accutase treatment and centrifugation, 
washed with PBS, resuspended in 600 μl PBS, filtered and placed in BD Flow Cytometry tubes. 
DAPI was added to each cell suspension at a final concentration of 5 μg/ml. Live cells were 
then sorted on an Influx cell sorter (BD) by excluding the DAPI positive cells. For each cell 
sample, 1, 5, 10 and 20 cells were seeded per well in a 96 well plate containing complete 
Neurobasal Media with or without doxycycline. The cells were then allowed to grow for 3-4 
weeks with no media changes or further doxycycline treatment. At the endpoint, the number of 
neurosphere-containing wells per group was counted and the data analysed using the Extreme 
Limiting Dilution Analysis (ELDA) software95. 
3.3.22 RNA sequencing 
The inducible BCAT1 knockdown constructs were used to investigate the transcriptional 
changes upon doxycycline-induced BCAT1 knockdown. A11shBCAT1 and A11shScr cells 
were treated with doxycycline or were kept as controls for 7 days, before harvesting them and 
extracting RNA using a RNeasy Mini Kit (Qiagen). RNA was quantified and quality tested 
using the Agilent 4200 TapeStation system. BCAT1 knockdown was confirmed on qPCR, 
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before submitting the samples for RNA sequencing analysis in the Genomics Core Facility at 
CRUK Cambridge Institute. For library preparation, the Illumina Truseq stranded mRNA kit 
was used, and single read sequencing was performed on a HiSeq 4000 machine (Illumina). 
The RNA sequencing results were processed by the Bioinformatics core facility who performed 
quality checks and generated a list of differentially expressed genes. For gene enrichment 
analysis, online tools including Metacore (Clarivate analytics) and EnrichR162,163 were used.  
3.3.23 Alpha-ketoglutarate quantification 
3.3.23.1 Fluorometric Assay 
For quantification of intracellular α-KG the fluorometric Alpha Ketoglutarate assay kit 
(Abcam) was used and the protocol slightly modified to increase the sensitivity of the assay. 
Cells were grown to 70-80% confluency in T75 flasks to give a cell number of greater than five 
million cells per sample. For metabolite extraction, all steps were performed on ice. The flask 
was placed on ice, the cell media was aspirated, and the cells washed with PBS and any 
remaining PBS aspirated. Perchloric acid (100 μl, 2M) was added directly on the cells and a 
cell scraper used to detach the cells. The extract was mixed for 10 minutes at 4oC and 
centrifuged at 21,000 g for two minutes at 4oC. The pH was then adjusted to 7 by addition of 
KOH (5M) before the extract was centrifuged again at 21,000 g for 10 minutes at 4oC. The 
supernatant was then used for analysis using the assay instructions provided by Abcam in a 96 
well black plate. In this assay, α-KG is transaminated with the generation of pyruvate which is 
used to convert a colourless probe to a fluorescent product. Fluorescence was measured using 
the Clariostar microplate reader (BMG Labtech).  
3.3.23.2 Liquid Chromatography Mass Spectrometry 
For a more accurate measurement of intracellular α-KG concentration, liquid chromatography 
mass spectrometry (LCMS) was used. Cells were seeded in 6-well plates and treated with 
doxycycline or kept as controls for four days. Cell number and cell volume were quantified on 
the day of the extraction, using one of the wells for each condition on a CASY cell analyser. 
For metabolite extraction, the plates were placed on ice, the media was aspirated and the cells 
were washed with PBS twice. Extraction solution (500 μl of 50% Methanol, 30% Acetonitrile, 
20% Ultrapure Water, d8-Valine at a final concentration of 5 μM per million cells) was added 
to each well and the plates incubated on dry ice for 15 minutes. Cells were scraped from the 
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wells, transferred to pre-cooled Eppendorf tubes and agitated at maximum speed for 15 minutes 
at 4oC. The extracts were then incubated for 1 hour at -20oC, vortexed and centrifuged at 21,000 
g for 10 minutes at 4oC. The supernatant was transferred to autosampler vials, which were 
submitted for LCMS Analysis at the Frezza Lab (MRC Cancer Unit).  
3.3.24 Global DNA methylation analysis 
For quantification of relative cytosine, 5-methylcytosine and 5-hydroxymethylcytosine levels 
in cells, LCMS analysis was performed by the Pharmacokinetics and Bioanalytics core facility 
in the institute. Cells were harvested using Accutase detachment and centrifugation and DNA 
was extracted using a Purelink Genomic DNA Mini Kit (Invitrogen) following manufacturers’ 
guidelines. For DNA degradation to 2-deoxynucleosides, up to 1 μg DNA was incubated with 
5 units DNA Degradase Plus (Zymo Research) for four hours at 37oC.  
3.3.25 [2-13C,15N]leucine infusion experiment 
[2-13C,15N]leucine infusions were performed to investigate the involvement of leucine in the 
TCA cycle and the fate of nitrogen in the tumours. A11shScr and A11shBCAT1 tumour-bearing 
mice were fed with a doxycycline-containing diet or vehicle diet for 7-10 days. For the infusion, 
they were anaesthetised and their tail vein cannulated. The infusion protocol consisted of a 
bolus injection of 300 mg/g body weight and a continuous infusion of 0.0069 mg/g body weight 
min-1 for 150 minutes using an infusion pump. At the end of the infusion, the mice were 
sacrificed by cervical dislocation followed by blood collection in EDTA coated tubes, 
dissection and flash freezing of the tumour and the contralateral hemisphere in liquid nitrogen. 
The blood samples were processed by centrifugation at 2000 g in Eppendorf tubes for 20 
minutes to collect the plasma. Labelled leucine enrichment was measured in metabolite extracts 




3.4.1 Differential expression and activity of BCAT isozymes was observed 
across a panel of patient-derived glioblastoma cells 
3.4.1.1 Protein levels in cell lysates 
For studying the role of branched chain amino acid metabolism in glioblastoma, a panel of 
patient-derived glioblastoma cell lines was used, including: A11, S2, SP20 and A25. The 
commercially available human glioma cell lines U87 and U251 were also used for comparison, 
as well as a colorectal cancer cell line, Colo205. Western Blots were performed on whole cell 
lysates to assess the expression of BCAT1 and BCAT2 across the panel of cell lines with 
GAPDH or beta actin as loading controls. Differential BCAT1 and BCAT2 expression was 
observed across the different cell lines (Figure 24). 
 
Figure 24 BCAT1 and BCAT2 expression in a panel of GBM patient-derived cells. (A) Representative Western Blots of 
BCAT1 and BCAT2 in cell lysates, with GAPDH and beta-actin used as loading controls. Quantitative analysis of BCAT1 (B) 
and BCAT2 (C) protein expression across the panel of cell lines. Each point on the graphs corresponds to an independent 
experiment and error bars represent Standard Deviations.(D) BCAT1 and BCAT2 mRNA levels relative to levels of b-actin 
mRNA from 2 independent experiments. (E-F) Western Blot of CoxIV and beta-actin in cell lysates (E) and quantitative data 
from it.  
U87 which is an established cell line and was used here as a reference since it was used by 
Tönjes et al in their investigation of the role of BCAT1 in glioblastoma51, showed moderate 
levels of BCAT1 expression and no BCAT2 expression. Of the patient-derived cell lines, A25 
showed the highest BCAT1 expression, even higher than U87 and U251. A11 showed moderate 
BCAT1 expression and SP20 had lower levels of BCAT1 while S2 had the lowest levels of 
BCAT1, which were not detectable on a western blot. 
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BCAT2 protein levels showed an opposite pattern. U87 showed no detectable BCAT2. Of the 
patient-derived cell lines, A25 which had the highest BCAT1 levels showed the lowest 
expression of BCAT2, whereas S2 had high BCAT2 levels. A similar pattern was observed 
when measuring mRNA levels of BCAT1 and BCAT2. Interestingly, mRNA levels of BCAT2 
were higher than those of BCAT1 across all the cell lines and U87 had high levels of BCAT2 
mRNA even though this was not reflected in the levels of the protein. 
In order to establish whether the differences in BCAT2 levels between cell lines were a result 
of different mitochondrial content in the cells, Western Blots for Cytochrome c oxidase subunit 
4 (COX IV) were performed. BCAT2 levels were not correlated with mitochondrial content 
(Figure 24). 
3.4.1.2 Protein levels in spheroid culture and xenograft lysates 
Since protein expression is often highly dependent on the cell’s environment, we assayed 
BCAT1 protein expression in two more models, which are more representative of human 
glioblastoma. We performed western blots on lysates of cells grown in spheroid culture, instead 
of a monolayer, and in lysates of tumours grown following intracranial implantation of the cells 
in athymic rats. The Western Blots indicated that the pattern of expression across the panel of 
cell lines persists in spheroid culture and in the orthotopic tumours, as shown in Figure 25. 
BCAT1 expression is higher in A11 cells grown as neurospheres than in monolayer culture and 
even higher in the tumours, which might be a result of BCAT1 upregulation in hypoxia as 
discussed later (Figure 31).  
 
Figure 25 Western Blot of BCAT1 expression in spheroid culture and in orthotopic tumours. Neurosphere lysates were 
generated from A11 cells and two genetically engineered clones of S2: S2myc which overexpresses c-Myc and S2strawberry 
which overexpresses mStrawberry. PDOX lysates were generated from tumours derived from A11 and S2 cells. (A) Western 
Blot for BCAT1, with GAPDH as a loading control (B) Quantitative expression data for monolayer culture, neurosphere culture 




Immunohistochemical analysis was performed on sections from rat brain containing A11, S2 
and SP20 PDOXs in order to observe the expression pattern of BCAT1 in these GBM models. 
S2 PDOXs showed minimal BCAT1 staining, in accordance with the Western Blot data. A11 
and SP20 showed higher BCAT1 staining which was heterogeneous with some cells expressing 
more enzyme than others (Figure 26). SP20 tumours are highly heterogeneous and invasive and 
therefore histology on these sometimes reveals tumour cells dispersed through the normal brain 
parenchyma (Figure 26 G,I) and more rarely, a clear tumour mass containing mostly cancer 
cells can be seen (Figure 26 H).  
 
Figure 26 Immunohistochemical staining for BCAT1 in PDOXs in athymic rats. Representative images of sections from S2 
(A-C), A11 (D-F) and SP20 (G-I) tumours. Each image is from a different animal. 
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3.4.1.4 S2 cells are IDHwt  
BCAT1 has been shown to be downregulated in IDHmut GBM and upregulated in IDHwt 
GBM. DNA sequencing for IDH1 and IDH2 was performed on DNA extracted from S2 cells, 
confirming that they do not have IDH mutations (Figure 27).  
 
Figure 27 Sequencing of S2 cells revealed no mutation in codons 132 and 172 of the IDH1 and IDH2 genes, respectively. 
3.4.1.5 Enzyme activity levels in cell extracts 
Using a modified protocol for the coupled spectrophotometric assay developed by Cooper et 
al158, the levels of total BCAT activity were measured in whole cell lysates of the glioblastoma 
primary cell lines and compared with established glioblastoma cell lines, including U87. An 
overview of the reaction is shown in Figure 28. This assay follows the conversion of L-leucine 
to its ketoacid, a-ketoisocaproate (KIC), via the transamination reaction catalysed by BCAT1 
and BCAT2. In the presence of excess leucine dehydrogenase, any KIC produced will be 
converted to leucine, oxidising NADH. Therefore, by recording absorbance at 340 nm, which 
is a measure of the NADH concentration, and measuring the rate of decrease of NADH levels, 
the BCAT activity can be estimated. The limitation of this assay is the presence of glutamate 
dehydrogenase in the cell lysates, which can convert α-KG (present in the reaction mixture) to 
glutamate, also oxidising NADH. Therefore, the measured reduction in absorbance at 340 nm, 
is actually the result of the combined activities of BCAT1, BCAT2 and Glutamate 
Dehydrogenase. The addition of the no Leucine Dehydrogenase control, enabled us to measure 
the contribution of the glutamate dehydrogenase activity to the reduction in NADH levels158. 
By subtracting the rate of NADH oxidation in the reaction without Leucine Dehydrogenase 
from the rate of NADH oxidation in the full reaction, an estimate of the combined BCAT1 and 




Figure 28 Overview of the spectrophotometric assay. In the presence of BCAT in the cell lysate, leucine will be converted to 
KIC while α-KG is converted to glutamate. An excess of leucine dehydrogenase will convert the KIC produced to leucine, using 
NADH. Decreases in NADH concentration are measured from the decrease in absorbance at 340 nm. 
The total BCAT activity was similar across most of the cell lines, at approximately 8 nmol 
NADH/minute/mg protein. A25 cells, which showed very high levels of BCAT1 on the western 
blots, had much higher total enzyme activity compared to the other cells. 
To distinguish between the relative contribution of BCAT1 and BCAT2 towards the total 
activity measured by the spectrophotometric assay we used gabapentin, which is a competitive 
and selective inhibitor of BCAT1 but not BCAT2. Gabapentin was added at increasing 
concentrations (0 mM to 40 mM) to the assay in order to eliminate the activity of BCAT1 and 
thus enable measurement of the remaining BCAT2 activity. The decrease in NADH absorbance 
at 340 nm in the control samples, which is a measure of glutamate dehydrogenase activity, was 
not affected by gabapentin.  
Figure 29B demonstrates inhibition of BCAT1 by increasing gabapentin concentrations in 
enzyme extracts. The pattern of enzyme activities measured across the panel of cell lines 
showed good agreement with the protein levels measured by Western Blot, indicating that the 
protein level is a good measure of the activity levels in the cells. For example, A25 cells, which 
showed the highest BCAT1 expression (Figure 24), also showed the highest reduction in 
enzyme activity following gabapentin treatment. S2 cells, on the other hand, which showed no 
BCAT1 expression on the western blot showed no reduction in the total activity upon 
gabapentin treatment. In addition, U87 cells showed no BCAT2 expression on western blot, 
which was confirmed by the very small residual BCAT activity upon BCAT1 inhibition with 




Figure 29 Measurement of BCAT activity in cell lysates using a spectrophotometric assay. (A) The combined BCAT1 and 
BCAT2 activities were compared across the panel of patient-derived primary cells as well as the established human cell line, 
U87 and the rat cell line, C6. Each point represents a different biological replicate. Two-tailed t-tests were performed to 
compare the total activities of different cell lines. *p<0.05, **p<0.01, ***p<0.001 (B) Total BCAT activity in cell lysates in 
the presence of increasing concentration of gabapentin. (C) The activity measured in the presence of 20 mM gabapentin is 
plotted as BCAT2 activity and the difference between the activity measured in the absence of gabapentin and the presence of 
20 mM gabapentin is plotted as BCAT1 activity. Error bars represent Standard Error of the Mean (SEM). 
3.4.2 BCAT1 expression is regulated by c-Myc and hypoxia 
3.4.2.1 c-Myc regulates BCAT1 expression 
It has been suggested that c-Myc regulates BCAT1 expression53. To confirm this and to 
investigate the effect of c-Myc on BCAT2 expression, a genetically engineered clone of the S2 
cell line, which overexpresses c-Myc, was used. Overexpression of c-Myc was confirmed in 
lysates of these cells by western blot (Figure 30). Although S2 cell lysates showed no BCAT1 
protein, the lysates of S2myc cells, showed BCAT1 expression on western blots (Figure 30), 
confirming that BCAT1 expression is regulated by c-Myc, as suggested in the literature53. 
BCAT2 levels, on the other hand, were not affected by c-Myc overexpression (Figure 30). This 
is explained by the presence of a c-Myc binding element in its 5’ unstranslated region and the 
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absence of c-Myc binding elements on BCAT2164,165. BCAT1 and BCAT2 are located on 
different chromosomes and while BCAT1 is known to play an important role in embryogenesis, 
organogenesis and in proliferating cells, BCAT2 is not documented to play the same role164.  
 
Figure 30 c-Myc affects BCAT1 but not BCAT2 expression in S2 cells. Western Blots of BCAT1, BCAT2 and c-Myc as well 
as their beta-actin loading controls are shown for S2 and S2myc cell lysates. 
3.4.2.2 The effect of hypoxia on BCAT1, BCAT2 and c-Myc expression 
The first intron of the human BCAT1 gene includes a hypoxia response element and it has been 
suggested that expression of BCAT1 is regulated by HIF-1α166. To investigate the role of 
hypoxia in regulation of BCAT1 expression in glioblastoma, U251, A11 and SP20 glioblastoma 
cell lines were grown in hypoxia (1% O2) and normoxia in 100 mm dishes and then harvested 
for protein extraction. Western blots of whole cell lysates of U251, A11 and SP20 demonstrated 
elevated levels of BCAT1 in cells grown under hypoxia compared to cells grown under 
normoxia (Figure 31). On the other hand, S2 cells grown at oxygen concentrations as low as 
0.1% continued to show no BCAT1 expression (Figure 32). Hypoxia did not have an effect on 
BCAT2 levels, as shown by western blot (Figure 33). The western blots of c-Myc in A11 cells 
showed a significant reduction in c-Myc levels in A11 cells grown under hypoxia, compared to 
the cells grown under normoxia (Figure 33). No such effect was evident in the SP20 cell lysates, 
but these have lower baseline levels of c-Myc and quantitation was more difficult.  
Therefore, the regulation of BCAT1 by HIF-1α has been confirmed in A11 and SP20 cells and 
the regulation by c-Myc has been confirmed in S2 cells. The dependence of A11 and SP20 cells 
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on c-Myc has not been investigated and the relative effects of c-Myc and HIF-1α in the cells 
are unknown.  
 
Figure 31 Hypoxia-induced BCAT1 overexpression in U251, A11 and SP20 cells. Western blots of BCAT1 and beta actin 
loading control for three or four replicates of lysates from cells (U251 cell line as well as A11 and SP20 patient-derived cell 
lines) grown in normoxic and hypoxic conditions (1% Oxygen) for 72 hours and quantitation of band intensities normalised to 
beta actin. Error bars represent the Standard Deviations. Two-tailed unpaired t-tests were used to compare the normoxia and 
hypoxia groups for each cell line. ns p>0.05, *p<0.05, **p<0.01 
 
Figure 32 S2 cells showed no BCAT1 expression under hypoxic conditions. Western blot of lysates from 3 biological 
replicates of cells grown in normoxic conditions and cells grown in a hypoxia chamber at 0.1% O2 concentration. GAPDH 
was used as a loading control. An A11 cell lysate was run on the same gel as a positive control for BCAT1 expression. The 





Figure 33 Effect of hypoxia on BCAT2 and c-Myc protein levels in A11 and SP20 cells. Western blots of BCAT2 and beta-
actin in A11 and SP20 cells under normoxic and hypoxic conditions. Quantitation of BCAT2 band intensities relative to beta-
actin are shown in the top panel. Western blots of c-Myc and beta-actin in A11 and SP20 cells under normoxic and hypoxic 
conditions. Quantitation of c-Myc band intensities relative to beta-actin are shown in the bottom panel. Error bars represent 
the Standard Deviations from three biological replicates. Two-tailed t-tests were performed to compare the expression levels 
in normoxia and hypoxia. *p<0.05. 
3.4.2.3 Constitutive BCAT1 knockdown in A11 cells persists over multiple 
passages 
Based on previous literature suggesting an important role for BCAT1 in glioblastoma, the 
following experiments were performed to further investigate the mechanistic role of BCAT1. 
In order to investigate the phenotypes associated with BCAT1 expression in glioblastoma cells, 
BCAT1 levels were modulated in A11 and S2 patient derived cells using constitutive and 
inducible lentiviral plasmids expressing BCAT1. Constitutive knockdowns have the limitation 
of compensation effects, while inducible knockdowns can avoid those effects enabling the 
investigation of short-term knockdown mediated effects. However, the limitation of the 
inducible knockdown system is the induction with doxycycline, in this case, which can itself 
have confounding effects on the cells, including cell metabolism effects167,168. 
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Transfection of the A11 cells with the constitutive shBCAT1 expressing lentivirus led to good 
BCAT1 knockdown, which was sustained with repeated passages, as shown in Figure 34. 
 
Figure 34 Western blot of BCAT1 and GAPDH confirmed BCAT1 knockdown persists with repeated passages. (A) 
Quantitative analysis of BCAT1 protein expression in shBCAT1 expressing cells relative to the shScr expressing controls. (B) 
Representative Western Blot of BCAT1 and GAPDH loading control in cell lysates. 
3.4.2.4 Optimisation of inducible BCAT1 knockdown  
For inducible BCAT1 knockdown in A11 cells, increasing doxycycline doses (10, 50 and 100 
ng/ml) were used to determine the optimal dose. All three concentrations produced a sufficient 
knockdown (Figure 35), and for further experiments, 50 ng/ml was used. Time course 
experiments were performed to determine the time needed for BCAT1 knockdown to be 
established. Fifty ng/ml doxycycline was used for varying time periods (48, 72 and 96 hours) 
to investigate the kinetics of shRNA expression and subsequent knockdown of the protein. 
BCAT1 protein levels were sufficiently reduced after 72 and 96 hours of doxycycline treatment 
and the doxycycline treatment itself did not seem to have a significant effect on BCAT1 
expression. However, the A11shScr construct had baseline differences in BCAT1 expression 





Figure 35 Optimisation of BCAT1 knockdown by doxycycline induction. (A) Levels of BCAT1 relative to GAPDH loading 
control in shScr and shBCAT1 cell lysates treated with increasing concentrations of doxycycline. (B) Quantitative Western 
Blot data from 3 independent experiments of the time course experiment, showing BCAT1 expression relative to the no 
doxycycline treatment control, with error bars representing SEM. Two-tailed t-tests were performed to compare the levels of 
BCAT1 across different conditions. ns: p>0.05, *p<0.05, **p<0.01, ***p<0.001 (C) Representative Western Blot showing 
BCAT1 expression and GAPDH loading control for A11shScr and A11shBCAT1 cells treated with doxycycline for 24-96 hours 
as well as no treatment controls. 
3.4.2.5 BCAT1 Knockdown leads to reduced BCAT activity in cell lysates 
Total BCAT activity in lysates of A11shBCAT1 and A11shScr cells was compared to the 
activity of lysates of control cells which had not been induced with doxycycline, using the 
BCAT spectrophotometric assay. Total BCAT activity of BCAT1 knockdown cells was 
significantly reduced compared to control lysates (Figure 36A). To directly compare BCAT1 
enzyme activity between BCAT1 knockdown and control cell lysates, gabapentin was added to 
the spectrophotometric assay. The reduction in the total activity measured with increasing 
concentrations of gabapentin was lower in the knockdown cells compared to the control cells, 
demonstrating that BCAT1 activity levels were reduced upon BCAT1 knockdown. The 
remaining activity at 40 mM gabapentin was unchanged, demonstrating that BCAT2 activity 
was unchanged (Figure 36B and C). When directly comparing BCAT1 protein levels and total 
BCAT activity in the same lysates, the change in BCAT1 protein was greater than the change 
in activity levels (Figure 36D), suggesting that post-translational modifications of the enzyme 
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might compensate for the reduced levels of protein expression. Both isoforms of BCAT have a 
redox-active CXXC motif, which can undergo oxidation by H2O2, nitrosation and 
glutathionylation, all of which lead to modulation of enzymatic activity169-171. 
 
Figure 36 Measuring BCAT activity in BCAT1 knockdown and control lysates using the BCAT spectrophotometric assay. 
(A) Lysates of cells expressing a control shRNA (shScr) and shBCAT1, untreated and treated with doxycycline, were assayed 
for total BCAT activity. The activity in the doxycycline-induced cells relative to the activity in the non-induced cells is plotted 
for every biological replicate (n=5) and the error bars represent the Standard Deviations. A two-tailed t-test was performed 
to compare the activity levels between the two groups. **p<0.01 (B) Increasing concentrations of gabapentin were used in the 
spectrophotometric assay to selectively inhibit BCAT1 in the BCAT1 knockdown cell lysates and their controls. Error bars 
represent SEM from 2 independent experiments. (C) The activity measured at 40 mM gabapentin was plotted as BCAT2 activity 
and the difference between the total BCAT activity at 0 mM gabapentin and BCAT2 activity was plotted as BCAT1 activity. 
Error bars represent SEM for two independent experiments. (D) The change in total BCAT activity of the shScr control cells 
and BCAT1 knockdown cells when induced with doxycycline is compared to the change in protein levels of BCAT1 in the same 
lysates. 
3.4.2.6 BCAT1 overexpression in S2 and A11 cells leads to increased levels of 
the protein as well as a fusion protein 
For BCAT1 overexpression experiments, a vector containing the mStrawberry sequence and 
the BCAT1 coding sequence, separated by an E2A sequence was used. For control cells, the 
BCAT1 sequence was replaced with a Luciferase sequence. BCAT1 overexpressing cells are 
labelled as A11 BCAT1 and S2 BCAT1 for A11 and S2 cells, respectively. Control cells, which 




Figure 37 Western Blot analysis of BCAT1 overexpressing A11 and S2 cells and their luciferase-expressing controls. (A) 
Representative Western Blot of BCAT1 and GAPDH loading control in different clones of S2 cells. S2Str: Strawberry and 
Luciferase expressing control, S2BCAT1: BCAT1 overexpressing clone, S2myc: cMyc overexpressing clone. (B) Quantitative 
data from Western Blots showing BCAT1 expression relative to GAPDH for the different cell lines. Error bars represent SEM. 
Two-tailed t-tests were used to compare between the Str controls and BCAT1 overexpressing cells. ***p<0.001, ****p<0.0001 
(C) Western Blot of BCAT1 and GAPDH for A11 and S2 BCAT1 overexpressing cells and controls. The band at 40kDa 
represents BCAT1. The 2 bands at 65-70 kDa only appear in the BCAT1 overexpressing cell lysates. (D) The same bands at 
65-70 kDa also appear in Western Blots when blotting for Red Fluorescent Protein (RFP). 
Western blots of A11 and S2 BCAT1 overexpressing cells showed higher BCAT1 protein 
expression compared to the luciferase expressing controls, and also showed mStrawberry 
protein expression (Figure 37). Two more bands (65-70 kDa) also appeared on the BCAT1 
Western Blot as well as on the Red Fluorescent Protein (RFP) Western Blot suggesting that it 
represents fused mStrawberry and BCAT1 proteins. This is probably the result of using a 
construct containing two genes separated by an E2A sequence, where ribosome skipping is 
unsuccessful, leading to read-through translation of a fused protein172. 
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3.4.2.7 Overexpression of BCAT1 in A11 and S2 cell lines leads to increased 
BCAT activity 
The effect of BCAT1 overexpression on enzyme activity was investigated in lysates of the 
original cell lines as well as the control clones and the overexpressing clones (Figure 38). BCAT 
activity in the control clones did not differ from those in the lysates of the original cell lines. 
Lysates of the BCAT1 overexpressing clones showed a tenfold increase in total BCAT activity, 
when compared to the control clones, in accordance with the increase in BCAT1 protein levels 
seen on Western Blot, suggesting that the overexpressed protein is active. When gabapentin 
was added to the reaction, BCAT1 inhibition observed in lysates from overexpressing cells was 
less than expected, and the measurable activity at 40 mM gabapentin concentration was much 
higher than the expected BCAT2 activity. This can be explained by the high Ki of gabapentin 
for BCAT1173, whereby there is still about 13% residual BCAT1 activity at a gabapentin 
concentration of 40 mM. 
 
Figure 38 BCAT1 overexpression in A11 and S2 cells led to increased BCAT activity as measured by the spectrophotometric 
assay. (A) Bar chart showing total activity levels measured in independent experiments for the parental cell lines (A11, S2) as 
well as the controls (A11Str, S2Str) and the BCAT1 overexpressing cells (A11BCAT1, S2BCAT1). (B) The total BCAT activity 
measured at different concentrations of gabapentin, demonstrating inhibition of BCAT1 with increasing gabapentin 
concentration. (C) Western Blot of BCAT2 and GAPDH loading control from lysates of A11 and S2 BCAT1 overexpressing 
cells and their respective controls. 
3.4.3 The reaction favours transamination of BCAAs to BCKAs  
3.4.3.1 BCAT1 overexpression leads to higher 13C-labelled KIC generated from 
13C-labelled leucine in culture 
Since the transamination reaction catalysed by BCAT1 is reversible, it was important to 
understand which reaction was favoured, forward or reverse, which is greatly dependent on the 
relative concentrations of the substrates of the reaction.  
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Labelling experiments with [1-13C]leucine were performed to investigate the net flux in the 
reaction and assess the changes in the rate of amino acid transamination to its respective 
ketoacid, KIC, upon BCAT1 overexpression. Cells were incubated with BCAA-free DMEM 
media and supplemented with [1-13C]leucine at a concentration of 0.8 mM for 48 hours. The 
[1-13C]KIC to [1-13C]leucine ratio in the media was measured using 13C NMR and normalized 
to the protein content determined after the metabolite extraction. BCAT1 overexpression in 
both A11 and S2 cells led to an increased ratio of [1-13C]KIC to [1-13C]leucine in the media 
compared to the controls. In addition, A11 control cells transaminated leucine at a faster rate 
than S2 control cells (Figure 39A). These results suggest that in cell culture, BCAT1 favours 
the forward reaction, generating BCKAs that are released into the media. 
3.4.3.2 BCAT1 knockdown leads to reduced secretion of glutamate in cell 
culture  
Further evidence for the forward reaction being favoured in cultured GBM cells was provided 
by quantifying glutamate released into the culture medium of A11 BCAT1 knockdown cells 
and control cells. This was achieved using a spectrophotometric assay, which couples glutamate 
oxidation and NADH production, by glutamate dehydrogenase with a bioluminescent detection 
system, where a luciferin pro-substrate is reduced to the active luciferase substrate.  
Following induction of BCAT1 knockdown with doxycycline, equal numbers of viable cells 
were seeded in a 96 well plate with fresh media in order to control for the effects caused by 
proliferation differences. Quantification of the glutamate in cell media revealed a significant 
decrease in glutamate secretion by cells upon BCAT1 knockdown (Figure 39B). This effect 
could be a direct result of BCAT1 knockdown leading to reduced glutamate production from 
α-KG, or an indirect effect of BCAT1 knockdown on the expression of glutamate transporters 
or on glutamate metabolism in the cell. For further investigation of this effect, tracing 
experiments with [15N]leucine would be necessary. 
3.4.3.3 Glioblastoma tumours consume Branched Chain Amino Acids 
BCAAs differ from other amino acids in that they are poorly metabolised during the first pass 
through the liver, due to the low levels of BCAT1 and BCAT2 expression in hepatocytes. 
Therefore, changes in circulating levels of BCAAs can be used as markers for several 
pathologies, including insulin resistance149,174. In cancer, it appears that changes in plasma 
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levels of BCAAs is context dependent, with elevated levels of BCAAs being observed in mice 
with early pancreatic ductal adenocarcinoma45 and in patients with breast cancer44 but reduced 
levels of BCAAs observed in mice with non-small cell lung cancer45. In order to investigate the 
systemic effect of glioblastoma on BCAAs, the concentration of BCAAs was measured in blood 
plasma samples that were taken from healthy rats and tumour-bearing rats. Rats with a visible 
tumour on T2-weighted MRI scans had reduced concentrations of BCAAs in their plasma 
samples when compared to rats which did not show signs of tumour growth (Figure 39C). No 
differences were seen between different Patient Derived Orthotopic xenografts (PDOXs), 
suggesting that the systemic effects of glioblastoma on BCAA metabolism were not dependent 
on BCAT1, since S2 PDOXs, which show no BCAT1 expression also led to reduced circulating 
BCAA levels. From three rats that were sampled at different time points during tumour 
progression, we observed greatly reduced plasma BCAA concentrations when the tumour first 
appeared on MRI and as the tumour size increased, the plasma concentrations of BCAAs then 
increased (Figure 39D). Even though the reduction in plasma levels of BCAAs can be attributed 
to many factors including uptake and consumption in the tumour for catabolism or protein 
synthesis as well as other effects of the tumours on systemic BCAA metabolism, it suggests 




Figure 39 BCAT1 favours transamination of BCAAs to BCKAs in glioblastoma. (A) The 13C-labelled KIC to leucine ratio in 
cell media normalised to the amount of protein. Cells were incubated with labelled leucine for 48 hours and the concentrations 
of labelled leucine and KIC measured using 13C NMR. (B) The concentration of glutamate in cell media as measured using a 
spectrophotometric enzyme-based assay. Each point represents the mean of technical replicates from each independent 
experiment (n=3) and the error bars represent the Standard Deviations. Two-tailed paired t-tests were performed to compare 
the glutamate concentration between the doxycycline treated and untreated cells. ns: p>0.05, **p<0.01 (C) Plasma BCAA 
concentrations in rats, with healthy rats representing a pool of non-implanted rats as well as rats that were implanted but did 
not show signs of tumour growth on MRI. A11 includes rats implanted with A11shScr and A11shBCAT1 cells but in which the 
shRNA expression was not induced with doxycycline. Each point represents a measurement from a different rat or from 
repeated samples from the same rat. Two-tailed t-tests were performed to compare the plasma BCAA concentration of healthy 
rats with tumour-bearing rats. *p<0.05 (D) Rats that were repeatedly sampled over time revealed a reduction of circulating 
BCAAs with initial tumour growth with recovery of the BCAA plasma concentration over time. (E) Illustration of BCAA 
metabolism in the cytoplasm (pink) and mitochondrion (dark red) of the cell. 
3.4.4 BCAT1 activity affects proliferation of A11 cells but not S2 cells 
BCAT1 has been shown to be involved in the proliferation of commercially available 
glioblastoma cell lines51. To confirm whether BCAT1 plays a role in cell proliferation in the 
patient derived glioblastoma cells used here, pharmacological inhibition and genetic 
manipulation of BCAT1 expression were used. Pharmacological inhibition of BCAT1 by high 
doses of gabapentin and 4-methyl-5-oxohexanoic acid led to reduced cell proliferation in the 
panel of patient derived cells, but these effects appeared to be non-specific. However, BCAT1 
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knockdown and BCAT1 overexpression in A11 cells led to significant reduction and increase, 
respectively, in cell proliferation rate. BCAT1 overexpression in S2 cells did not result in 
increased cell proliferation.  
3.4.4.1 Inhibition of BCAT1 by gabapentin led to reduced proliferation rate 
Gabapentin has been used in many studies to investigate the role of BCAT1 in vitro, as it 
competitively inhibits BCAT1 but has no effect on BCAT2. Cell proliferation assays were 
performed for the panel of patient derived GBM cell lines in the presence of increasing 
concentrations of gabapentin to investigate the effect of BCAT1 inhibition on cell proliferation. 
Twenty mM gabapentin led to a significant reduction in the proliferation rate of A11, SP20, 
S2myc and U87 cells but less so in S2 cells (Figure 40A-F). Twenty mM gabapentin also led 
to morphological changes in the cells, resulting in a more rounded shape (Figure 40J). The low 
potency of gabapentin was observed in the spectrophotometric assay of BCAT activity, where 
20 mM gabapentin was needed to maximally inhibit BCAT1. This high concentration needed 
to significantly inhibit cell proliferation raises a concern about possible off-target effects. For 
this reason, BCAT1 inhibition by a more specific inhibitor, 4-methyl 5-oxohexanoic acid 
(MOHA) was used to investigate proliferation effects in A11 cells (Figure 41). A similar 
reduction in proliferation rate was observed using this inhibitor at 10 mM. However, increased 
staining with Incucyte Cytotox red reagent suggests the inhibitor had cytotoxic effects, which 




Figure 40 Effects of gabapentin on glioma cell proliferation. (A-D) Representative growth curves showing mean percentage 
confluence over time, as measured by the Incucyte Software (Essen Biosciences) for glioma patient-derived cell lines A11(A), 
SP20(B), S2(C) and S2myc(D). (E,F) The data from five independent experiments are summarised as the increase in percentage 
confluence relative to the untreated controls (E) as well as the doubling times obtained following exponential curve fitting 
performed in Prism (GraphPad) (F). The error bars represent the Standard Deviation. Two-tailed t-tests were performed to 
compare the untreated control cells to the gabapentin treated cells. ns: p>0.05, *p<0.05, **p<0.01, ***p<0.001 (G-J) 
Representative images of A11 cells at the point of seeding (G,I) and 5 days later (H,J) after treatment with 0 mM and 20 mM 
gabapentin, illustrating the inhibition of proliferation caused by gabapentin. Incucyte Cytotox Red reagent (Essen Bioscience) 





Figure 41 Effects of 4-methyl-5-oxohexanoic acid on A11 cell proliferation. (A-D) Representative Incucyte 10X images of 
A11 cells 3 hours after seeding (A,C) and 5 days later (B,D) after treatment with 0 mM (A-B) or 10 mM (C-D) inhibitor. 
Incucyte Cytotox Red reagent (Essen Bioscience) was used at a 1:4000 dilution to stain for cell death, showing that the inhibitor 
is cytotoxic. (E) Growth curves plotted for the mean of 3 replicate wells of A11 cells incubated with increasing concentrations 
of 4-methyl-5-oxohexanoic acid. The doubling time calculated from fitting the curve to an exponential function is plotted in 
(F), illustrating the dose dependent increase in doubling time with inhibitor concentration. 
3.4.4.2 Knockdown of BCAT1 but not BCAT2 inhibits proliferation of A11 cells  
To further investigate the role of BCAT1 in cell proliferation and exclude any off-target effects 
of drug treatment, we made BCAT1 knockdown constructs for the A11 patient-derived cells. 
Both inducible and constitutive BCAT1 knockdown constructs were used. Constitutive BCAT1 
knockdowns showed reduced proliferation rates compared to the shScr controls at early passage 
numbers but regained their original growth rates at later passages, even though the knockdown 
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was maintained, suggesting that the cells had compensated for the loss of BCAT1 expression, 
potentially through altered flux through other metabolic reactions (Figure 42). Treatment with 
gabapentin (0-20 mM) as well as the more specific inhibitor 4-methyl-5-oxohexanoic acid (0-
20 mM) had very similar effects in the BCAT1 knockdown late passage cells and the control 
cells, suggesting that the proliferation effects seen upon pharmacological treatment are, at least 
partly, off-target effects (Figure 42). 
 
Figure 42 Cell proliferation following constitutive BCAT1 knockdown in A11 cells. The proliferation rate of A11 cells 
following constitutive shBCAT1 expression and expression of a control shRNA (shScr) were compared, demonstrating 
inhibition of proliferation following BCAT1 knockdown (A) which was reversed in later passages (B). The points on the growth 
curves represent the mean confluence of three wells from one experiment . (C-D) Growth curves of A11 cells expressing shScr 
(C) or shBCAT1 (D) and treated with gabapentin or 4-methyl-5-oxohexanoic acid (MOHA). (E) The doubling time of the cells, 
calculated by fitting an exponential curvel to the growth curves, relative to their respective untreated control are plotted for 
the two cell lines. 
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Induction of BCAT1 knockdown with doxycycline also led to a reduced proliferation rate, but 
the effect was smaller than that seen with gabapentin treatment, also suggesting that at least 
part of the effect seen following gabapentin treatment was non-specific (Figure 43). To further 
confirm inhibition of proliferation following induced BCAT1 knockdown, proliferation was 
also assessed by measuring number of viable cells over time using Trypan Blue dye exclusion 
cell counting (Vicell) and using a Luciferase based proliferation assay (RealTime-Glo MT Cell 
Viability Assay (Promega)). In the latter assay, a cell permeable pro-substrate is reduced by the 
viable cell to produce a luciferase substrate which diffuses out of the cell and is used by 
NanoLuc luciferase to produce a luminescence signal. The inhibition of proliferation caused by 
knockdown of BCAT1 was clear and reproducible when measured with the luciferase-based 
assay (Figure 44). Using the same assay, we investigated whether branched chain keto acid 
(BCKA) supplementation could reverse the BCAT1 knockdown effects. Addition of BCKA at 
concentrations up to 0.8 mM of each of α-ketoisocaproate, α-ketoisovalerate and α-keto-β-
methylvalerate did not lead to an increase in the proliferation rate of the BCAT1 knockdown 
cells and it led to a slight inhibition of control cell proliferation (Figure 44).  
BCAT2 knockdown in the same cells as well as in S2 cells did not cause a proliferation defect 
similar to BCAT1 knockdown as measured by the RealTime Glo assay, suggesting that the two 
BCAT isoforms play different roles in the cell (Figure 45). 
 
Figure 43 Cell proliferation following doxycycline-induction of BCAT1 knockdown. (A) Growth curves of A11 cells 
expressing shScr or shBCAT1 and induced or non-induced with doxycycline (50 ng/ml). The points represent the mean 
confluence from three independent experiments. (B) The proliferation rate, in terms of fold-increase in cell confluence from 
the initial timepoint to the final timepoint normalised to the increase in the respective non-induced control cells (n=5). A two-





Figure 44 Inducible BCAT1 knockdown leads to reduced cell proliferation as measured by a Trypan Blue dye exclusion 
assay and a luciferase-based assay. (A) Equal numbers of inducible A11shScr and A11shBCAT1 cells were seeded in 6 well 
plates and were treated with doxycycline (50 ng/ml) or were untreated. The number of viable cells over time was measured 
using the ViCell instrument and the fold increase in cell numbers over a period of three days was plotted for the four conditions. 
Each point on the graph represents the fold change in independent experiments (n=4). Two-tailed t-tests were performed to 
compare the proliferation in doxycycline induced and non-induced cells. ns: p>0.05, *p<0.05 (B-D) A luciferase-based assay 
was used to measure cell viability in control cells and BCAT1 knockdown cells over time. (B) is a representative example of 
the growth curves plotted when measuring luminescence over time and in (C) the fold-change in luminescence over two days 
is plotted, with each point representing the mean of three technical replicates for each independent experiment (n=7). The 
error bars represent the Standard Deviations. Two-tailed t-tests were performed to compare the proliferation in the different 
groups. ns: p>0.05, ****p<0.0001 (D) Cells were supplemented with increasing concentrations of BCKA (0 mM – 0.8 mM of 
each ketoacid). Each point represents the mean of three technical replicates from an independent experiment (n=3) and the 




Figure 45 BCAT2 knockdown does not have a significant effect on the proliferation rate of A11 and S2 cells. (A) Summary 
plot showing the proliferation rate of doxycycline treated cells relative to the untreated controls for A11 and S2 cells transfected 
with the shScr, shBCAT1 or shBCAT2 lentiviral vectors. Each point corresponds to the mean proliferation from an independent 
experiment and error bars represent Standard Deviation. Two-tailed t-tests were performed to compare the BCAT1 and BCAT2 
knockdown cells to their respective shScr controls. ns: p>0.05, ****p<0.0001. (B) Western Blot of BCAT2 and actin loading 
control to confirm the knockdown of BCAT2 in A11 and S2 cells. The quantitative expression level of BCAT2 relative to the 
non-doxycycline treated control is shown for A11 and S2 cells. 
3.4.4.3 The reduced proliferation rate of A11 BCAT1 knockdown cells is 
explained by partial cell cycle arrest 
The reduced proliferation rate of A11 cells upon BCAT1 knockdown could be a result of cell 
cycle arrest. In order to identify cell cycle changes, the cells were fixed and permeabilized with 
ethanol and their nuclear DNA stained with propidium iodide. Cell cycle analysis was 
performed on cells that had been synchronised using a double thymidine block protocol as well 
as on non-synchronised cells. In non-synchronised cells, BCAT1 knockdown resulted in a 
higher proportion of cells in G1 phase and smaller proportions in G2 and interphase (Figure 
46). When synchronized, control cells progressed through the cell cycle phases while the 










Figure 46 Cell cycle analysis of A11 cells reveals partial G1 cell cycle arrest upon BCAT1 Knockdown. A11shScr and 
A11shBCAT1 cells were treated with doxycycline or were untreated for at least four days before they were fixed and 
permeabilised for DNA staining. (A) Representative example of propidium iodide staining for the four cell conditions with the 
y-axis normalised to the mode of each histogram. (B) Quantitative cell cycle analysis using the FlowJo cell cycle package from 
five independent experiments showing the distribution of cells in the cell cycle phases. Error bars represent SEM. (C-E) The 
mean percentage of cells in each of the three cell cycle phases with error bars representing Standard Deviations of five 
independent experiments. For statistical analysis, two-tailed paired t-tests were performed to compare doxycycline-induced 




Figure 47 Cell synchronisation revealed that BCAT1 knockdown caused partial cell cycle arrest. (A)Histograms showing 
propidium iodide staining, normalised to the mode of each distribution, for four timepoints following release of the cells from 
thymidine block. (B) Distribution of cells in the cell cycle phases. 
3.4.4.4 BCAT1 overexpression results in increased proliferation of A11 but not 
S2 cells 
A11 cells showed moderate baseline levels of BCAT1 protein whereas S2 cells had no 
detectable BCAT1 on western blots. We hypothesized that if BCAT1 plays such an important 
role in cell proliferation, as suggested in the literature, then overexpression of the protein could 
potentially increase the proliferation rate of the cells. Constitutive overexpression of BCAT1, 
as detected by spectrophotometric assays of enzyme activity in cell lysates, led to an increased 




Figure 48 Proliferation rates of cells overexpressing BCAT1 and Luciferase-expressing controls. (A,B) Increase in cell 
counts was measured using the ViCell instrument. The cell numbers measured from five independent experiments were pooled 
and nonlinear regression analysis was performed to fit exponential growth curves for the different cell lines. A comparison 
between the growth rate constant revealed significantly different rate constants between A11 BCAT1 overexpressing cells and 
luciferase and mStrawberry expressing controls (p<0.01) (A), but no statistically significant differences between S2 BCAT1 
and controls (p>0.05) (B). (C-E) Cells were seeded in 6-well plates and incubated in the Incucyte microscope to measure 
increase in cell confluence over time. Representative growth curves of A11 BCAT1-overexpressing cells and their control cells 
(C) and S2 BCAT1-overexpressing cells and their respective control cells (D) are plotted. (E) Exponential curves were fitted 
to the growth curves of the cells in four independent experiments and the doubling times for the cells are plotted with error 
bars representing Standard Deviations.Two-tailed t-tests were performed to compare the Str cells and the BCAT1 
overexpressing cells. *p<0.05, ***p<0.001 
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3.4.5 BCAT1 plays a role in the invasive phenotype of A11 cells but not S2 
cells  
3.4.5.1 BCAT1 knockdown leads to reduced A11 cell migration and invasion  
 
Figure 49 Inducible BCAT1 knockdown in A11 cells led to a small reduction in the ability of the cells to migrate across a 
scratch wound. (A-B) Incucyte images showing the migration of A11shBCAT1 cells without doxycycline treatment (A) and 
following doxycycline treatment (B) over 36 hours after the formation of the scratch wound. The relative wound density from 
pooled data from five independent experiments is plotted over time for A11shScr (C) and A11shBCAT1 (D) cells, showing a 
small reduction in the migration of BCAT1 knockdown cells. (E) The relative wound density at 33 hours after the scratch 
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wound, relative to the no doxycycline control is plotted for each of four independent experiments. Error bars represent Standard 
Deviation. 
The effect of inducible BCAT1 knockdown on the capacity of cells to migrate on plastic and 
invade through Matrigel was investigated using the Scratch Wound assay. A small reduction in 
both migration (Figure 49) and invasion (Figure 50) were observed in A11 cells upon BCAT1 
knockdown. The cells differ in their morphology in the two assays, with the migrating cells 
maintaining their original morphology (Figure 49) while the invading cells are much more 
elongated (Figure 50).  
 
Figure 50 Inducible BCAT1 knockdown in A11 cells led to a reduction in the ability of the cells to invade through a Matrigel 
layer in the scratch wound assay. (A-B) Representative images showing the invasion of A11shBCAT1 cells, without doxycycline 
induction (A) and with doxycycline induction (B), through the Matrigel layer, which was deposited in the scratch wound, over 
a period of 36 hours. (C-D) Relative wound density over time of pooled data from three independent experiments for A11shScr 
(C) and A11shBCAT1 (D) cells. (E) Wound density at 33 hours post scratch wound formation, relative to control cells that 
were not induced with doxycycline for A11shScr and A11shBCAT1 cells. Error bars represent Standard Deviation. 
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3.4.5.2 Constitutive overexpression of BCAT1 leads to higher migration and 
invasion capacity in A11 cells but no change in S2 cells 
In order to further define the role of BCAT1 in the invasive phenotype of GBM cells, A11 and 
S2 cells constitutively overexpressing BCAT1 were compared with their respective strawberry 
and luciferase expressing controls in a scratch wound migration assay and in a scratch wound 
invasion assay, similarly to the BCAT1 knockdown experiments, as well as in three-
dimensional neurosphere Matrigel assays.  
We observed a trend towards increased migration and invasion of A11 cells overexpressing 
BCAT1 but no change in the S2 cells, as measured in a scratch-wound assay (Figure 51). Three-
dimensional invasion assays were set up to investigate the invasion properties of the cells in a 
more biologically relevant setting101. In these experiments, patient-derived glioblastoma cells 
were grown as spheroid cultures, with the 3D structure mimicking the tumour micro-
environment. The neurospheres were then embedded in Matrigel and imaged in the Incucyte 
microscope every 3 hours for four days, while the cells were in the process of invading through 
the Matrigel. Upon BCAT1 overexpression, more cells could be seen leaving the sphere and 
invading the basement membrane, whereas A11 control neurospheres grew uniformly with less 
activity on their surface. To quantify these changes, a Python script was used to measure the 
area covered by cells, including and excluding the neurosphere. The area covered by cells, 
excluding the neurosphere, is the invaded area, which when normalised to the area of the 
neurosphere, shows an increased invasion capacity in the BCAT1-overexpressing A11 cells 
when compared to the control cells. S2 cells, on the other hand, showed no significant changes 
upon BCAT1 overexpression (Figure 52). S2 cells are able to proliferate and invade in the 
absence of baseline BCAT1 expression, and the absence of any significant changes upon 




Figure 51 BCAT1 overexpression leads to slightly increased migration and invasion in A11 cells but not in S2 cells. The 
mean relative wound density from 15 technical replicates of one independent experiment are plotted over time in a migration 
scratch wound assay for A11 (A) and S2 (B) cells overexpressing BCAT1 or luciferase as a control. Similarly, the mean relative 
wound density from 15 technical replicates of one independent experiment are plotted over time in a two-dimensional scratch 




Figure 52 Investigation of the invasion capacity of cells following BCAT1 overexpression in three-dimensional invasion 
assays. (A-D) Representative images from a three-dimensional invasion assay at the start of the experiment, where the spheroid 
is embedded in matrigel (A,C) and 24 hours later (B,D) for A11Str cells (A,B) and A11 BCAT1 overexpressing cells (C,D). The 
BCAT1 overexpressing cells cover a larger area over time compared to the control cells. (E) The area invaded by the cells 
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over time was quantified and normalised to the area of the sphere for six replicates in each of three independent experiments 
and the mean of biological replicates is plotted for A11 Str and A11 BCAT1 cells (E), as well as S2 Str and S2 BCAT1 cells 
(F), with error bars representing SEM. Multiple t-tests corrected for multiple comparisons using the Holm-Sidak method were 
performed to compare the Str and BCAT1 overexpressing cells. *p<0.05, **p<0.01, ***p<0.001. (G,H) Illustration of the cell 
detection algorithm, with the original image in (G) and the detected cells in (H). 
3.4.5.3 Cell surface expression of CD147 may be linked to the changes in 
invasion profiles 
To investigate whether CD147, which has already been implicated in cell migration and 
invasion might be involved in the mechanism through which modulation of BCAT1 expression 
leads to changes in cell invasion, the cell surface expression of CD147 was compared between 
cell lines. BCAT1 knockdown in A11 cells led to significantly higher levels of CD147 surface 
expression while BCAT1 overexpression in A11 cells had the opposite effect. BCAT1 
overexpression in S2 cells had a smaller effect (Figure 53).  
The changes in the amount of cell surface expressed CD147 may reflect changes in the secretion 
of the protein, suggesting that BCAT1 knockdown leads to less CD147 secretion which could 
contribute to the effects on cell migration and invasion. It has been suggested that CD147 exists 
in both soluble and membrane-bound forms and that through secretion of CD147 by cancer 
cells, the surrounding stromal cells upregulate matrix metalloproteinases leading to tissue 
remodelling57,175. Measurement of secreted CD147 in media would enable further investigation 
of this hypothesis. 
The co-localisation of CD147 with MCT1 and MCT4 transporters and the role of CD147 in 
facilitating the expression of the transporters on the plasma membrane raise more hypotheses 




Figure 53 Expression of CD147 on the surface of GBM cells is increased upon inducible knockdown of BCAT1 and is 
reduced upon constitutive BCAT1 overexpression. The surface expression of CD147 in A11shScr and A11shBCAT1 cells was 
measured by flow cytometry and the Median Fluorescence Intensity (MFI) of cells treated with doxycycline was plotted relative 
to untreated control cells (left). The MFI of A11 and S2 BCAT1 overexpressing cells is plotted relative to their Strawberry-
Luciferase controls (right). Each point represents a biological replicate in an independent experiment. Two tailed t-tests were 
perfomed to compare the MFI between samples. **p<0.01, ***p<0.001  
3.4.6 Modulation of BCAT1 expression in A11 and S2 cells led to small 
changes in resistance to radiotherapy 
BCAT1 has been suggested to play a protective role against reactive oxygen species in glioma, 
via glutamate synthesis, which is required for glutathione synthesis155. More specifically, 
glutaminase inhibition in IDH mutant glioma cells, where 2-hydroxyglutarate was shown to 
inhibit BCAT activity, led to reduced glutathione synthesis and sensitisation of glioma cells to 
radiation in vitro and in vivo. We thus hypothesised that modulation of BCAT1 expression 
might have an effect on the cells’ resistance to radiotherapy. Cells were irradiated in 6-well 
plates at 16 and 20 Gy. The effects of radiotherapy were assessed with either flow cytometry 
and Sytox green staining or using the Vicell machine to quantify cell death using Trypan blue 
staining. BCAT1 knockdown in A11 cells led to a small increase in the sensitivity of cells to 
radiotherapy (Figure 54) while BCAT1 overexpression in both A11 and S2 cells led to a small 















































































Figure 54 Cell irradiation leads to increased cell death in BCAT1 knockdown cells. Flow cytometry dot plots showing Sytox 
Green staining on the x-axis and NADH levels, as measured by the UV detector on the y-axis, where the percentage of necrotic 
cells (Sytox positive) is shown in Q2. Four conditions were tested, control cells that were not irradiated, cells that were 
irradiated with 4 Gy every day for four days, cells that were irradiated with 16 Gy 48 hours before measuring cell death and 
cells irradiated with 16 Gy 96 hours before measuring cell death.  
 
Figure 55 BCAT1 overexpression leads to increased radiotherapy resistance in both A11 and S2 cells. Cells were treated 
with a single dose of 20 Gy using an irradiator and cell viability was measured using Trypan Blue dye exclusion in the Vicell 
and normalised to the viability of control untreated cells. Two-tailed t-tests were used to compare the Str control cells and 
BCAT1 overepxressing cells. *p<0.05 
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3.4.7 BCAT1 knockdown leads to changes in the transcriptional profile of 
A11 cells 
To further investigate the mechanism through which BCAT1 expression promotes cell 
proliferation, RNA sequencing analysis was performed to compare the transcriptional profiles 
of A11 BCAT1 knockdown and control cells. RNA sequencing under four different conditions 
(A11shScr and A11shBCAT1 with and without doxycycline treatment), followed by pairwise 
distance clustering of the groups, revealed that the BCAT1 knockdown samples clustered 
together and were significantly different to the other three control groups. The replicates of the 
three different control groups all clustered together, suggesting that the only transcriptionally 
different group was the BCAT1 knockdown group (Figure 56). 
 
Figure 56 Clustering heat map, based on the pairwise distance between samples, considering read counts at all annotated 
features. The four BCAT1 knockdown samples clustered together and away from the other three control groups.  
Principal Component Analysis (PCA) of the variance-stabilizing transformed raw counts based 
on the top 500 most variable features showed that most of the variance in the samples was 



















































































































contributed to some variance across the samples, which was accounted for in subsequent 
analyses (Figure 57). 
 
Figure 57 Principal Component Analysis of the variance-stabilizing transformed raw counts based on the top 500 most 
variable features from the pairwise analysis between A11shBCAT1 induced and non-induced samples. The first component, 
which is responsible for most of the variance in the samples, separated the BCAT1 knockdown sample and the second 
component illustrates the effects of extraction on different days. 
Pairwise comparisons between all the test groups were made and each comparison yielded a 
list of differentially expressed genes. As expected from the clustering analysis and PCA, 
comparing the shBCAT1 + dox treatment group against any of the other three control groups 
yielded many more differentially expressed genes than any other comparison. Interestingly, 
very few differentially expressed genes appeared when comparing any of the three control 
groups (Figure 58). The presence of no statistically significant differentially expressed genes 
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between shScr cells with doxycycline treatment and shScr cells with no doxycycline treatment, 
suggested that doxycycline treatment did not have major transcriptional effects on the cells. 
This suggested that using the comparison between shBCAT1 cells with and without 
doxycycline for investigating transcriptional effects upon BCAT1 knockdown was valid. Also, 
there was a large overlap between the differentially expressed genes when comparing BCAT1 
knockdown cells with any of the three control groups, further validating the experiment (Figure 
59). 
Numerator Denominator Upregulated Downregulated 
A11shScrdox A11shScr 0 0 
A11shBCATdox A11shBCAT 2994 3548 
A11shBCATdox A11shScr 2872 3251 
A11shBCATdox A11shScrdox 2801 3191 
A11shBCAT A11shScr 114 60 
A11shBCAT A11shScrdox 164 99 
Figure 58 Numbers of significantly upregulated and downregulated genes between different comparison groups. A11 
BCAT1 knockdown sample group compared with any of the other 3 control groups yielded a high number of differentially 
expressed genes, whereas the three control groups were very similar to each other, yielding small numbers of differentially 
expressed genes. 
 
Figure 59 Illustration of the overlap between the differentially expressed genes when comparing BCAT1 knockdown 
samples against the three control groups. The numbers shown in the Venn diagram include both upregulated and 
downregulated genes. Most of the differentially expressed genes were found in the intersection of all three comparisons 
suggesting that they are truly an effect of the knockdown of BCAT1. 
When directly comparing A11shBCAT1 cells which were induced with doxycycline versus 
A11shBCAT1 cells that were not induced, the transcriptional profile of the cells was 
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significantly different with thousands of upregulated and downregulated genes. Focusing on 
the top 200 most significantly differentially expressed genes, the BCAT1 knockdown cells 
showed a clear distinction from all other test groups (Figure 60). 
 
Figure 60 Heat map showing how the top 200 most significantly differentially expressed genes in the pairwise analysis of 
A11shBCAT1 induced and non-induced clustered across all test samples. 
3.4.8 Gene enrichment analysis revealed a connection between BCAT1 
expression and HIF stabilisation 
To further investigate the transcriptional changes upon BCAT1 knockdown, gene enrichment 
analysis was performed using the list of genes that were differentially expressed in the BCAT1 
knockdown cells versus the control cells. This showed that a number of pathways and cellular 















































































































processes were affected upon BCAT1 knockdown (Figure 61). Many of the processes being 
affected were related to cell cycle progression, with many cyclins and cell cycle checkpoint 
proteins being downregulated (Figure 62), which is in agreement with the partial cell cycle 
arrest observed in the cells upon BCAT1 knockdown (Figure 46 and Figure 47).  
 
Figure 61 Gene enrichment analysis results using Metacore (Clarivate Analytics) tool. The list uploaded to the tool included 
the genes that were differentially expressed in both comparisons of A11shBCAT1+dox transcripts with A11shBCAT1 without 
dox and A11shScr+dox transcripts. The top process networks (A) and pathway maps (B) that were enriched in the gene list are 




Figure 62 BCAT1 knockdown leads to downregulation of the processes controlling G1/S cell cycle transition. Imagemap of 
the regulation of G1/S cell cycle transition, generated using Metacore. The differentially expressed genes from both 
A11shBCAT1+dox vs A11shBCAT1 and A11shBCAT1+dox vs A11shScr+dox comparisons are shown next to the protein name, 
numbered 1 and 2, respectively, with blue representing downregulation and red representing upregulation. 
In addition to cell cycle changes, the HIF-1α pathway was in the top enriched pathway maps 
from gene enrichment analysis. The downregulation of the HIF pathway upon BCAT1 
knockdown was validated in vitro and in vivo, by blotting for HIF-1α as well as the products of 
HIF1 target genes, Carbonic Anhydrase IX (CAIX) and Hexokinase II (HKII) in cell lysates 
and in PDOX tumour lysates. Induction of BCAT1 knockdown with doxycycline led to reduced 
levels of HIF-1α and reduced levels of HKII and CAIX. Doxycycline treatment of control cells 
also led to reduced levels of  HIF-1α but the effect upon BCAT1 knockdown was bigger (Figure 
63). The effect of BCAT1 on CAIX levels was also confirmed in BCAT1 overexpressing cells 
which had higher CAIX levels compared to their controls. Additionally, immunohistochemical 
staining of patient derived orthotopic xenografts established in rats following injection of A11 
cells, showed co-localisation of high BCAT1 staining with CAIX, MCT1 and MCT4 staining, 




Figure 63 BCAT1 controls HIF transcriptional activity in GBM models. (A) The log(fold change) in expression when 
comparing A11shBCAT1 cells induced with doxycycline versus cells not induced is plotted for every HIF target that was 
revealed in the enrichment analysis by Metacore. (B) Quantitative data from western blots for CAIX expression from lysates 
of A11shScr and A11shBCAT1 cells treated with doxycycline relative to the non-doxycycline induced controls. Each point 
represents a measurement from an independent experiment and the error bars represent Standard Deviations. A two-tailed t-
test was performed to compare the two groups. **p<0.01 (C) Western blots for BCAT1, HIF-1a, HKII, CAIX and β-tubulin 
loading control from lysates of A11shScr and A11shBCAT1 PDOXs. (D) Western blots for CAIX and beta actin loading control 
from cell lysates of control and BCAT1 overexpressing A11 and S2 cells. (E-F) For measurement of HIF-1a levels in A11 
control and BCAT1 knockdown cells, cells were incubated at 1% O2 for 8 hours, before cell lysis and protein extraction. A 
representative western blot of HIF-1a and beta-actin loading control is shown in (E) and the densitometric data from all 




Figure 64 Immunohistochemical staining showing co-localisation of BCAT1 with MCT1, MCT4 and CAIX. Representative 
examples of IHC images from sections of a rat brain containing an A11 tumour, stained for BCAT1 on the left and MCT1 (A), 
MCT4 (B) and CAIX (C) on the right. The images are from a representative tumour and only the tumour (with its necrotic core 
and the periphery) is visible in the Field of View. 
FOXM1 is a transcription factor that has been documented to play multiple roles in 
glioblastoma96-98,109,110. FOXM1 is a direct target of HIF, with HIF binding sites found in the 
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FOXM1 promoter region106. Analysis of the RNA sequencing data revealed that FOXM1 as 
well as many of its target proteins were downregulated upon BCAT1 knockdown. FOXM1 
downregulation was confirmed in vitro in lysates of A11 BCAT1 knockdown cells and control 
cells as well as in vivo in PDOX in mice (Figure 65).  
 
Figure 65 FOXM1 transcription factor and its targets are downregulated upon BCAT1 knockdown in A11 cells. (A) The 
mean logarithmic fold change in transcript numbers when comparing A11shBCAT1 cells that were induced with doxycycline 
and those that were not induced is plotted for each target gene of FOXM1, showing significant enrichment of FOXM1 
transcriptional targets in the differentially expressed genes upon BCAT1 knockdown. The target genes of FOXM1 were 
acquired from Pathway Enrichment analysis using EnrichR online tool. (B) Quantitative data from Western Blots of cell lysates 
showing the expression of FOXM1 relative to the non-induced cells for shScr and shBCAT1 cells. Each point represents a 
measurement from an independent experiment and the error bars represent the Standard Deviations. Two-tailed t-test analysis 
was performed to compare the two cell lines (n=5). *p<0.05 (C) Western blots of BCAT1, FOXM1 and β-tubulin loading 
control in lysates of dissected brain tumours from mice. To induce BCAT1 knockdown, mice were fed with doxycycline-
containing diet for 10 days. 
RNA sequencing analysis showed that a number of genes that have been associated with 
glioblastoma stem-like cells were significantly downregulated upon BCAT1 knockdown in 
A11 cells, including ALKBH5, ANP32E, CENPF, FANCI and FOXM1. A neurosphere 
formation assay was performed and Extreme Limiting Dilution Analysis (ELDA) was used to 
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compare A11 BCAT1 knockdown cells with control cells. Knockdown of BCAT1 was induced 
in the cells by incubating with doxycycline for seven days before sorting 1, 5, 10 and 20 cells 
in each well of a 96-well plate. Doxycycline treatment was discontinued following seeding of 
the cells in the plate and the cells were incubated for at least three weeks before the number of 
sphere-containing wells was measured. Therefore, the effect of BCAT1 knockdown on cell 
proliferation had minimal contribution to the phenotype measured. Instead, the frequency of 
cells capable of replication at the time of seeding determined the number of neurospheres being 
formed. From three independent experiments, a significant reduction in stem cell frequency was 
observed upon BCAT1 knockdown in A11 cells, suggesting that BCAT1 knockdown reduced 
the neurosphere-forming potential of the cells (Figure 66).  
 
Figure 66 BCAT1 knockdown led to a reduction in the capability of A11 cells to form neurospheres. (A) Representative 
example of data from a Neurosphere formation assay used as input for the Extreme Limiting Dilution Analysis (ELDA), where 
‘dose’ represents the number of live cells seeded in the well, ‘tested’ represents the number of technical replicates and 
‘response’ represents the number of wells with observable spheres at the endpoint. (B) Bar graph showing 1/stem cell frequency 
calculated by ELDA for A11shScr and A11shBCAT1 cells treated with doxycycline relative to their respective no doxycycline 
controls, with each point representing an independent experiment and error bars representing Standard Deviations. A two-
tailed t-test was performed to compare the two cell lines N=3, *p<0.05 
EMT, or glial-to-mesenchymal transition (GMT) for glioblastoma, is associated with the 
migratory ability of cells. BCAT1 knockdown led to reduced cell invasion and BCAT1 
overexpression led to increased cell invasion in A11 cells (Figure 49 to Figure 52). Important 
markers of GMT were differentially expressed in RNA sequencing analysis of A11 BCAT1 
knockdown cells and controls. These include Snai1 and ZEB1, which are transcriptional 
regulators of GMT and were downregulated to 40% and 51%, respectively, in A11shBCAT1 
cells treated with doxycycline when compared with the untreated cells. This suggests that the 
reduced invasion of A11 cells observed upon BCAT1 knockdown might be because the cells 
become more glial-like and less mesenchymal-like.  
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3.4.9 α-KG accumulation as a potential mechanism for HIF destabilisation 
upon BCAT1 knockdown 
Supplementation of BCAT1 knockdown cells with BCKAs did not rescue the cells from the 
proliferation defect caused by BCAT1 knockdown suggesting that the primary role of BCAT1 
in GBM cells is not the generation of BCKAs for entry into the TCA cycle (Figure 44). 
Knockdown of BCAT2, the mitochondrial isoform of the transaminase found in a complex with 
BCKDC, which catalyses the rate-limiting oxidation of BCKA, in A11 and S2 cells had no 
significant effect on the proliferation of the cells, suggesting that the two BCATs play different 
roles in glioblastoma and that generation of TCA cycle intermediates is not the main role of 
BCAT1 (Figure 45).  
Other potential mechanisms of action of BCAT1 that have been suggested in the literature are 
generation of glutamate, which is required for glutathione synthesis155, and regulation of mTOR 
activity44,177. However, LCMS analysis of A11 BCAT1 knockdown and control cell extracts, 
revealed that both glutamate and glutathione levels were increased in cells in which BCAT1 
was knocked down compared to the control cells, suggesting that BCAT1 knockdown does not 
impair the cells’ ability to synthesise glutathione. Additionally, intracellular levels of BCAAs 
were not significantly changed upon BCAT1 knockdown, suggesting that leucine mediated 
control of the mTOR pathway is not affected. In addition, western blots of lysates of A11 
control and A11 BCAT1 knockdown tumours revealed no difference between the levels of P-
S6 relative to total S6, suggesting that mTOR signalling is not affected by BCAT1 knockdown 




Figure 67 BCAT1 knockdown does not inhibit glutathione synthesis or mTOR signalling. LCMS analysis of glutamate (A) 
and glutathione (B) in extracts of A11 cells expressing shScr or shBCAT1. Error bars represent Standard Deviations. T-tests 
were performed to assess the differences between the doxycycline-induced and non-induced cells (n=5). Ns: p>0.05, **p<0.01, 
****p<0.0001 (C) Western blot analysis of total S6 and phosphorylated S6 in lysates of an A11 PDOX. (D) LCMS analysis of 
leucine, isoleucine and valine concentrations in cell extracts. Error bars represent Standard Deviation. 
The global changes in the transcriptional profile of A11 cells upon BCAT1 knockdown as well 
as the destabilisation of HIF-1α point towards a mechanism with multiple downstream effects. 
BCAT1 knockdown leads to reduced cytosolic transamination of BCAAs into BCKAs but also 
reduced conversion of α-KG to glutamate. A potential mechanism for the effects seen upon 
BCAT1 knockdown could be the increased availability of α-KG in the cytoplasm that can then 




Figure 68 Increased availability of α-KG could explain the effects seen upon BCAT1 knockdown. Increased availability of 
α-KG leads to activation of enzymes including TET demethylases, leading to DNA demethylation as well as the prolyl 
hydroxylases, such as PHD2, leading to HIF-1a degradation. These effects could lead to the phenotypic changes seen upon 
BCAT1 knockdown. 
α-KG-mediated effects would also include an increase in DNA demethylation resulting from 
the increased activity of TET enzymes. Indeed, A11 BCAT1 knockdown cells showed a 
significant increase in the relative level of 5-hydroxymethylcytosine reflecting increased TET 
activity (Figure 69).  
 
Figure 69 BCAT1 knockdown leads to activation of TET DNA demethylase enzymes. (A) Proportion of 5-
hydroxymethylcytosine in DNA extracted from A11shScr and A11shBCAT1 cells following doxycycline treatment compared to 
the untreated controls. (B) The ratio of 5-methylcytosine to 5-hydroxymethylcytosine in DNA extracts. Each point represents a 
biological replicate. A paired two tailed t-test was performed to assess the statistical significance of the differences between 
groups. N=4 for all groups, ** p<0.01, ns: p>0.05 
α-KG acts as a co-substrate in the prolyl hydroxylase reactions, while fumarate and succinate 
have been shown to act as inhibitors of these reactions31. Supplementation of A11 cells with 
dimethyl α-KG, a membrane-permeable analogue of α-KG, phenocopied the effects of BCAT1 
knockdown, in terms of reduced cell proliferation (Figure 70). Conversely, addition of Diethyl 
Succinate, a membrane permeable analogue of succinate and 3-nitropropionic acid, an inhibitor 
of succinate dehydrogenase which causes succinate accumulation, both led to reversal of the 
156 
 
BCAT1 knockdown effects. A competitive inhibitor of all α-KG dependent dioxygenases, 
dimethyloxalylglycine (DMOG), also rescued the BCAT1 knockdown effects, suggesting that 
the proliferation defect observed upon BCAT1 knockdown is probably mediated via increased 
activity of α-KG dependent dioxygenases, even though DMOG has been documented to also 
cause non-specific effects178. Taken together, these data suggest that BCAT1 knockdown leads 
to reduced proliferation via an increase in the concentration of α-KG and consequently the 
activity of α-KG-dependent dioxygenases, including the TET and Prolyl Hydroxylase enzymes 
and not via reduced flux through the TCA cycle.  
 
Figure 70 α-KG accumulation is responsible for the effect of BCAT1 knockdown on the proliferation of A11 cells. A 
luciferase-based assay was used to assess the proliferation rate of A11 BCAT1 knockdown and control cells. The effects of 
increasing concentrations of BCKAs (A), dimethyl α-KG (B) and diethyl succinate (DES) and Nitropropionic Acid (NPA) (C) 
were investigated. Each point represents the mean from three technical replicates of each independent experiment and error 
bars represent Standard Deviations. Two-tailed t-tests were performed to compare the different groups. (D-F) A11 BCAT1 
knockdown and control cells were supplemented with 150 μM and 300 μM Dimethyloxalylglycine (DMOG). The relative 
increase in luminescence for A11shScr (D) and A11shBCAT1 (E) cells induced with doxycycline are plotted next to the 
untreated controls. Each point represents the mean from technical replicates of each independent experiment (n=3) and error 
bars represent Standard Deviations. (F) Cell proliferation rate relative to the control cells that were not treated with 
doxycycline with each point representing a biological replicate (n=3-4). Two-tailed t-tests were performed to compare the 
groups.(G) Schematic summary of the effects of α-KG, fumarate, succinate and DMOG on the activity of α-KG-dependent 




Additionally, α-KG supplementation of cells for 24 hours led to greatly reduced HIF-1α levels 
when the cells were grown at 1% oxygen for 8 hours, mimicking the effect of BCAT1 
knockdown and providing further evidence that increasing availability of α-KG in the cells 
leads to greater HIF-1α degradation (Figure 71). High concentrations of α-KG were used in this 
experiment because of the low cell membrane permeability of α-KG and therefore, even though 
there was no evidence of cytotoxicity, the reduced levels of HIF-1α could also be a reflection 
of early stages of cell death. 
 
Figure 71 α-KG supplementation of A11 cells leads to reduced HIF-1a levels measured on Western Blot. Representative 
western blots of HIF-1α and beta actin loading control in A11shScr and A11shBCAT1 cells, treated with doxycycline and their 
non-treated controls. Cells were supplemented with 10 mM α-KG for 24 hours and were incubated in 1% O2 for eight hours 
before cell lysis, in order to enable measurement of HIF-1α levels. The numbers above the Western Blot bands represent the 
densitometric quantitation relative to the first band, A11shScr control cells. 
Intracellular α-KG concentrations were measured using a fluorometric assay and LCMS to 
determine whether BCAT1 knockdown in A11 cells led to the accumulation of α-KG. In 
addition, the relative concentrations of α-KG from orthotopic tumour tissue extracts were 
measured using LCMS. However, no significant differences in α-KG levels were measured by 
either method (Figure 72), although the intratumoural levels of α-KG were slightly higher in 
BCAT1 knockdown tumours induced with doxycycline diet when compared to the vehicle diet 
controls. Both methods quantify the total intracellular pool of α-KG, therefore there could still 
be an increase in the cytosolic levels of α-KG that is masked by changes in the mitochondrial 
levels. There was a trend toward increased BCAT2 expression upon BCAT1 knockdown 
(Figure 73). This increased BCAT2 activity could potentially lead to increased consumption of 
α-KG in the mitochondria, which could mask any increase in the cytoplasm and thus no 




Figure 72 Quantification of α-KG levels showed no significant changes upon BCAT1 knockdown. (A) α-KG concentration 
in nmol/mg extracted protein, as measured by a fluorometric assay. Each point represents the calculated concentration value 
from an independent experiment. (B-C) α-KG concentration measured by LCMS and normalised to cell count (B) or cell volume 
(C). (D) Relative α-KG concentration of mouse orthotopic xenograft tissue lysates as measured on LCMS. Error bars represent 
Standard Deviations. 
 
Figure 73 BCAT2 upregulation following BCAT1 knockdown in A11 cells. Quantitative analysis of BCAT2 western blots of 
lysates of A11shScr and A11shBCAT1 cells induced with doxycycline relative to the untreated controls. Error bars represent 
Standard Deviations. Each point represents one of three independent experiments. A two-tailed t-test was performed to 


































BCAT1 upregulation has been documented in several types of cancer, including glioblastoma51, 
breast179, ovarian48 and hepatocellular180 cancer as well as Acute Myeloid Leukaemia50. 
However, different studies have attributed different potential roles to BCAT1 in terms of its 
contribution to cancer progression. Indeed, it has been suggested that the role of BCAT1 is 
largely dependent on the tissue of origin45. In glioblastoma, BCAT1 upregulation has been 
demonstrated in IDH wild type tumours when compared to healthy brain. BCAT1 inhibition as 
well as knockdown in the long established U87 human glioblastoma cell line led to reduced 
proliferation in vitro and reduced tumour growth in vivo51 and it was suggested that upregulation 
of BCAT1 promotes cell proliferation through enhanced generation of TCA cycle 
intermediates. 
Here the role of BCAT1 in glioblastoma has been explored using patient derived cells that better 
recapitulate aspects of the human disease than U87. Differential expression of BCAT1 was 
observed across a panel of patient derived IDH wild type glioblastoma cells with BCAT1 being 
expressed in all cells with the exception of S2 cells. This was unexpected, since S2 cells were 
derived from a primary human GBM tumour and BCAT1 has been identified as the best 
classifier to distinguish primary GBM from secondary GBM, diffuse astrocytoma and 
anaplastic astrocytoma51. The possibility that these cells might be IDHmut was explored, but 
the cells did not have the common IDH mutations. To validate the role of BCAT1 expression 
in cell proliferation, gabapentin was used as a selective inhibitor for BCAT1, as well as a more 
specific inhibitor, 4-methyl-5-oxohexanoic acid. Although changes in cell proliferation were 
observed in vitro upon treatment with both agents, concentrations of at least 10 mM were 
needed in order to see an effect and, in some cases, cytotoxic effects were also observed. 
Concentrations of 10-50 mM gabapentin have been used in other cancer related BCAT1 studies 
in order to achieve BCAT1 inhibition and this was attributed to the fact that gabapentin 
competes with leucine for binding to BCAT1 and leucine is present in the mM range in the 
cytoplasm of cancer cells173. However, when treating A11 BCAT1 knockdown cells and control 
cells with the two inhibitors, similar effects were observed in both cells, suggesting that the 
inhibitors were causing off-target effects. Similar non-specific effects were observed upon 
gabapentin treatment of colorectal carcinoma cells, which lack BCAT1 expression173. This 
suggests that many of the effects observed upon gabapentin treatment in cancer cells are not 
necessarily BCAT1 specific.  
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The role of BCAT1 in promoting cell proliferation was validated in A11 cells, where BCAT1 
knockdown led to reduced proliferation in vitro as well as partial cell cycle arrest. BCAT1 
overexpression on the other hand, led to increased cell proliferation in vitro. Smaller effects on 
migration, invasion and resistance to radiotherapy were also observed, in accordance with the 
literature on glioblastoma and other cancer types51,53,54,179,181. Conversely, S2 cells, which 
showed no baseline BCAT1 expression, showed no significant changes upon BCAT1 
overexpression, suggesting that the phenotype of these cells is not affected by BCAT1 
expression and activity. S2 cells and A11 cells have a very different mutation status, with A11 
cells harbouring mutations in NF1, PIK3R1 and PTEN while S2 cells harbour mutations in 
TP53, STAG2, NF1, RB1, TERT and PTEN. Orthotopic tumours derived from A11 cells and S2 
cells, labelled in the referenced paper as GB4 and GB1, respectively, have shown differential 
lactate labelling in hyperpolarised 13C pyruvate imaging, suggesting that these tumours are 
metabolically different182. Therefore, it is possible that the metabolic and genomic differences 
between the two cell lines render them more or less dependent on BCAT1 expression.  
We have shown upregulation of BCAT1 by overexpression of c-Myc in S2 cells, which is in 
agreement with the literature which has shown that the BCAT1 promoter contains a c-Myc 
binding site47,53,183. We have also observed upregulation of BCAT1 in hypoxia in all the tested 
cell lines (A11, SP20 and U87), with the exception of S2 cells, where incubation at an O2 
concentration of 0.1% did not lead to observable BCAT1 expression. In previous studies, HIF-
1α and HIF-2α have been shown to bind to the hypoxia response element in the first intron of 
the human BCAT1 gene and HIF-1α has been shown to be responsible for hypoxia-induced 
BCAT1 expression in U251 and U87 GBM cells166. A potential explanation of the inability of 
S2 cells to respond to hypoxia could be a mutation in the hypoxia response element on the 
BCAT1 gene in these cells. 
In most cancers, including breast cancer and hepatocellular carcinoma, BCAT1 upregulation 
was shown to lead to increased transamination of BCAAs to their respective BCKAs, while in 
pancreatic ductal adenocarcinoma, elevated levels of BCAAs were observed in plasma45 and in 
chronic myeloid leukaemia, increased expression of BCAT1 led to increased generation of 
BCAAs from BCKAs50. In the patient-derived glioblastoma models, the reaction appears to 
favour the forward direction, since BCAT1 overexpression in cells in vitro led to increased 
labelling of [1-13C]KIC from [1-13C]leucine and BCAT1 knockdown led to reduced glutamate 
secretion. In addition, the plasma levels of BCAAs were reduced upon growth of orthotopically 
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implanted patient derived xenograft tumours, similarly to a previously published study in non-
small cell lung cancer models61 suggesting that the tumour is consuming the amino acids or 
initiating systemic effects leading to increased BCAA consumption (Figure 39). 
The mechanism by which BCAT1 facilitates cell proliferation in glioblastoma remains unclear. 
A number of hypotheses have been proposed for the role of BCAT1, including the generation 
of BCKAs which can be further catabolised to generate TCA cycle intermediates51 and also the 
generation of glutamate, which is required for the synthesis of glutathione155. Additionally, 
upregulation of BCAT1 in glioblastoma has been shown to lead to increased secretion of 
BCKAs through MCT1 into the tumour microenvironment. BCAT1 and MCT1 were found to 
be located in close proximity, suggesting possible functional interaction between the two 
proteins. The secreted BCKAs can be taken up by macrophages and reaminated to BCAAs 
leading to reduced phagocytic activity154.  
In this study, the proliferation defect of A11 cells was not rescued by supplementation of 
BCAT1 knockdown cells with increasing concentrations of BCKAs, suggesting that reduced 
generation of BCKAs to feed the TCA cycle is not the mechanism mediating the reduced 
proliferation rate. The uptake of BCKAs upon supplementation in the media was not confirmed 
by LCMS, but good uptake was expected given the high expression of MCT transporters in the 
cells and given the in vivo data in Chapter 4, where injection of [1-13C]Ketoisocaproate in A11 
glioma bearing rats led to uptake of the substrate and conversion to [1-13C]leucine. 
Additionally, knockdown of the mitochondrial isoform of the enzyme, BCAT2, which is part 
of the metabolon catalysing BCAA catabolism184, did not affect the cells’ proliferation rate. 
Disassociation of BCAT1 activity from the generation of TCA cycle intermediates has been 
documented in other cancers as well as glioblastoma, suggesting that even though BCAT1 
catalyses the first step in the catabolic pathway of BCAAs, the BCKAs produced from BCAAs 
might not always be committed for further catabolism. For example, in hepatocellular 
carcinoma, transcriptomic, enzymatic and metabolomic analyses revealed that the pathway of 
BCAA catabolism, with the exception of BCAT1 and BCAT2, was suppressed when compared 
to adjacent healthy liver tissue185. Nevertheless, BCAT1 upregulation promoted cell 
proliferation and chemoresistance to cisplatin55, suggesting that the role of BCAT1 in 
promoting proliferation and chemoresistance may be independent of the rest of the catabolic 
pathway of BCAAs.  
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To understand the mechanism responsible for reduced proliferation upon BCAT1 knockdown 
in A11 cells, RNA sequencing analysis was performed, which revealed that BCAT1 is a 
regulator of the transcriptional activities of HIF and FOXM1, with BCAT1 knockdown leading 
to reduced levels of HIF-1α, downregulation of HIF targets such as CAIX and HKII and 
reduced levels of FOXM1, both in vitro and in vivo. Conversely, BCAT1 overexpression led to 
upregulation of CAIX. The importance of HIF in GBM progression has already been 
established, with high HIF-1α activity being implicated in tumour progression and maintenance 
of a tumour stem cell phenotype186. Therefore, the effects of BCAT1 knockdown, including 
reduced cell proliferation and migration can be explained by reduced HIF activity. The 
frequency of cells with self-renewal capacity was assessed using a neurosphere formation assay, 
where BCAT1 knockdown cells had a significantly lower frequency of cells with the potential 
to form a neurosphere when compared to controls.  
The association of BCAT1 levels with HIF-1α activity in GBM cells has not been described 
before, however BCAT1 mediated stabilisation of HIF-1α has been documented in Acute 
Myeloid Leukaemia (AML) cells187. In this study, the authors performed isotope labelling 
experiments with 13C-labelled BCAAs and showed an absence of 13C-labelled TCA cycle 
intermediates in both control and BCAT1 knockdown cells, suggesting that BCAT1 catalysed 
transamination of BCAAs does not contribute to TCA metabolism via generation of BCKAs. 
Instead, they report increased incorporation of BCAA nitrogen into non-essential amino acids 
and nucleotides. Furthermore, they suggest that BCAT1 acts primarily as a regulator of 
intracellular α-KG levels. They showed that the effects of BCAT1 knockdown were 
phenocopied by addition of dimethyl α-KG, a cell permeable variant of α-KG, suggesting that 
BCAT1 knockdown leads to cell proliferation changes through an increase in α-KG 
concentration. Additionally, exogenous administration of an octyl derivative of α-KG led to 
downregulation of HIF-1a, phenocopying BCAT1 knockdown effects, while overexpression of 
HIF-1a in BCAT1 knockdown cells led to rescue of the proliferation and survival defects. A 
significant increase in intracellular α-KG concentration was reported upon induction of BCAT1 
knockdown in three AML cell lines as well as in the MDA-MB-231 breast cancer cell line and 
U87 and U251 GBM cell lines. Conversely, BCAT1 overexpression in leukaemia cells led to a 
reduction in intracellular α-KG levels. 
α-KG homeostasis has been shown to be essential in cancer cells, due to the role of α-KG as a 
co-substrate for a number of α-KG-dependent dioxygenases including EGLN1 and the TET 
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family of DNA demethylases. Owing to its central role in metabolism, the concentration of α-
KG can be regulated by many reactions and enzymes, one of which is BCAT1. Here, we saw 
downregulation of HIF and its targets, an increase in the amount of 5-hmC in DNA, reduced 
proliferation and reduced frequency of cancer stem cells upon BCAT1 knockdown in A11 cells, 
all of which would be the effects of an increase in α-KG levels in the cell cytosol. Also, 
supplementation of A11 cells with dimethyl α-KG led to reduced cell proliferation, 
phenocopying the effects of BCAT1 knockdown. Conversely, supplementation of cells with 
diethyl succinate and 3-nitropropionic acid, both of which lead to succinate accumulation and 
thus inhibition of the α-KG dependent dioxygenases, led to an elimination of the BCAT1 
knockdown effect. The same effect was observed upon treatment of the cells with DMOG, an 
inhibitor of α-KG dependent dioxygenases. Supplementation of the cells with dimethyl α-KG 
did not lead to HIF downregulation, but instead, dimethyl α-KG led to stabilisation of HIF-1a 
as seen by the increased levels of CAIX. This has been documented previously by Hou et al, 
where dimethyl α-KG led to a transient stabilisation of HIF-1a via inhibition of PHD2102. 
However, supplementation of the cells with 5 mM and 10 mM α-KG led to destabilisation of 
HIF-1a, phenocopying the effects of BCAT1 knockdown.  
Measurement of intracellular α-KG levels upon BCAT1 knockdown, however, failed to show 
that the effects of BCAT1 knockdown are mediated via an accumulation of α-KG, since no 
consistent increase in α-KG levels was measured. However, the central role of α-KG in cellular 
metabolism renders it a tightly controlled metabolite, meaning that increased flux of α-KG in 
various reactions, including its conversion to succinate, catalysed by α-KG dehydrogenase, to 
isocitrate, catalysed by IDH, and to glutamate, catalysed by glutamate dehydrogenase, as well 
as its consumption in hydroxylation reactions and transamination reactions could very quickly 
compensate for an increase in concentration caused by BCAT1 knockdown. Raffel et al in their 
studies on AML cells quote specific timepoints for cell harvest after doxycycline induction of 
BCAT1 knockdown when measuring changes in α-KG concentration, which differ between cell 
lines, for example 12 hours for SKM-1 cells but 48 hours for HL-60 cells and 96 hours for 
MDA-MB-231 cells187. In A11 cells, we saw some reduction in BCAT1 levels on Western Blot 
at 48 hours after initiation of doxycycline treatment with maximum BCAT1 knockdown being 
reached by 72 hours of doxycycline treatment. Therefore, the levels of α-KG at 96 hours after 
initiation of doxycycline treatment might already be compensated for by increased flux in other 
reactions. Additionally, the total intracellular pool of α-KG is measured, whereas the expected 
changes would occur in the cytosolic pool. BCAT1 knockdown in the A11 cells will possibly 
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lead to increased BCAA transamination in the mitochondria by BCAT2, leading to increased 
consumption of mitochondrial α-KG masking the reduced consumption in the cytoplasm. This 
might not have been the case in the U87 cells investigated by Raffel et al187 owing to the absence 
of BCAT2 expression, as shown in Figure 24. 
BCAT2, the mitochondrial isoform of the transaminase, is not often investigated in studies on 
BCAT1. No changes in BCAT2 mRNA levels were found between IDHwt and IDHmut 
tumours in the study by Tonjes et al51. However, in a later study, BCAT2 upregulation was 
documented in IDH wild type glioblastoma and low expression of BCAT2 correlated with 
improved patient survival188. We observed here an inverse relationship between BCAT1 and 
BCAT2 expression in a panel of patient derived glioblastoma cells, with S2 cells showing the 
highest levels of BCAT2 protein expression and no BCAT1 protein expression and A25 cells 
showing the highest BCAT1 and lowest BCAT2 expression. The differences in BCAT2 
expression were not a reflection of differences in mitochondrial content. More work needs to 
be done, however, to understand whether the two isoforms can complement each other and 
share similar roles in the cells. However, evidence presented here points towards different roles 
for BCAT1 and BCAT2 in cancer cells. We showed that BCAT1 but not BCAT2 expression 
was regulated by c-Myc and hypoxia and that BCAT1 knockdown but not BCAT2 knockdown 
led to reduced proliferation rate in A11 cells. In addition, we have shown that BCAT1 
knockdown did not lead to any significant changes in the intracellular levels of BCAAs. BCAT2 
was shown to be bound to the E1 decarboxylase enzyme of the Branched Chain Ketoacid 
Dehydrogenase Complex (BCKDC), forming a metabolon that enables coupling of the first two 
steps of BCAA catabolism184. Therefore, it is likely that BCAT2 plays the main catabolic role 
in the mitochondria of cells, with BCAT1 enabling metabolic regulation in the cytoplasm. In 
BCAT1 knockdown cells, the rate of BCAT2-mediated BCAA transamination is likely to 
increase owing to the higher substrate availability, which might explain the absence of any 





A panel of patient derived cells has been characterised with regard to expression of BCAT1 and 
BCAT2. The role of BCAT1 was further investigated with a focus on A11 cells which express 
moderate levels of BCAT1 and BCAT2. Knockdown of BCAT1 led to phenotypic changes in 
these cells, with the most significant effect being observed on the cell proliferation rate. This 
was not rescued by exogenous supplementation of BCKAs. The BCAT1 knockdown effects are 
mediated by HIF-1α destabilisation and increased DNA demethylation, most likely resulting 






Chapter 4 - In vivo imaging of BCAA 
metabolism using Hyperpolarised 13C 
Magnetic Resonance Spectroscopic Imaging 
 
4.1 Abstract 
Hyperpolarised 13C imaging is a metabolic imaging technique which has been used pre-
clinically and clinically to investigate altered metabolism. Hyperpolarised [1-
13C]Ketoisocaproic acid is a substrate that can be used to image Branched Chain Amino Acid 
Metabolism in cancer, and more specifically to assay upregulation of BCAT1 in different types 
of cancer. We have investigated here the potential of hyperpolarised [1-13C]Ketoisocaproic 
Acid to image BCAT1 activity in a subcutaneous murine lymphoma tumour model and in 
Patient Derived Orthotopic Xenograft models of glioblastoma. The substrate performed well in 
the lymphoma but in the orthotopic glioblastoma tumours exchange of label between [1-
13C]Ketoisocaproic and endogenous leucine was limited by the availability of the glutamate co-





BCAA metabolism plays an important role in normal physiology and cancer pathophysiology. 
As discussed in Chapter 3, the transamination reaction catalysed by BCAT1 is essential for the 
maintenance of rapidly proliferating glioblastoma cells. Therefore, it would be beneficial to be 
able to image BCAA metabolism in vivo, for diagnostic and prognostic purposes as well as for 
guiding treatment. Hyperpolarised 13C MRSI has already been used in rodents to image 
conversion of a 13C-labelled BCKA ([1-13C]Ketoisocaproate (KIC)) to its respective BCAA 
([1-13C]leucine)189,190.  
 
Figure 74 Imaging the first step of BCAA metabolism using hyperpolarised [1-13C]KIC. The substrate enters the cell through 
Monocarboxylate Transporters, such as MCT1 and MCT2, and can be converted to [1-13C]leucine in the cytosol, in the reaction 
catalysed by BCAT1 and in the mitochondria, by BCAT2. 
By using hyperpolarised [1-13C]KIC, and measuring its conversion to [1-13C]leucine, Karlsson 
et al189 and Butt et al190, used MRI to image the activity of BCAT in tumours and in healthy 
brain, respectively. The 13C resonance of [1-13C]KIC is at 172.6ppm and that of [1-13C]leucine 
at 176.8ppm, enabling the metabolites to be distinguished. When 13C labelled KIC was injected 
into EL4 tumour-bearing mice, [1-13C]leucine was detected, with good contrast between the 
tumour and surrounding healthy tissue189. When the same technique was applied to a rat breast 
cancer model, R3220AC, however, minimal leucine was detected, owing to the much lower 
levels of BCAT activity189. This suggests that some cancers, including lymphoma, overexpress 
BCAT, but that this is not a general feature of neoplasms. In the normal healthy brain, Butt et 
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al observed that the hippocampal regions demonstrated increased BCKA transamination when 
compared to the rest of the brain190. In the same study, hyperpolarised [1-13C]pyruvate and [1-
13C]KIC were injected simultaneously. The distribution and signal intensities of the two 
substrates were similar, suggesting that KIC was able to successfully cross the blood brain 
barrier. MCT2, which is the main transporter in the rodent brain has high affinity for pyruvate, 
KIC and lactate190. KIC is also a substrate for MCT1, with a Km of 0.67 mM compared to a Km 
for pyruvate of 1 mM190,191. In both tumour and normal brain studies, maximum leucine signal 
was observed between 20 and 35 seconds following injection of the substrate.  
More recently, Suh et al used hyperpolarised 13C KIC imaging to assess BCAA metabolism in 
vitro and in vivo in a rat glioma model, F98192. Interestingly, reduced transamination of 
hyperpolarised 13C KIC to 13C leucine was measured in the glioma compared to normal brain. 
Conversely, increased H13CO3- was measured in the tumours compared to the contralateral 
healthy brain. When assessed in vitro for BCAT enzyme activity and protein expression, these 
tumours were seen to have similar total BCAT activity levels to the contralateral normal 
appearing brain. However, the tumours showed lower BCAT1 and higher BCAT2 levels 
compared to the normal brain, which is not representative of the upregulation of BCAT1 in 
human IDHwt glioblastoma. In fact, the tumour model used in this study is a rat cell line which 
has been grown since 1971, therefore its resemblance to human glioblastoma is unknown. 
In this study we hypothesised that hyperpolarised 13C KIC imaging in vivo in patient derived 
orthotopic xenograft models of glioblastoma that express high BCAT1 levels would show faster 
conversion to leucine and hence higher leucine signal in the tumours when compared to the 





4.3.1 Cell culture 
EL4 murine lymphoma cells (ATCC) were grown in suspension in RPMI medium (Gibco) 
supplemented with 10% Foetal Bovine Serum (FBS) and 2 mM glutamine. Cells were harvested 
by centrifugation and washed with Phosphate Buffered Saline (PBS).  
Glioblastoma cells were grown as described in Chapter 3.  
4.3.2 Establishment of tumour models 
4.3.2.1 Implantation of subcutaneous lymphoma tumours in mice 
A suspension of 5 x 106 EL4 cells in 200 µl Foetal Bovine Serum (FBS) was injected 
subcutaneously in the right flank of female C57BL/6 mice (Charles River). Tumours were 
grown for 8-11 days before they were imaged. 
4.3.2.2 Patient Derived Orthotopic Xenograft implantations 
For intracranial implantations of glioma cells in rats, the procedure described in Chapter 3 was 
used. 
4.3.3 Magnetic Resonance Imaging and Spectroscopy in vivo 
Animals were placed in a 7.0 T magnet (Agilent). For the mouse imaging experiments, a 42 
mm diameter 1H and 13C transmit volume coil was used as well as a 20 mm diameter 13C 
receive-only surface coil, which was placed over the tumour. For the rat imaging experiments 
a 72 mm diameter volume coil was used for 1H and a 20 mm diameter transmit and receive 
surface coil for 13C, which was placed over the rat’s head, with the rat in a prone position, unless 
otherwise stated. The rats and mice were anaesthetised by inhalation of 2-3% isoflurane in 
air/O2 (75/25% vol/vol, 2 L/min). Respiration and body temperature were monitored over the 
course of the imaging experiment. The body temperature of the animal was maintained with a 
stream of warm air.  
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4.3.3.1 Substrate hyperpolarisation 
[1-13C]Ketoisocaproate and [1-13C]pyruvate were hyperpolarised using a HyperSense DNP 
polarizer (Oxford Instruments, Abingdon, UK) at 1.2 K in a magnetic field of 3.35 Tesla (T), 
with micro-wave irradiation at 94.1 GHz.  
4.3.3.1.1 [1-13C]Ketoisocaproate 
[1-13C]sodium ketoisocaproate was purchased from Cambridge Isotope Laboratories (MA) and 
converted to [1-13C]ketoisocaproic acid using the following procedure: [1-13C]ketoisocaproic 
acid, sodium salt was placed in a 10-ml round bottom flask and dissolved in water. The solution 
was stirred at 0oC and acidified using 1 ml of concentrated Hydrochloric Acid. After 2 hours of 
stirring at 0oC, the aqueous layer was extracted with diethyl ether (3 × 3 mL). The combined 
organic layers were dried with anhydrous magnesium sulphate, filtered, and concentrated under 
nitrogen gas to give [1-13C]KIC as a colourless oil. The purity of [1-13C]KIC acid was 
confirmed by 1H NMR. 
For hyperpolarisation of [1-13C]KIC, the recipe was modified from previous literature189,190,193 
as follows: 63 mg [1-13C]KIC was mixed with OX063 radical (GE Healthcare, Amersham, UK) 
(15 mM final concentration) and gadoterate meglumine (DOTAREM, Guerbet, Roissy, France) 
(1.5 mM final concentration) and hyperpolarised for about an hour. The hyperpolarised 
substrate was dissolved in 6 ml of buffer containing 40 mM Hepes, 94 mM NaOH, 30 mM 
NaCl and 100 mg/L EDTA. For the mice 400 μl and for the rats 2 ml of this solution were 
injected intravenously via a tail vein. 
4.3.3.1.2 [1-13C]pyruvate 
[1-13C]pyruvic acid was purchased from Cambridge Isotope Laboratories (MA). 44 mg [1-
13C]pyruvic acid was mixed with 15 mM OX063 radical (GE Healthcare) and 1.4 mM 
gadoterate meglumine (DOTAREM, Guerbet) and loaded in the HyperSense polarizer, where 
it was polarised for about an hour. The substrate was then dissolved in 6 ml of buffer containing 
40 mM Hepes, 94 mM NaOH, 30 mM NaCl and 100 mg/L EDTA and 400 μl of this solution 
was immediately injected intravenously into the tail vein of the mouse to be imaged. 
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4.3.3.2 Hyperpolarised 13C KIC MRI experiments 
4.3.3.2.1 Subcutaneous tumour imaging in mice 
For T2-weighted proton anatomical images of the mice, a Fast Spin Echo sequence was used. 
For this, 15 axial slices with a Field-of-View (FOV) of 40 mm x 40 mm and 2 mm thickness 
were acquired with a matrix size of 256 x 256, TR of 2 s and an effective TE of 48 ms, with 8 
echoes acquired.  
For acquisition of the time course of hyperpolarized [1-13C]KIC metabolism in EL4 tumours, 
signal was acquired from a 10 mm thick slice (40mm x 40mm FOV) containing the tumour, for 
180 seconds from the start of hyperpolarized 13C KIC injection. The 13C spectra were acquired 
with a 600 μs 10o flip angle pulse, with a TE of 0.5 ms, TR 1 second. 1024 spectral points were 
acquired, covering a spectral width of 6010 Hz.  
For two-dimensional chemical shift imaging in a 16 x 16 matrix, an 8 mm thick slice was 
selected (FOV 40 mm x 40 mm), based on the T2-weighted proton images, that contained the 
tumour. The image was acquired with a TR of 47 ms, TE of 0.85 ms and a 600 μs pulse with a 
flip angle of 10o. 256 spectral points were acquired covering a spectral width of 6010 Hz. For 
higher resolution imaging of EL4 tumours, a 6 mm thick slice was imaged in a 32 x 32 matrix, 
with a TR of 30 ms, TE of 0.85 ms, and a 600 μs pulse with a flip angle of 10o. 128 spectral 
points were acquired covering a spectral width of 6010 Hz. In both cases, the k-space was 
acquired from the centre, spiralling outwards with repeated excitation pulses. 
4.3.3.2.2 Brain imaging in rats 
For T2-weighted proton anatomical images of the rat brain, a Fast Spin Echo sequence was 
used. For this, 15 axial slices with a FOV of 40 mm x 40 mm and 2 mm thickness were acquired 
with a matrix size of 128 x 128, TR of 1.8 s and TE of 50 ms, with 8 echoes acquired. 
For Chemical Shift Imaging in rat brain, signal was acquired from a slice of 8-10 mm thickness, 
in a 16 x 16 matrix, with a TR of 47 ms, TE of 0.75 ms and a 600 μs pulse with a flip angle of 
75o, unless otherwise stated. 256 spectral points were acquired covering a spectral width of 
6010 Hz. The k-space was acquired from the centre, spiralling outwards with repeated 
excitation pulses.  
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4.3.3.3 1H Spectroscopy Experiments 
Proton magnetic resonance spectra were acquired using a 9.4T spectrometer with a Bruker 
console from two 2.5×2.5×3 mm voxels, one placed inside the tumour and one in contralateral 
normal appearing brain tissue, using a PRESS acquisition and CHESS water suppression194 
pulse sequences. A 72 mm diameter volume coil for transmit (RAPID Biomedical) and a 
surface coil placed over the rat's head for receive (Bruker). Spectra were acquired with an echo 
time (TE) of 30 ms, a repetition time of 2 s and 256 averages. Water reference spectra were 
acquired with an identical pulse sequence and timings using 16 averages. A basis set of model 
metabolite spectra was simulated using NMRSIM with the timings of the experimental PRESS 
sequence but idealised 90˚ and 180˚ pulses. Simulated spectra were based on published 
chemical shifts and coupling constants195 for alanine, aspartate, choline, creatine, gama-
aminobutyric acid, glucose, glutamine, glutamate, glycine, glutathione, myo-inositol, lactate, 
N-acetyl-aspartate, N-acetyl-aspartyl-glutamate, phosphoethanolamine and taurine. Data and 
simulated spectra were transferred to MATLAB (The Mathworks, Natick, MA, USA) for 
spectral fitting. Raw in vivo FIDs were QUALITY196 corrected for frequency, phase and 
lineshape using the water reference spectrum with line broadening set to a consistent 24 Hz 
with a gaussian window function before Fourier transformation. The real part of the spectral 
regions were fitted with the model spectra with 24 Hz Gaussian lineshapes, a cubic spline 
baseline and 8 simulated broad singlets for fatty-acid resonances (dialylic bounded methylene 
at 2.8 ppm, methylene adjacent to a carboxyl at 2.3ppm, methylene adjacent to an allyl at 2.1 
ppm, three methylenes around 1.3 ppm and two methyls at 0.9 ppm). A trust-region reflective 
least squares fitting was used to fit the real part of each spectrum between 4.2 and 0.6 ppm and 
quantified assuming the water reference peak was 46 M197 with no correction for T1 or T2 
relaxation. 
4.3.4 Ex vivo measurements of BCAT activity 
For measuring total BCAT activity and the contribution of BCAT1 and BCAT2 activities to the 
total activity, the tissues were dissected immediately after sacrificing the animals and snap-
frozen in liquid nitrogen. Tissue was homogenized and assayed using the spectrophotometric 
assay, as described in Chapter 3.  
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4.3.5 Ex vivo measurements of metabolites by 1H NMR 
For measuring BCAA levels in healthy brain and in A11 orthotopic xenografts, tissue was snap 
frozen in liquid nitrogen. Metabolites were extracted using a methanol/chloroform/water 
extraction method198. Around 250 mg frozen tissue was homogenised in 4 ml cold methanol 
using the Precellys homogeniser. The homogenate was incubated on ice for 15 minutes and 
then 4 ml cold chloroform was added. The methanol/chloroform mixture was vortexed and 
incubated for another 15 minutes on ice before 4 ml of H2O were added. The mixture was 
incubated at -20oC overnight, followed by centrifugation at 21000 g for 40 minutes at 4oC for 
separation of the layers. The aqueous phase was dried using a stream of nitrogen gas and 
lyophilised, while the protein in the interphase was extracted using RIPA buffer for protein 
quantification.  
For 1H NMR, the lyophilised extracts were dissolved in D2O containing 10 mM TMSP standard. 
1H spectra were acquired on a 600 MHz spectrometer (Bruker) with an 11 μsec pulse with a 
flip angle of 90o and a repetition time of 5.3 seconds. 512 scans were summed, with a spectral 
width of 17 ppm (10000 Hz) and 65536 data points. All spectra were processed using a 





4.4.1 BCAT activity can be imaged with hyperpolarised [1-13C]KIC in EL4 
subcutaneous tumours 
In a surface coil-localised 13C spectroscopy experiment, signals from both [1-13C]KIC (at 172.6 
ppm) and its transamination product, [1-13C]leucine (at 176.8ppm), were acquired following 
intravenous injection of hyperpolarised [1-13C]KIC into an EL4 tumour-bearing mouse (Figure 
75). Following fitting of the individual spectra using the AMARES (Advanced Method for 
Accurate, Robust and Efficient Spectral fitting) algorithm in the OXSA Matlab toolbox199, the 
time course data was observed. The signal obtained from [1-13C]KIC peaked at around 10 
seconds after injection and declined quickly thereafter, disappearing completely by 50 seconds, 
whereas the signal from [1-13C]leucine peaked later, at about 30 seconds, and lasted longer, as 




Figure 75 Transamination of hyperpolarised 13C KIC to 13C leucine in vivo measured using 13C Magnetic Resonance 
Spectroscopy. For the 13C excitation, a 10o flip angle pulse, with a TR of 1 second was used. 1024 spectral points were acquired, 
covering a spectral width of 6010 Hz. (A) A stack of spectra acquired every second between 1 and 80 seconds after injection, 
showed that the 13C KIC signal (peak on the right) peaked first and then declined quickly, while its transamination product, 
13C leucine (peak on the left) built up over time and lasted longer. (B) The spectra were fitted using the AMARES algorithm 
and the peak area for the fitted KIC and leucine peaks was plotted over time. (C) The absolute values of the summed spectra 
for the entire duration of the experiment (180 seconds). The chemical shift of leucine is 176.8 ppm and that of KIC is 172.6 
ppm. 
Chemical Shift Imaging (CSI) was then performed in EL4 tumour bearing mice. A low 
resolution (16 x 16 matrix for a 40 x 40 mm2 slice) imaging experiment (Figure 76) 
demonstrated that it was possible to image the metabolism of hyperpolarized [1-13C]KIC to [1-
13C]leucine in vivo in this subcutaneous tumour, in agreement with previously published data189. 
The highest [1-13C]leucine signal was observed near the edges of the tumour, although [1-




Figure 76 2D 13C CSI in a murine EL4 tumour. The axial 1H reference image was acquired using a Fast Spin Echo Sequence. 
Twenty five seconds after the start of injection of 400 μl of hyperpolarised [1-13C]KIC via the tail vein of the mouse, a chemical 
shift imaging sequence with TR 47ms, TE 0.85ms and a 600 μs 10o flip angle pulse was used to acquire a 16 x 16 matrix of 13C 
spectral information. A false colour image of [1-13C]KIC (A) and [1-13C]leucine (B) signal in the mouse, normalised to the 
maximum signal in the image. The signal was interpolated from a 16 x 16 matrix to a 128 x 128 matrix and the image is overlaid 
on the reference anatomical 1H image. (C) The false colour image depicts the non-interpolated leucine signal in the tumour, 
normalised to the maximum signal in the mouse. The spectra from the two voxels with the highest leucine signal intensity are 
shown. 
Higher resolution CSI was performed in EL4 tumour-bearing mice, to compare 13C KIC 
imaging to 13C pyruvate imaging. Mice were imaged on two consecutive days with the two 
substrates. In these imaging experiments, pyruvate was mostly seen in the large vessels 20 
seconds after the start of injection of the substrate, while lactate was distributed across the 
tumour. In some tumours lactate labelling was seen evenly throughout the tumour (Figure 77B) 
whereas in other tumours the labelling was more focal (Figure 77F). The distribution of [1-13C] 
leucine in these tumours was similar to the distribution of [1-13C]lactate. High [1-13C]KIC 
signal was also observed in the tumours, in contrast to the 13C pyruvate signal, suggesting that 
label exchange between KIC and leucine is slower than the exchange between pyruvate and 
lactate.  
In order to investigate the dependence of 13C labelling of leucine on BCAT1 activity, a mouse 
was imaged on consecutive days with and without gabapentin administration. Gabapentin 
administration one hour before imaging with hyperpolarised [1-13C]KIC led to a decreased 13C 
leucine signal in the tumour compared to the signal observed in the same tumour the previous 
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day (Figure 77D,J), despite the very similar 13C KIC distribution on both days (Figure 77C,I). 
This suggests that BCAT1 inhibition leads to decreased label exchange between KIC and 
leucine. Some leucine was still detectable in the tumour, which could be from uninhibited 
BCAT2 activity or residual BCAT1 activity. 
 
Figure 77 Chemical shift imaging of hyperpolarised 13C pyruvate and 13C KIC in EL4 tumour-bearing. Hyperpolarised 13C 
pyruvate and 13C KIC were compared by imaging the same mice on consecutive days. Images (32 x 32 matrix size) were 
acquired from a 6 mm thick slice in both cases, using a 10o, 600 μs excitation pulse. For pyruvate imaging, the acquisition was 
started 20 seconds after the start of injection and for KIC imaging after 25 seconds. 13C-labelled pyruvate, lactate, KIC and 
leucine false colour images are shown for two mice (A-D first mouse, E-H second mouse). The images were normalised to the 
maximum signal in the image. (I-L) The same mouse imaged using hyperpolarised 13C KIC on the third consecutive day, 1 h 
after an intravenous injection of gabapentin solution (300 μl of 30 mg/ml solution). (I,J) False colour images represent the 
intensity of 13C KIC (I) and 13C leucine (J), normalised to the maximum signal in images (C) and (D), respectively, to enable 
direct comparison. (K,L) Summed spectra from all tumour containing voxels showing the KIC and leucine peaks in the images 
acquired before (K) and after (L) gabapentin administration. The spectra were normalised to the signal-to-noise ratio to enable 
direct comparison. The KIC to leucine ratio in (K) is 0.173 and in (L) it is 0.097. 
4.4.2 BCAT activity can be imaged with hyperpolarised [1-13C]KIC in 
healthy rat brain 
Both BCAT isoenzymes have been shown to be expressed in healthy brain in humans and 
rats200. Conversion of [1-13C]KIC to [1-13C]leucine was detected in healthy rat brains in CSI 
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experiments (Figure 78). The leucine to KIC ratio calculated from summed spectra of brain-
containing voxels was lower than from summed spectra of EL4 tumour-containing voxels. This 
may be caused by multiple factors, including different circulation kinetics in rats compared to 
mice, rate of delivery of the substrate to the subcutaneous tumour compared to the brain, MCT 
expression, BCAT1 and BCAT2 activities and the endogenous glutamate and leucine pool 
sizes. 
 
Figure 78 Hyperpolarised 13C KIC imaging in healthy rat brain. [1-13C]KIC (A) and [1-13C]leucine (B) images overlaid on 
reference 1H images of the brain of a healthy rat. For the reference 1H image, 15 axial slices of thickness 2 mm and 40 mm x 
40 mm field of view were imaged using a Fast Spin Echo sequence. For the 13C CSI, signal was acquired from a 10 mm thick 
slice using a 700 μs long excitation pulse with a 53o flip angle. The acquisition was started 20 seconds following the start of 
injection of hyperpolarised 13C KIC. The original voxel size is shown (16 x 16 matrix) and the signal was normalised to the 
maximum signal in the image. (C) Representative summed spectrum across brain voxels showing the 13C KIC peak (172.6 ppm) 
and the 13C leucine peak (176.8 ppm). (D) The leucine to KIC ratio in healthy rat brain is smaller than the ratio in subcutaneous 
EL4 tumours. Ratios were calculated by dividing the area of the leucine peak by the area of the KIC peak in the summed spectra 
from the brain and tumour voxels. Each dot represents a measurement from a different animal. For healthy brain, black dots 
represent CSI acquisitions performed 20 seconds after the start of injection of hyperpolarised KIC with rats in a supine position 
and red dots represent CSI acquisitions performed 35 seconds after the start of injection of hyperpolarised KIC with rats in a 
prone position. A two-tailed t-test was performed to compare the two groups. N=5 for healthy brain, N=4 for subcutaneous 
EL4 tumours, *p<0.05 . 
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4.4.3 In vivo measurements of BCAT activity in Patient Derived Orthotopic 
Glioblastoma Xenografts 
To investigate the capability of hyperpolarised 13C KIC imaging to measure BCAT activity in 
vivo in glioblastoma, athymic nude rats implanted with patient derived glioblastoma cells were 
used. The cells used for implantation were the A11 cells as well as the genetically engineered 
clones including the inducible A11shBCAT1 and A11shScr clones, the A11 BCAT1 
overexpressing cells and the A11 Luciferase overexpressing cells, all of which were described 
in Chapter 3. The leucine to KIC ratios measured by CSI in the A11 tumour containing regions 
of the brain were comparable to those generated in the contralateral normal appearing brain 
(Figure 79A,B) and much lower than those produced in the subcutaneous EL4 tumours. 13C 
KIC images showed homogeneous substrate uptake in normal appearing brain and in tumour 
regions. In order to investigate whether BCAT activity in the tumours was limiting, rats were 
implanted with A11 BCAT1 overexpressing cells. BCAT1 overexpression led to lower leucine 
to KIC ratio measured upon hyperpolarised 13C KIC imaging (Figure 79B). Measurement of 
total BCAT activity in tissue lysates revealed that the A11 glioma had lower total BCAT and 
BCAT1 activities than healthy brain. However, BCAT1 overexpression led to a three-fold 
increase in the tumour BCAT activity. Therefore, enzyme activity does not seem to be limiting 




Figure 79 Hyperpolarised 13C KIC imaging in PDOXs. (A) T2-weighted MR image of an axial slice showing the healthy left 
hemisphere and tumour in the right hemisphere. The boxes indicate the voxels from which the summed spectra shown on each 
side of the image were acquired. Leucine is at 176.8 ppm and KIC is at 172.6 ppm. (B) The leucine to KIC ratio calculated for 
each imaging experiment from the summed spectra from healthy brain and tumour voxels. Each point represents a measurement 
from an independent imaging experiment. For A11 tumours, rats implanted with doxycycline-inducible A11shScr and 
A1shBCAT1 cells and that had not been fed doxycycline in the diet were pooled together. Error bars represent Standard 
Deviations. (C) Total BCAT activity in tissue lysates measured using a spectrophotometric assay. Each point represents an 
independent measurement. A11 contains pooled data from doxycycline-inducible A11shScr and A11shBCAT1 tumours in 
animals that had not been fed with doxycycline. Error bars represent Standard Deviations. (D) Total BCAT activity measured 
in the spectrophotometric assay with increasing concentrations of gabapentin. Error bars represent SEM. Two-tailed t-tests 
were performed to compare the mean leucine to KIC ratio and total enzyme activity across different tumour types. 
*p<0.05,**p<0.01, ***p<0.001, ****p<0.0001  
While the activity measured using tissue lysates in the spectrophotometric assay is the activity 
in the presence of high substrate concentrations, the activity measured in vivo with 
hyperpolarised [1-13C]KIC is dependent on the concentrations of glutamate and 13C KIC as co-
substrates that could be limiting. In addition, the endogenous leucine pool will also affect the 
rate of label exchange. Delivery of [1-13C]KIC to the tumours appeared equally rapid in the 
A11 tumours and the contralateral normal appearing brain, as determined by CSI experiments 
(Figure 80A-B). Additionally, the A11 gliomas express both MCT1 and MCT4 transporters 




Figure 80 Hyperpolarised 13C KIC delivery and uptake into the tumour does not limit leucine labelling. Representative 
example of a T2-weighted 1H image of an orthotopic A11 glioma (A), with the dashed line delineating the tumour region, 
overlaid with the [1-13C]KIC signal (B). (C-D) Immunohistochemical staining of an orthotopic A11 tumour for MCT1 (C) and 
MCT4 (D).  
Gliomas show enhanced uptake of branched chain amino acids through the upregulated Large 
Neutral Amino Acid Transporter (LAT1)201. 1H NMR measurements on extracts of A11 tumour 
and normal appearing brain confirmed that A11 tumours have a larger pool of endogenous 
branched chain amino acids, including leucine, when compared to the contralateral normal 
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appearing brain (Figure 81A-C). Therefore, label exchange is unlikely to be limited by the 
endogenous leucine pool in these tumours. 
Conversely, glutamate levels in the tumours could potentially limit the KIC to leucine 
conversion. The in vitro experiments in Chapter 3 demonstrated high rates of glutamate release 
by the cells into the media, suggesting that the intracellular concentration of glutamate in these 
cells would be expected to be maintained at a low level. In addition, BCAT1 knockdown in 
A11 cells led to an increase in the intracellular levels of glutamate, as measured by LCMS 
(Figure 67A). Therefore, it is possible that BCAT1 overexpression leads to reduced intracellular 
levels of glutamate and hence decreased interconversion of KIC and leucine. We performed 1H 
spectroscopy experiments in tumour-bearing rats to compare glutamate levels in tumour voxels 
and contralateral healthy brain voxels. Glutamate concentrations were much lower in the 
tumour regions compared to the contralateral normal appearing brain (Figure 81D-F), 
suggesting that glutamate might be limiting the KIC to leucine conversion in the tumours. 
 
Figure 81 Co-substrate availability may be limiting for the exchange of label between KIC and leucine. The concentrations 
of branched chain amino acids in an A11 tumour and in the contralateral healthy hemisphere were determined from 1H NMR 
measurements on tissue extracts. The spectra of the healthy hemisphere sample (A) and the A11 tumour sample (B) are plotted, 
with the BCAAs peaks appearing between 0.9 and 1.1 ppm. The triplet at around 0.97 ppm corresponds to the leucine protons. 
Integration of the total BCAA signals and normalisation to protein content is shown in (C). 1H spectroscopy experiment in two 
A11 tumour-bearing rats was performed to compare the concentration of glutamate in the healthy hemisphere and in tumours. 
Representative examples of the fitted spectra acquired from the healthy hemisphere (D) and a tumour region (E) from a 2.5 x 
2.5 x 3 mm3 voxel.  The phased spectra are shown in black, the fitted spectra in red, the baseline in yellow and the glutamine 





Imaging the transamination reaction catalysed by BCAT using hyperpolarised [1-13C]KIC has 
been demonstrated previously, both in healthy rat brain190 and in EL4 tumours189 as well as in 
cells in vitro193. More recently, hyperpolarised [1-13C]KIC was used to compare the rate of 
oxidation of the ketoacid by measuring the generation of H13CO3- from injected [1-13C]KIC in 
healthy livers and livers with hepatocellular carcinoma185. In this study, the potential for using 
hyperpolarised [1-13C]KIC to image upregulated BCAT1 activity in vivo in glioblastoma was 
examined. The technique was optimised using subcutaneous EL4 lymphoma tumours, which 
show high levels of BCAT1 and the results obtained were in agreement with the literature. [1-
13C]KIC hyperpolarised relatively well and quickly, was well tolerated by the mice and was 
distributed around the body quickly. EL4 tumours were able to take up the substrate and the 
label was rapidly exchanged with the endogenous leucine pool. Imaging healthy rat brains 
demonstrated that [1-13C]KIC could quickly cross the blood brain barrier, enabling the 
acquisition of sufficient signal from the brain. 
Given the important role of BCAT1 in glioblastoma, as discussed in Chapter 3, a method to 
assess its activity in vivo non-invasively would be beneficial both for prognostic purposes and 
to detect response to the new therapies targeting BCAT1202. We investigated the ability of 
hyperpolarised 13C KIC to image BCAT activity in glioblastoma patient derived orthotopic 
xenografts in rats. The images acquired showed no contrast between healthy rat brain and the 
tumours in terms of [1-13C]leucine generation, with very similar leucine/KIC ratios measured 
in tumour regions and in the normal appearing contralateral brain hemisphere. In a clinical 
setting, however, there may be contrast between tumour and normal brain as BCAT activity of 
rat brain is higher than that in human brain, with rat brains having an average BCAT activity of 
1944 ± 94 mU/g wet weight and human brains 510 ± 49 mU/g wet weight203. 
Imaging of hyperpolarised 13C KIC metabolism has recently been attempted in a rat glioma 
model, where the authors reported much lower leucine to KIC ratios (0 to 0.008) than the ratios 
we observed in A11 tumours, with higher ratios in the contralateral normal appearing brain. 
The authors suggested that the tumour cells showed increased oxidation of the injected 
substrate, generating H13CO3- instead of transamination to 13C leucine, and they explained this 
by showing that there was lower BCAT1 expression but higher Branched Chain Ketoacid 
Dehydrogenase (BCKDC) in the tumour compared to the normal brain. However, the ratio of 
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both 13C leucine and H13CO3- signals to the KIC signal were very low (<0.005), and greatly 
affected by background noise. Additionally, given that human glioblastoma shows significant 
upregulation of BCAT1 when compared to healthy brain, whereas the cell line used in this study 
showed low expression of BCAT1, this result is not representative of human glioblastoma. 
The [1-13C]leucine signal generated in the brain (healthy and tumour-bearing) in this study was 
considerably lower than in the EL4 tumours. This was neither explained by the total BCAT 
activity nor the BCAT1 activity measured in tissue lysates, which were similar in EL4 tumours, 
healthy rat brain and in A11 gliomas. Also, A11 tumours overexpressing BCAT1, which had a 
three-fold higher total BCAT activity, still had very low [1-13C]leucine signals, which were 
even lower than in the control A11 tumours. This suggests that BCAT activity is not limiting 
for the KIC to leucine conversion in these glioma tumours and instead it appears that 
overexpression of the enzyme further limits the conversion rate. For 13C KIC to be converted 
to leucine, sufficient levels of BCAT should be present, but also sufficient concentrations of 
the glutamate co-substrate are required. The Km of BCAT1 for KIC is 0.063 mM and of BCAT2 
0.16 mM. The Km for glutamate on the other hand is 13 mM for BCAT1 and 24 mM for BCAT2, 
therefore low glutamate concentrations could slow the reaction significantly204. GBM cells have 
been shown to excrete large amounts of glutamate in vitro, maintaining a very low intracellular 
glutamate concentration, which we also demonstrated in the A11 cells (Figure 39B)51,205. Using 
1H MRS, we showed that A11 PDOX GBM tumours had lower glutamate concentrations when 
compared to the contralateral healthy hemisphere. Moreover, as discussed in Chapter 3, BCAT1 
knockdown in A11 cells led to a significant increase in the intracellular glutamate pool, possibly 
via increased flux through aminotransferase enzymes other than BCAT1. Therefore it is 
possible that BCAT1 overexpression leads to a reduction in the intracellular glutamate pool in 
these tumours, which would explain the lower transamination rate observed in vivo. Glutamate 
concentrations in EL4 tumours were assayed ex vivo in a previous study and were found to be 
2.2 μmol/g tissue and significantly higher than adjacent muscle tissue (0.3 μmol/g) suggesting 
that glutamate availability was not limiting in hyperpolarised 13C KIC imaging of EL4 
tumours189.  
A potential solution to this problem would be to increase the glutamate levels in the tumours 
prior to imaging with hyperpolarised 13C KIC. Injection of glutamate into tumour bearing 
animals would be challenging given that glutamate uptake into the brain is limited by the blood-
brain barrier and that high levels of glutamate are excitotoxic206. Also, glioma cells show low 
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glutamate uptake, with a Vmax<10% of that of normal astrocytes205. A bolus injection of 
glutamine, instead, would in theory lead to a transient increase in intracellular glutamate levels 
owing to the high glutaminase activity in gliomas. Glioma cells show increased uptake of 
glutamine, as detected using 18F-Fgln PET experiments, and upregulation of glutaminase, 
which converts glutamine to glutamate207. Alternatively, inhibition of glutamate release from 
glioma cells using a metabotropic glutamate receptor antagonist could lead to intracellular 
accumulation of glutamate facilitating the 13C labelling of leucine from [1-13C]KIC205. An 
increase in intracellular glutamate concentration in the tumour could potentially enable the in 
vivo assessment of BCAT activity and would also boost the leucine signal generated, which 
was very low in these imaging experiments. The rate of conversion of hyperpolarised [1-
13C]leucine to [1-13C]KIC would not be limited by the concentration of glutamate and therefore, 
[1-13C]leucine could be a better imaging substrate for this purpose. However, [1-13C]leucine 
does not have favourable hyperpolarisation properties as it has a shorter T1 than [1-13C]KIC and 
would also need to be dissolved in a solvent before polarisation whereas [1-13C]KIC can be 
used at its neat concentration as a liquid208. 
The unlabelled leucine pool could also be a limiting factor in the amount of 13C leucine signal 
detected. However, studies on various cancer cell lines, including the rat C6 glioma cell line, 
have shown increased uptake of BCAAs via the upregulated LAT1 transporter201. In vivo MR 
spectroscopy experiments in a study by Suh et al showed that the leucine pool in a rat glioma 
model (F98) was significantly higher (0.278 ± 0.035 μmol/g wet tissue) than the contralateral 
healthy brain (0.075 ± 0.001 μmol/g wet tissue)192. These values are in agreement with the 
concentrations calculated here from ex vivo 1H NMR analysis of A11 tumour and contralateral 
normal appearing brain extracts. This suggests that the endogenous leucine pool in the A11 
tumours is not limiting for 13C label exchange when compared to the contralateral hemisphere. 
The presence of both isoenzymes and their contributions to the observed activity need to be 
taken into account. BCAT1 and BCAT2 have different activities, and in addition, the location 
of BCAT2 in the mitochondria might mean that it makes a different contribution to the signal 
observed compared to BCAT1, which is in the cytoplasm. In preliminary experiments in EL4 
tumour bearing mice, we saw that BCAT1 inhibition by gabapentin led to a greatly reduced 
leucine to KIC ratio suggesting a large contribution of BCAT1 on the conversion of 13C KIC to 
13C leucine in EL4 tumours. These experiments were limited by the high growth rate of the 
tumours, which led to changes in tumour size and possibly also metabolism between 
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consecutive days. Also, the need for repeated cannulation of these mice greatly limited the 
number of mice that were scanned on both days due to inability to cannulate an injured tail vein.  
Imaging of hyperpolarised 13C KIC is a promising technique and may prove useful in measuring 
BCAT1 upregulation non-invasively in some cancers. However, the dependence of label 
exchange between KIC and leucine on many factors, other than BCAT1 activity will need to be 
taken into account. In glioblastoma, more models need to be imaged using this technique in 
order to understand whether it provides useful prognostic information.  
4.6 Conclusion 
Hyperpolarised 13C KIC is a promising substrate for studying BCAT activity in tumours and 
this was demonstrated in subcutaneous EL4 lymphoma tumours. However, the rate of label 
exchange in this reaction depends on multiple factors, including enzyme activity, the rate of 
substrate delivery, the activity of the MCT transporters and the sizes of the endogenous 
glutamate and leucine pools. In orthotopic patient derived glioma xenografts in rats, imaging 
of hyperpolarised 13C KIC does not provide a direct measure of BCAT activity, which is most 







Chapter 5 - General Discussion 
Metabolic imaging techniques are becoming essential tools for investigating cancer 
metabolism, particularly in the clinic, potentially enabling identification of new therapeutic 
targets and biomarkers of cancer. Some of these techniques, including hyperpolarised 13C 
imaging, can be used clinically, to stage disease and monitor treatment response, which can be 
used to guide treatment.  
In this thesis, the use of imaging with hyperpolarised [1-13C]pyruvate imaging was cross-
validated with MSI, another novel metabolic imaging technique. The two techniques generated  
positively correlated images of [1-13C]lactate in subcutaneous murine lymphoma tumours 
following injection of hyperpolarised [1-13C]pyruvate. The two techniques are complementary 
in the possibilities that they offer for imaging cancer metabolism, in that MSI enables the 
acquisition of high resolution images of a large number of metabolites, isotopically labelled or 
unlabelled, while 13C MRSI with hyperpolarised [1-13C]pyruvate generates only low resolution 
images of [1-13C]lactate and [1-13C]pyruvate, but these can be obtained non-invasively and in 
real time, thus providing kinetic information. In this study, using both techniques on the same 
tumours enabled an understanding of the factors influencing labelling kinetics.  
Hyperpolarised [1-13C]Ketoisocaproic acid is a novel substrate that has been demonstrated in a 
number of publications, where label flux between hyperpolarised [1-13C]KIC and [1-
13C]leucine and H13CO3-, catalysed by BCAT1/2 and BCKDC respectively, were measured 
following injection of hyperpolarised [1-13C]KIC in mice and rats. This appears to be a 
promising technique given the recent interest in Branched Chain Amino Acid metabolism in 
cancer. However, as with any imaging substrate, it is important to understand what information 
it can provide and how useful it could be in a clinical scenario.  
In this project, I have studied the role of BCAT1 in patient derived glioblastoma cells and 
xenografts in rodents, where I have shown that BCAT1 promotes cell proliferation via the 
regulation of HIF and FOXM1 transcriptional activity. BCAT1 knockdown in A11 
glioblastoma cells led to a significantly different transcriptional profile, which could explain 
the reduced rate of cell proliferation as well as the reduced neurosphere forming ability of the 
cells. The proliferation defect in the cells could be mimicked by supplementation of the cells 
with dimethyl α-KG and could be rescued by DMOG. These results, in addition to changes in 
190 
 
the levels of 5-hydroxymethyl cytosine in the DNA of cells suggest that the effects of BCAT1 
knockdown are mediated through activation of α-KG dependent dioxygenases. Therefore, the 
role of BCAT1 in these cells is to regulate the cytosolic pool of α-KG which has pleiotropic 
effects in the cells leading to a highly proliferative phenotype.  
α-KG is a metabolic regulator of tumour fate owing to its central role in metabolic reactions as 
well as its role as a substrate for the α-KG dependent dioxygenases, in particular prolyl 
hydroxylase enzymes controlling HIF-1α degradation and the DNA and histone demethylase 
enzymes controlling gene expression27. α-KG can tightly control the degradation rate of HIF-
1α, with a Km of the prolyl hydroxylase for α-KG of about 50 μM, close to the physiological 
concentration of the metabolite, suggesting that even small changes in the levels of α-KG can 
have profound effects on the stability of HIF-1α and hence the hypoxic response of the cells27. 
The fact that all three TCA cycle intermediates which have oncogenic activity, succinate, 
fumarate and 2HG act through competitive inhibition of the α-KG dependent dioxygenases, 
highlights the role of α-KG as an obligate substrate of those enzymes controlling tumour fate. 
Owing to the regulatory role of α-KG, several attempts have been made to increase the 
intracellular levels of the metabolite as an anti-cancer agent24,27. For example, intraperitoneal 
injections of α-KG in a mouse model of breast cancer led to a significant reduction in primary 
tumour growth as well as the number of lung and lymph node metastases209. The problem with 
exogenous administration of α-KG is its low cell permeability, therefore the ketoacid is 
frequently attached to hydrophobic carriers in order to increase membrane permeability39. 
The identification of the processes regulating α-KG homeostasis in a cancer cell is thus an 
important step towards finding therapeutic targets for cancer and it is likely that targeting 
BCAT1 in glioblastoma, potentially in combination with inhibition of other α-KG regulating 
enzymes, can lead to the desired increase in α-KG levels in the tumour and hence arrest of 
tumour growth. A similar approach was followed by Atlante et al, where an inhibitor of α-KG 
dehydrogenase was administered to mice implanted orthotopically with breast cancer cells. This 
led to accumulation of α-KG and reduced incidence and area of lung metastases210. 
The ability to image the activity of BCAT1 non-invasively could be beneficial in terms of 
obtaining prognostic information about the tumour and in guiding treatment. However, 
hyperpolarised [1-13C]KIC did not perform as well as we had hoped it would, in terms of 
measuring BCAT1 activity in vivo. In fact, overexpression of BCAT1 in patient derived 
orthotopic xenografts in rats led to reduced leucine signal in the tumour. This is a result of the 
191 
 
many factors that affect the rate of label exchange between [1-13C]KIC and the endogenous 
leucine pool. The injected substrate needs to be delivered to the tumour, taken up by the cancer 
cells and converted to leucine. The concentration of the co-substrate, glutamate as well as the 
endogenous leucine pool will affect the rate of label exchange. In this case, we have evidence 
that the intracellular glutamate levels are limiting for the exchange of label between the injected 
[1-13C]KIC and endogenous leucine pool. BCAT1 expression is associated with glutamate 
efflux from the cells, as documented before51 and as shown here. It also appears that BCAT1 
levels regulate the intracellular levels of glutamate, which would explain the decreased leucine 
signal observed when overexpressing BCAT1. This means that hyperpolarised [1-13C]KIC 
cannot be used as a direct probe for BCAT1 activity in this case.  
However, this limitation does not undermine the potential of the technique for imaging other 
tumours or pathologies. The changes in Branched Chain Amino Acid metabolism are very 
diverse in cancer and in human physiology and further research into the role of these metabolic 
pathways could identify potential scenarios where this imaging substrate might be useful. 
Additionally, as the hyperpolarised 13C imaging field advances, the ability to hyperpolarise 
other substrates, such as [1-13C]leucine, might prove more useful in providing a better measure 
of BCAT1 activity.  
Metabolism plays a major role in cancer development, progression, resistance to therapy and 
recurrence following treatment. Further research into the role of BCAT1 as well as the rest of 
Branched Chain Amino Acid metabolism in glioblastoma could lead to a better understanding 
of its role in the pathophysiology of this cancer, which could open new opportunities for 
treatment. In particular, the differences between the roles of BCAT1 and BCAT2 in 
glioblastoma cells and how metabolic fluxes through the reactions catalysed by each of these 
isoforms is affected by flux in the reaction catalysed by the other isoform would be interesting 
to investigate given that knockdown of the two enzymes does not have the same effects on the 
cells. Additionally, the association between Branched Chain Amino Acid metabolism and fatty 
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